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A RANDOMISED, CONTROLLED TRIAL OF THREE DRUG REGIMES FOR 
THE TREATMENT OF MALARIA IN PREGNANCY IN GHANA. 
HARRY TAGBOR 
London School of Hygiene and Tropical Medicine 
Department of Infectious and Tropical Diseases 
A thesis presented on a clinical trial of amodiaquine (AQ) and sulphadoxine-pyrimethamine (SP) 
used singly and in combination (AQ+SP) compared with chloroquine (CQ) for the treatment of 
900 pregnant women who had falciparum malaria infection detected by a screening programme 
using OptiMAL! ' antigen dipsticks during routine antenatal clinic sessions at the St. Theresa's 
hospital. Enrolment into the study began in March 2003 and ended in September 2004 but 
follow up of treated women continued to March 2005. 
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ABSTRACT 
Malaria in pregnancy is potentially fatal to both the mother and the foetus particularly in the 
primigravidac warranting prompt diagnosis and efficacious treatment. Amodiaquine (AQ) 
alone or its combination with sulphadoxine-pyrimethamine (SP) may be suitable options for 
treatment as the spread of P. fcrlcrparwn resistance to CQ and SP increases while the safety of 
the newer antimalarials including the artemisinins remain largely untested in pregnant 
women. We conducted a randomised controlled trial to assess the efficacy, safety and 
tolerability of AQ and SP alone or their combinations compared with CQ in pregnant 
women. 
Pregnant women of all parities attending antenatal clinic sessions at St. Theresa's Hospital in 
the Nkoranza district of Ghana with a gestational age of 16 weeks and above were screened 
for malaria antigens with OptiNIAL! 
' dipsticks. Two hundred and twenty five pregnant 
women with positive antigen tests and parasitaernia confirmed microscopically were enrolled 
into each of four arms of the study. The women were followed up on days 3,7,14 and 28 
after the start of treatment to assess the effect of treatment on peripheral parasitaemia, 
haemoglobin, bilirubin, liver transaminases and white cell counts. In addition, participants' 
reports of adverse effects were recorded and monitored during the follow-up visits. 
Parasitological, haematological and neonatal outcomes were also assessed at delivery and sir 
weeks postpartum. 
The parasitological failure up to day 28 was, 29.8% (62/208), 16.4°iä (34/ 208), 7.5% (16/ 
212) and 2.4% (5/ 210) in the CQ, SP, AQ and the AQ+SP groups respectively. The 
parasitological failure corrected for new infections using msp-2 genotyping, was 14.4%, 
10.6%, 2.8°%%, and 1.0% the CQ, SP, AQ and the AQ+SP groups respectively.. 
The mean Hb increased by 0.4g/dl (95% CI; 0.3 to 0.5 p<O. 00I) and 0.9g/dl (95% CI; 0.8 to 
1.0 p<0.001) by day 14 and 28 respectively relative to the baseline mean Hb. 
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At day 3,75°, o (625/869) of women reported an adverse event of which general weakness, 
dizziness, vomiting, itching and nausea were most frequent. Compared to women who 
received CQ, women in the AQ (OR=1.9,95% Cl, 1.7 - 3.2 p=0.01) and the AQ+SP 
(OR=3.0; 95% Cl, 1.7 - 5.1 p<0.001) groups were more likely to report an adverse effect; 
women in the SP group were less likely to report an adverse event OR=0.3; 95° o CI, 0.2 - 0.4 
p<0.001). 
The mean activities of aspartate and alaninc aminotransferase increased relative to enrolment 
levels at day 14 but decreased towards baseline levels at day 28 in all the treatment groups. 
On the contrary the mean activity of gamma glutamyl transferase increased throughout up to 
day 28, but this increase was within normal range in all the treatment groups. The mean 
concentrations of total bilirubin and its fractions decreased both at day 14 and day 28 relative 
to baseline concentrations. The neutrophil counts increased after the start of treatment 
relative to baseline counts in all the treatment groups but overall, there was no significant 
difference between mean neutrophil counts at follow up days and the mean count at 
enrolment (p>0.05). 
We concluded that AQ alone or its combination with SP although associated with minor 
adverse events, are efficacious and safe and, could be one of the antimalarial treatment 
options available to pregnant women with P. fu/cipurzrnr malaria. 
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CHAPTER 1 INTRODUCTION 
1.1 DrPH Integrating Statement 
I have a medical background and have also been involved in health services management 
since my appointment as the director of health services of the Nkoranza district in Ghana 
in August 1995. I also doubled up as a resident senior medical officer of the St. Theresa's 
Hospital, Nkoranza. I also led a local team to successfully implement a model safe 
motherhood programme initiated by MaterCare International and funded by Canadian 
International Development Agency (CIDA). 
I won a GMP studentship in 2001 to study for the Doctor of Public Health programme at 
the London School of Hygiene and Tropical Medicine. The first part involved passing 
taught courses in evidence based public health practice, statistics and epidemiology run at 
the LSHTM from October 2001 to May 2002. 
From July - September 2002, I undertook a professional attachment (PA) with the 
National Malaria Control Programme (NMCP) of Ghana. The purpose of the attachment 
was to analyse the structure and work of the NMCP and its achievements in reducing the 
malaria burden in Ghana from 1992 to 2002. Specifically, it aimed to: (1) describe the 
operations of the NMCP; (2) analyse and characterize the public health impact of the 
activities of the NMCP; (3) explore the strength, weaknesses, opportunities and threats of 
the current structure of the NMCP in responding to the Global Malaria Control Strategy 
and the RBM initiative. During the PA, I (1) shadowed the NMCP manager; (2) observed 
malaria control programme operations at the district and regional levels; (3) interviewed key 
informants directly connected with the NMCP; (4) reviewed several documents on Ghana's 
health sector and malaria control activities. A report of the attachment was presented to the 
LSHTM. 
In August 2002 during my PA, the NMCP organised a national forum for health 
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professionals and research scientists to discuss the revision of the national antimalarial drug 
policy. A change to amodiaquine combination with artesunate or amodiaquine with 
sulphadoxine-pyrimethamine as first line treatments for uncomplicated malaria was 
considered. But there was no local data then to support any change. 
This event created the opportunity for me to develop a proposal for a randomised 
controlled trial of amodiaquine and sulphadoxine-pyrimethamine used singly or in 
combination for the treatment of malaria infection in pregnancy. This proposal was 
reviewed and approved by the research committee of the GMP and ethical approval was 
given by the Health Research Unit of the Ministry of Ghana and the London School of 
Hygiene and Tropical Medicine. The data generated from the research project forms the 
basis of this thesis. 
I was the principal investigator for the project and was responsible for: - 
" Designing the research protocol and standard operating procedures and responded to 
all queries from research review committee of the GMP and ethical committees in 
Ghana and in London. 
" Designing study drugs formulations and packaging in collaboration with Kinapharma 
Ltd of Ghana, the drug manufacturers to ensure blinding. 
0 Setting up project office at the St. Theresa's hospital mainly for project administration 
and data entry and management. 
" Recruiting and managing the project staff. 
" Conducting the initial and continuous practical skill-training courses for the field teams 
and data management team for them to understand the nature of the project and 
acquire knowledge and skills needed for their work. 
" Developing suitable record forms and database for the project. 
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" Participant enrolment and the supervising the entire project throughout the study 
period. 
" Managing the project data throughout the study period. 
" Wrote a statistical analysis plan which was approved by DSMB. 
" Analysing the trial data and writing the thesis. 
During the study period, I spent between one to two weeks in the laboratory to have hands 
on experience of the techniques involved in PCR genotyping at the Kintampo Health 
Research Centre and LSHTM, blood film microscopy and clinical chemistry analysis. 
Dissemination of study results so far. - 
1. Three posters on "Safety and efficacy of amodiaquine and sulphadoxine- 
pyrimethamine SP in Ghanaian pregnant women" have been presented at the 
annual meetings of BSP in Chester, UK in 6 to 10th April 2004; of ASHTM in 
Miami, USA held from 7 to 11`h November 2004 and at the 4`h MIM conference in 
Yaounde, Cameroon held from 13 to 18'h November 2005. 
2. Oral presentation of general findings at the annual expert oversight committee of 
the Gates Malaria Partnership (GMP) meeting in Banjul, the Gambia held from 10 
to 14'h May 2005. 
1.2 Study rationale 
Plasmodium falciparrim infection in pregnancy is associated with an increased risk of maternal 
anaemia, abortion, stillbirth, prematurity, intra-uterinc growth retardation and low birth 
weight. Preventive and control measures are available but the rates of maternal and foetal 
complications are still very high. This is because of the low uptake of malaria control 
programmes the wide spread and increasing P. falcrpamrm resistance to the cheap and 
commonly available chloroquine and sulphadoxine-pyrimethamine. Apart from insecticide 
treated bed nets (ITNs), the success of any chemoprophylaxis, intermittent preventative 
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OPT) or treatment programme depends heavily on the efficacy and safety of available 
antimalarial drugs. Unfortunately for pregnant women, the options for efficacious and safe 
antimalarials drugs are limited because they were always excluded from most drug trials for 
safety reasons. The introduction of new antimalarial regimes and changes in national drug 
policies means that pregnant women will advertently or inadvertently be exposed to these 
drugs whose safety profiles in pregnancy are largely unknown. Clinical trials, designed to 
investigate the efficacy and safety of affordable antimalarial drugs to replace CQ and SP for 
use in pregnancy are therefore warranted. Prior to this study, the national antimalarial drug 
policy for Ghana was chloroquine as first line drug both for treatment and prophylaxis in 
pregnant women. Discussions were ongoing to change the policy most probably to a 
combination regime of amodiaquine plus artesunate or amodiaquine plus SP. Evidence on 
the efficacy and safety of these regimes was lacking locally particularly for pregnant women. 
There were concerns over the safety of AQ when used in pregnancy. Whether or not, on 
balance, the potential benefits of these treatments outweigh the potential risks could only be 
determined in a prospective, randomised clinical trial. 
In anticipation of the withdrawal of chloroquine as the drug of choice for malaria treatment 
and the introduction of combination therapy involving AQ and SP for malaria, exploration 
of their efficacy and safety alone or in combination therapy in pregnant women was 
necessary and urgent. This study was therefore designed in response to the local search for an 
appropriate, efficacious and safe antimalarial drug regime for use in pregnant women. 
1.3 Study hypotheses 
1. Amodiaquine (AQ) and sulphadoxine-pyrimethamine (SP) used singly or in 
combination (AQ+SP) are significantly superior to chloroquine (CQ) in achieving 
parasitological clearance in Ghanaian pregnant women with antenatal Plasmodium 
falcipanim malaria infection. 
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2. Amodiaquine (AQ) and sulphadoxine-pyrimethamine (SP) used singly or in 
combination (AQ+SP) to treat antenatal malaria infection are as safe as chloroquine 
(CQ). 
1.4 Organisation of the thesis 
The thesis is divided into the following chapters: - 
Chapter 1 Introduction to the thesis 
This chapter presents the rationale and hypotheses of the study and provides a general 
overview of the organisation of the thesis. 
Chapter 2 Literature review 
This chapter presents a brief review of the global malaria situation and the epidemiology of 
malaria and its control in Ghana. This is followed by a review of the epidemiology of malaria 
in pregnancy, its pathogenesis, clinical features, diagnosis and control. A brief summary of 
the properties of the study drugs are also presented including known adverse drug events. 
Finally a brief review of how the efficacy and safety of antimalarial drugs used in pregnancy 
have been evaluated is presented. 
Chapter 3 Objectives, patients, methods and materials 
This chapter outlines the objectives and design of the study and provides a description of the 
study site and population. It also describes the pre-trial activities, ethical issues and the 
overall conduct of the trial including procedures used. 
Chapter 4 Results 1: - Screening and enrolment 
The first section of this chapter provides a description of the screening processes that led to 
randomisation of eligible pregnant women into the study. The second section presents a 
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description of the demographic and social characteristics of the study women, their clinical 
and obstetric assessments and baseline parasitological and haematological indices. 
Chapter 5 Results 2: - Treatment outcomes 
This chapter presents the parasitological and haematological outcomes during the initial 28 
days of follow up after the start of treatment. The proportions of parasitological failure in the 
AQ, SP and AQ+SP groups are compared to failures in the CQ group at days 14 and 28 of 
follow up. Mean changes in haemoglobin over enrolment levels at days 14 and 28 are 
compared within and between treatment groups. The chapter also describes the relationships 
between baseline prognostic factors and the parasitological and haematological outcomes of 
treatment. 
Chapter 6 Results 3: - Safety and tolerance 
This chapter presents the results of the safety and tolerance observations made among the 
study pregnant women over the 28-day follow up period after the start of treatment. The first 
section describes the types and incidence of adverse effects reported by women during post 
treatment follow up at days 3,7,14 and 28 and makes comparisons between treatment 
groups. A comparison is also made of the incidences of complaints obtained from a control 
group of untreated non-parasitaemic pregnant women who were screened at the same clinic 
and received the same number of follow up visit with those of enrolled parasitaemic pregnant 
women. The second section describes the levels of liver enzymes and bilirubin at days 0,14 
and 28 and makes comparisons between the treatment groups. This section also compares 
the white blood cell counts at days 0,3,7,14 and 28 based on a reference range of 4.0 - 11.0 
x 109/L within treatment groups and in all treatment groups compared with CQ. 
Chapter 7 Results 4: - Pregnancy outcomes 
This chapter presents results on the parasitological and haematological outcomes at delivery 
and postpartum. These outcomes are presented initially as the estimates of the treatment 
effect and then as an overall effect compared to baseline levels. There is also a descriptive 
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analysis of birth outcomes from women in the study and compared by treatment group. Also 
the overall incidences of adverse pregnancy outcomes in the study group are compared to 
local rates for abortion, stillbirth, congenital abnormality, and mean gestation at delivery 
obtained from St Theresa's Hospital's records. 
Chapter 8 Discussions and conclusions 
This chapter presents a discussion of the main study findings and their limitations within the 
context of what is already known. The implications of the findings for further research and 
policy for the control of malaria in pregnancy generally and for Ghana are presented. 
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CHAPTER 2 LITERATURE REVIEW 
2.1 Global burden of malaria 
The disease burden of malaria may be underestimated as data used in such computations are 
obtained mainly from the formal health system, excluding figures from the informal health 
sector (Sauerborn et al. 1991; Shepard et al. 1991; RBM/WHO 1999). Factors contributing to 
the high burden of malaria include the prevalence of Plasmodium falcipanim, presence of 
Anopheles gambiae, poverty, failures in health systems, rapidly emerging resistance to many 
drugs, war and refugee situations, poor sanitation, unplanned development activities in 
developing countries, and climatic changes (Brabin et al. 2001). These factors are more 
prevalent in Africa south of the Sahara which probably explains why the greatest burden of 
malaria is found in this region of the world (Snow et al. 1999). About forty percent of the 
world's population are at risk of malaria and nine out of ten cases come from Africa south of 
the Sahara (WHO 2000b). Children and pregnant women are most vulnerable and more 
likely to suffer the fatal complications of malaria including anaemia, hypoglycaemia and 
cerebral damage. About one million people are killed each year by malaria, the overwhelming 
majority of whom are children aged 5 years or younger. Ninety percent of malaria deaths 
occur in rural sub-Saharan Africa (WHO 2000b). Severe malaria in children under five years 
of age is also known to impact negatively on the development of children through 
neuropsychological impairment, poor growth and limitations in school achievements. 
However, the contributions of these to the malaria burden remain unclear (Holding and 
Kitsao Wekulo 2004). One of two reviews of studies reporting neuropsychological sequelae 
estimated that at least 1000 children are likely to suffer serious neurological deficits following 
cerebral malaria attacks each year (Mung'Ala Odera et al. 2004); the second review reported 
figures of 9000 to 19,000 (Murphy and Breman 2001). 
Malaria is both a cause and consequence of the poor socio-economic situation found in most 
of Africa south of the Sahara, which is one of the poorest regions of the world (RBM/WHO 
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1999). Malaria imposes suffering and poverty on individuals, households and governments of 
endemic countries (Bloland et al 1996; RBM/WHO 1999; Breman 2001; Breman et al. 2001). 
Income levels of malaria endemic countries are about a third less than those of countries 
without malaria. The estimated annual direct and indirect costs of malaria in Africa are more 
than 2000 million US dollars per year (Gallup and Sachs 2001; Sachs and Malaney 2002). 
Malaria is the cause of up to fifty percent of outpatient diagnoses and up to twenty percent of 
admissions at an estimated cost of $1.10 per outpatient visits in Malawi and $35 per 
admission in Kenya (RBM/WHO 1999). Families spend an average of 25% of their annual 
income on treatment, as well as paying costs for prevention and suffering loss of income. 
The costs of treating malaria for small farmers in Kenya and Nigeria have been estimated to 
be as high as 5% and 13% of total household expenditure respectively (RBM/WHO 1999). 
The cost of treating malaria accounts for about 3% of the average household income 
monthly and about half of curative health care costs incurred by households in Nigeria 
(Onwujekwe et al. 2000). Infection with malaria results in loss of productivity both in the 
formal and non-formal sectors of the economies of endemic countries (Bloland et al. 1996; 
Onwujekwe et al 2000; Breman et al 2001; Gallup and Sachs 2001; Sachs and Malaney 2002). 
Available evidence suggests that the adverse economic impact of malaria in Africa is greater 
than 1% of gross domestic product (GDP). For Kenya the overall production loss is 
estimated to be 2-6% of GDP, figures for Nigeria are 1- 5% (RBM/WHO 1999). 
Resistance to anti-malarial drugs is a significant public health problem for many malaria 
control programmes because parasites have demonstrated some level of resistance to almost 
every antimalarial drug currently available (Bloland and Ettling 1999; D'Alessandro and 
Buttiens 2001). Of particular worry is the rapid spread of resistance of P. falcrpanall to 
chloroquine and SP throughout sub-Saharan Africa. This has epidemiological, clinical and 
policy implications for malaria control in Africa. An example of the magnitude of the 
problem of falciparum resistance in eastern Africa is shown in Table 2.1. Increases in the 
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failure rates of CQ and SP monotherapies have necessitated reviews of national antimalarial 
drug policies across the East African sub region (EANMAT 2003). 
Table 2.1: - Clinical failure rates of chloroquine and SP in East Africa between 1998 and 2001. 
Estimated number 
Population of malaria cases 
Country (million) per year (million) Resistance to CQ (%) Resistance to SP (%) 
Burundi 6.5 2 50-90 13-63 
Kenya 30 8.2 66-87 
Rwanda 7.2 1.2 40 
Tanzania 32.8 8.6 28-72 
Uganda 21.1 5.3 10-80 
27-40 
16-45 
15-34 
11-60 
Adapted from "PRESS DOSSIER: Changing national malaria treatment protocols in Africa". February 2002, Nairobi, Kenya. 
Some studies also suggest that the spread of chloroquine resistance has led to a dramatic 
increase in malaria mortality in most epidemiological contexts in tropical Africa (Zucker et al.. 
1996; Trape 2001). 
Antimalarial drug resistance may contribute to the spread of malaria to new areas, to the re- 
emergence of malaria in areas where the disease had been eradicated and to the occurrence 
and severity of epidemics in some parts of the world (Bloland et al. 1993; Barat et al. 1998; 
Bloland et al. 1998; Bloland et al. 2000). 
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2.2 Malaria in Ghana 
2.2.1 Demographic and socioeconomic features 
Source: - hqp: //www. afro. who. int/malaria/countiy-profile/ghang. pdf 
Ghana is situated on the West Coast of Africa, and is bordered by Burkina Faso to the 
North, the Gulf of Guinea (537km) to the South, Togo to the East and Cöte d'Ivoire to the 
West. It covers an area of 238,538km2. It has a tropical climate with a temperature range 
from 18"C to 40"C. There are two main seasons - wet and dry. In the north, the wet season 
is short and lasts from May to August while the dry season increases in intensity with each 
month from September to April. In the south, the wet season, lasts from April to November, 
and is interrupted by a short dry spell in August. The annual rainfall, which ranges from 
700mm in the coastal area and the north to over 2000mm in the forest belt, delineates the 
country topographically into three ecological zones namely; the southern coastal plains, the 
rainforest middle belt and the savannah north. Ghana has a population of approximately 20 
million with an annual growth rate of 2.5% according to the 2000 Census, with an annual 
growth rate varying from region to region (GSS/NMIMR/ORC 2004). 
The budgetary allocation for the Ministry of Health was 699.4 billion cedis for 2002 
(approximately US$ 93.2 million). However, government's budgeted per capita expenditure 
on health for the year 2002 was US$6.90, as against the Commission on Macro Economics 
and Health's recommended US$34 per capita per year for health. The health budget is 
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currently between 8% and 12% of Central Government expenditure and ranks third after 
education and agriculture. These resources are inadequate and remain a major constraint to 
health services provision. The private, non-governmental, multilateral and bilateral agencies 
contribute greatly to the provision of health services, especially in the rural areas (MOH 1997; 
MOH 2002a; MOH 2002b). 
Ghana's health system is based on the Primary Health Care (PHC) approach in which 
functional District Health Management Teams (DHMT), as decentralized units, are 
responsible for the implementation and management of health policies and programmes. 
Each of the 110 districts in Ghana has a functional District Health Management Team 
(DHMT), but their capacities to efficiently plan, implement and monitor programmes vary 
considerably. The Ghana Health Service provides curative and preventive/promotive 
services at national, regional, district and sub district levels. The services are provided 
through a network of 172 hospitals, 1056 health centres/clinics and 361 maternity homes. 
These service delivery points include public, private for profit, private non-profit as well as 
the military, police and tertiary hospitals. 
2.2.2 Epidemiological pattent of malaria in Ghana 
Malaria and its outcomes in Ghana have been observed to vary with the prevailing season 
and the ecology of the country. Binka and others showed marked seasonal variations among 
children in northern Ghana, with parasite rates reaching 85% to 94% in the wet season 
(Binka et al. 1994). They found parasite rates to be highest in children aged 5-7 years, while 
parasite densities and rates of febrile illness were highest in those 6-11 months old and 
associated with low levels of haemoglobin. In southern Ghana, Afari and others showed that 
the crude parasite rates ranged from 19.6% to 33.5% in the dry season and from 33% to 44% 
in the wet season. Plasmodium falcipamm was found to be the predominant parasite species 
with high prevalence rates (up to 96%) in the rainy season compared to 80% in the dry 
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season. The prevalence of P. malariae was 20.4% and that of P. ovale 2.7% (Afari et al. 1992; 
Afari et al. 1993). Mixed infection rates were found more frequently in the dry season. 
In a community-based survey of 35 villages, Browne and others showed that the overall 
prevalence of malarial parasitaemia in subjects aged 2 years and above were 50.7% in the 
forest areas and very similar (49.7%) in the savannah areas of Ghana with P. falciparrrm being 
the most prevalent in all the ecological zones. P. malaride and P. ovale were found more 
commonly in the savannah and forest zones respectively. Asexual parasitaemia (of any 
species) was highest in the youngest age group of 2 to 9 years and then decreased with age. 
Mixed infections were observed in 24% and 30% of the parasitaemic subjects from the forest 
and savannah, respectively (Browne et al. 2000). 
In Ghana, it is estimated that malaria, measles, childhood pneumonia, sickle cell disease and 
severe malnutrition are the 5 most important causes of loss of healthy lives and between 
them account for 34% of healthy lives lost due to all diseases. Malaria is the first cause of 
morbidity accounting for about 40% of all OPD attendance (Binka et al. 1994). It is also the 
leading cause of mortality in children under five years, a significant cause of adult morbidity, 
and the leading cause of workdays lost due to illnesses. Malaria is the single most important 
infectious disease both in terms of admissions and as a cause of death in Ghana (Morrow 
1984; Asenso-Okyere and Dzator 1997). Malaria and anaemia accounted for 41% and 18% 
respectively of hospital deaths in the Kassena-Nankana district of northern Ghana in1996 
(Koram et al. 2000). Among pregnant women, malaria accounts for 13.8% of OPD 
attendance, 10.6% of admissions and 9.4% of deaths in Ghana (Marfo 2001). 
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2.2.3 Antimalarial drug resistance in Ghana 
Antimalarial drugs are not regulated in Ghana, resulting in prescribing patterns and 
preferences differing greatly between areas and population groups. Chooroquine, 
amodiaquine and SP are commonly sold over the counter in shops and pharmacies 
throughout Ghana (Agyepong et al. 2002; Abuaku et al. 2004). In 1986, soon after Hogerziel 
and others (Hogerzeil et al. 1985), reported full sensitivity of P. falciparum to chloroquine in an 
in vitro test, Neequaye reported a case of resistance to chloroquine in a sickle cell patient seen 
at the Korle-Bu Teaching Hospital who had been on routine chloroquine prophylaxis 
(Neequaye 1986). Subsequently, in the same hospital, Neequaye and Ofori-Adjei in 1988, 
separately documented P. falcipanim resistance in vivo at RI and RII levels in semi-immune 
children (Neequaye et al. 1988; Ofori-Adjei et al. 1988). Afari and others (Afari et al. 1992) 
conducted the first community studies to investigate the sensitivity of P. falcipanrm to 
chloroquine and other antimalarial drugs in Ghana in 1992 and 1993 in different ecological 
zones of Ghana. They observed resistance of P. falcipanrm to chloroquine to be greater in the 
coastal zones of Ghana compared to the forest zones. Afari and his team using the in vivo 
test, observed 91.1% sensitivity to chloroquine and 8.9% resistance response to chloroquine 
at RI (5.1%) and RII (3.8%) levels respectively. The distribution of resistance responses was 
about 17% to 23% in the coastal zone, 8.6% to 10% in the savannah zone and 3% to 6% in 
the forest zone. The RII responses occurred mainly in communities in the coastal zone. The 
investigators did not find any RIII resistance in any of the zones. The in vitro test showed 
resistance levels to be up to 60% and 4% in the coastal and forest zones respectively. 
Resistance to amodiaquine was recorded in 28.6% of the successful tests in the coastal zone. 
In 1994, Landgraf and others, in a peri-urban area of Accra that was one of the sites of the 
previous study by Afari and his team, found that resistance to chloroquine at the RI/RII level 
had risen to 45% among school children and, for the first time, reported 5 resistance 
responses at the RIII level (Landgraf et al. 1994). They also reported 37% resistance 
responses to SP at RII (84%) and RIII (16%) levels. 
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The Ghana Malaria Baseline Report of 2001 reported chloroquine efficacy tests carried out in 
six sentinel sites in Ghana (Marfo 2001). This showed that adequate clinical response to 
chloroquine ranged between 72% and 92%; early treatment failure ranged between 4% and 
18% whilst late treatment failure ranged between 4% and 14%. The highest clinical response 
of 92% was recorded in the capital, Accra, whilst the lowest was in Sunyani (tropical 
rainforest zone). Parasitological sensitivity ranged between 50% (Tarkwa) and 78% (Accra). 
RI resistance ranged between 14% and 28%, the highest occurred in Navrongo whilst the 
lowest was recorded in Accra. RII resistance was between 4% and 8% whilst RIII was 
between 4% and 14%; the highest was recorded at Yendi. Overall, sensitivity to chloroquine 
was only 58%, RI resistance was 20%, and RII was 7% whilst RIII resistance was 8%. 
The indirect cost (as computed by the amount of time spent in seeking care and taking care 
of the sick) per case of malaria is about 79% of the total cost of seeking treatment in Ghana. 
The estimated average cost of treating an episode of malaria including direct costs and the 
opportunity costs of travel and waiting time amounted to $8.67 or 3.7 days of male output or 
4.7 days of female output (Asenso-Okyere and Dzator 1997). 
2.2.4 Malaria control in Ghana 
Malaria control efforts have been fragmented, uncoordinated, and in some cases antagonistic, 
rather than synergistic (Marfo 2001). This is because the planning and execution of malarial 
control activities in Ghana, which started in the pre-independence era just before the Second 
World War, have been undertaken mainly by the Ministry of Health sometimes to the 
exclusion of other stakeholders. Furthermore, various groups and organizations have 
consequently been working independently of each other on issues relevant to malaria control. 
With this background the Ministry of Health fully embraced the principles of RBM and has, 
since 1998, taken steps to follow the principles of RBM within the policy framework of 
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Ghana's Vision 2020 development plan. Aikins and Marfo in 1999 independently traced the 
historical developments in the control of malaria in Ghana (Aikins 1999; Marfo 1999). 
2.2.4.1 Historical review of malaria control in Ghana 
1920s 
Malaria control activities in Ghana were initially restricted to a few urban areas covering 
about 20% of the country. These activities were aimed at malaria eradication and involved 
improvement of sanitation, institution of prophylactic measures and wide use of insecticides. 
There was construction of drains in urban areas aimed at eliminating stagnant waters and 
breeding sites of the mosquitoes. The World Economic Depression in 1930 caused the 
administration of quinine, proguanil and the twice a week pyrimethamine to schoolchildren 
in the country to be stopped. 
1930s 
Quinine was sold in post offices throughout the country with the intent of improving access 
to prophylactic care for the population in rural areas who had difficulty in accessing formal 
health services. 
1945 to late 1950s 
A malaria control unit of the Ministry of Health was set up in the Volta region in 1957 in 
collaboration with the WHO to oversee the malaria eradication programme. The focus of the 
eradication programme was environmental control to eliminate breeding sites. Larviciding 
agents such as kerosene and DDT and insecticides were introduced for domestic use. 
1959 -1963 
A chemoprophylactic strategy of using chloroquine-treated salt through the Pinotti pilot 
project was adopted in some communities in northern Ghana and other parts of the country. 
This was abandoned because of the high operational cost involved. 
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1961-1968 
The Ministry of Health with assistance from the WHO formed the National Malaria Service, 
headquartered at Ho in the Volta Region. This programme involved the training of many 
technicians and microscopists, which facilitated the conduction of malariometric and 
entomological research work on malaria in Ghana. Between 1964 and 1966 aerial spraying of 
mosquitoes was started together with treatment, on a large-scale, of permanent water bodies 
with diesel oil, DDT, dieldren or gamexane in Accra in addition to control activities in other 
parts of the country. 
1968 
Most of the above strategies did not achieve the desired impact because each phase relied on 
a single tool, rendering it ineffective. For example due to excessive use, resistance developed 
to DDT in some areas. Operational difficulties were experienced in maintaining these 
activities over extended periods. These problems were compounded by the diminishing 
sources of funding for the initiatives. By the end of 1967, it was realised that the malaria 
eradication strategies were not sustainable and so, in 1968, on the advice of WHO, malaria 
eradication campaigns were terminated in Ghana. 
1970s and 1980s 
Following the end of the malaria eradication campaign, malaria control received little support 
for two decades as there was a global perception that disease-specific approaches were 
ineffective. 
1990s 
A National Malaria Control Programme (NMCP) was formed in 1992, following the launch 
of the Global Malaria Control Strategy in 1992. The NMCP drew up a National Malaria 
Action Plan for the period 1993 to 1997 "to reduce the incidence of malaria to such low 
levels that it would cease to be a public health hazard in Ghana". This ambitious objective 
was set within the framework of the Global Malaria Control Strategy to prevent mortality, 
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reduce morbidity and the social and economic loss due to malaria. The objective was to be 
achieved through active case management, chemoprophylaxis and personal protective 
measures such as screening of houses and use of bed nets. Health education programmes of 
the Ministry of Health on television and radio supported these measures. However, due to a 
"top-to-bottom" approach to implementation, lack of financial and human resources and 
inadequate laboratory services this plan was not fully implemented. 
In 1998, the Medium Term Strategic Plan for Malaria Control was drawn up to cover the 
period 1998 to 2001 with a general objective to "strengthen the development and 
implementation of sustainable malaria control in Ghana". The plan was drawn up in 
response to an objective of the Ministry of Health's Medium Term Health Strategic Plan 
(1998 - 2001) to reduce malaria case fatality rate from 24 to 8 in 2001 and increase bed net 
use from 24% to 80% by 2001 (MOH 1995). 
In 1999, as part of the Medium Term Strategic Plan for malaria control a National Malaria 
Control Technical Committee of 12 experts was inaugurated to: - 
i. Review the plans, preparation, and pace for the implementation of malaria control 
activities in the country. 
ii. Advise the NMCP on collaboration with other interested organisations. 
iii. Advise on any other developments in the implementation of the National Malaria 
Action Plan. 
In 1999, Ghana signed up to the Roll Back Malaria initiative. The Ministry of Health 
accepted the principles of the RBM initiative as being in consonance with the goals of the 
ministry's Medium Term Health Strategic Plan (1998 - 2001) and committed itself to its 
implementation. The goals of the medium term health strategy were: - 
i. To provide universal access to a basic package of health services. 
ii. To improve the quality and efficiency of the health services. 
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iii. To foster linkages with other sectors to provide health care to the population. 
Overall the Ghana RBM initiative emphasizes strengthening health services and making 
effective prevention and treatment strategies more widely available. 
2.2.4.2 National Malaria Control Programme 
The National Malaria Control Programme (NMCP) was set up in 1992 under the Parasitic 
Diseases Unit of the Disease Control Unit of the Ministry of Health and charged with 
planning, monitoring and evaluation of malaria control activities at the national level (Aikins 
1999). 
In response to the RBM initiative, the NMCP is currently implementing a malaria control 
strategy that involves multi and inter-sectoral partners working together on an agreed plan 
(Strategic Plan to Roll Back Malaria) to reduce death and illness due to malaria by 50% by the 
year 2010. This plan was developed following a long consultative process initiated by the 
NMCP in 2000 to sensitise and build consensus on malaria control among various 
stakeholders at all levels of the health services delivery system. 
The goal of the RBM initiative in Ghana is to reduce malaria specific morbidity and mortality 
by 50% by the year 2010 through the 
i. Promotion of multiple malaria prevention strategies. 
H. Improvement of malaria case management at all levels (from household to health 
facility). 
iii. Commissioning of focused and evidence-based researches into malaria. 
iv. Improvement of partnership between all stakeholders in health at all levels including 
the community. 
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2.2.4.3 National antimalarial drug policy 
Until April 2005, chloroquine was the first line drug of choice in Ghana for treating 
uncomplicated malaria at all levels of the health system with SP or quinine as second line 
drugs. Chloroquine was also used for chemoprophylaxis in pregnant women. The policy 
recommended a full therapeutic dose of chloroquine for the pregnant woman on first contact 
and 300mg weekly throughout pregnancy at the antenatal clinic and then for 6 weeks 
postpartum. The current antimalarial drug policy recommends amodiaquine plus artesunate 
combination for uncomplicated malaria and quinine is the recommended drug of choice for 
managing severe malaria. 
Current national malaria control policy in pregnancy in Ghana 
Pregnant women with malaria in their second or third trimester are to be treated with quinine 
or amodiaquine plus artesunate. The treatment of choice for those in the first trimester is 
quinine. The Ministry of Health has also implemented the policy of intermittent preventive 
treatment of pregnant women using SP (SP-IPT) in Ghana. It is to be administered between 
16 to 36 weeks of gestation with at least a month's interval between doses. The policy change 
was effected early this year in 20 selected districts while the following activities (Banda et al.. 
2004) to manage the policy change and implementation are currently going on in the country 
in order to scale up national implementation of the policy: - 
i. Orientation workshops for health workers on the possible adverse affects of SP. 
ü. Printing and distribution of Adverse Drug Reaction (ADR) reporting forms to clinics 
and hospitals for recording ADRs when they occur. 
iii. Establishment of ADR management mechanisms whereby ADRs will be managed and 
the cost absorbed by an exemption package for pregnant women. 
iv. Printing of new ANC cards, registers and posters to facilitate the education of the 
public, especially pregnant women on the SP-IPT implementation. 
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v. Negotiations with the Ministry of Finance and the donor community for SP to be 
purchased and made available to pregnant women free. 
Some district hospitals in Ghana apart from the selected 20 including the St. Theresa's 
hospital have taken the initiative to implement the policy. 
National mother-to-child HIV transmission control policy 
There is no specific programme currently in Ghana to combat mother-to-child transmission 
of HIV other than the general HIV education that a mother-to-be, or any other person, can 
get from the health volunteer in their community. However, HIV testing and counselling is 
found at most district and regional hospitals including St. Theresa's. 
The Ghana AIDS Commission has currently made antiretroviral therapy available in only 3 
regions but plans to make it available at all regional hospitals, at an affordable rate, by 
December of this year. 
At St. Theresa's Hospital, the Hope Association was formed in August 2000 with the help of 
two US Peace Corps Volunteers. It is a support group for people living with HIV/AIDS 
(PLWHAS) in Nkoranza District. Its aim is to bring together those testing HIV positive, as 
well as AIDS orphans and other vulnerable children to help them live positively. Its 
membership is made up of trained counsellors from the hospital and a group of volunteers 
with HIV/AIDS (PLWHAS). 
The association has been conducting workshops for people living with HIV/AIDS both on 
nutrition and self-care, and for community volunteers on HIV transmission information, 
prevention, and home based care for PLWHAS. Over the years, the association has trained 
many community volunteers who go from house to house to educate other community 
members. It has set up a volunteer counselling and testing unit in the hospital. At the unit, a 
trained counsellor does the primary counselling and another member usually a PLWHAS, is 
responsible for moving laboratory documents back and forth to cut down on breaches of 
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confidentiality. The association receives supplementary funding and support from the Ghana 
AIDS Relief Fund (GARFUND) and the Catholic Relief Services (CRS) and, with this 
support, it is possible to supply monthly doses of vitamins and ration of food supplements to 
members with HIV/AIDS. 
2.3 Malaria in pregnancy 
2.3.1 Epidemiology 
Malaria in pregnancy is a major public health concern in endemic countries where it is 
estimated that more than one billion women are at risk of malaria and liable to suffer from its 
consequences when pregnant (Menendez 1995). The pattern of malaria in pregnancy depends 
on a woman's pre-existing immunity, which is influenced by the local malaria transmission 
profile. It is also influenced by parity, gravidity, gestational age, age and HIV/AIDS (WHO 
2004). P. falciparzim and P. vivax are the most important causative agents in pregnant women 
living in malaria transmission areas with P. falciparrrm being more frequently associated with 
severe morbidity (Singh et al. 1996; Singh et al. 2001). 
In high transmission areas, the incidence of falciparum malaria infection is higher in pregnant 
women than in the non-pregnant population (Brabin 1985; Singh el a!. 1999). The risk of 
malaria in pregnancy is higher in young mothers of low gravidity and parity (Steketee el a!. 
1988; Brabin 1991; Brabin et a!. 1999; Singh et a!. 1999; Rogerson et a!. 2000; Zhou et al. 2002). 
Zhou and others showed that, in Cameroon, young primigravidae are 2 to 3 times more at 
risk of malaria than multigravidae and about 3 times more at risk than older women (Zhou et 
a!. 2002). Similarly, Verhoeff and others showed in Malawi that the prevalence of P. falcipanrm 
infection at a first antenatal visit was about three times higher in primigravidae than in 
multigravidae (P < 0.001) (Verhoeff et a!. 1999). Saute and others in Mozambique, found 
younger age, lower parity and the second trimester of pregnancy to be associated with risk of 
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peripheral parasitaemia in pregnancy in a univariate analysis but only younger age remained 
significant when other factors were adjusted for (Saute et al. 2002). 
HIV/AIDS and malaria in pregnancy interact adversely to increase the risk of severe 
maternal anaemia and low birth weight; treatments may not be effective and more doses may 
be required for SP-IPT (Steketee et al. 1996; Brabin 1997; Chandramohan and Greenwood 
1998; Parise et al. 1998; Verhoeff et al. 1999; ter Kuile et al. 2004). 
2.3.2 Pathogenesis 
The pathogenic mechanisms of malaria in pregnancy are illustrated in Figure 2.1 (WHO 
2004). The complications of malaria in pregnancy result mainly from placenta parasitisation, 
maternal anaemia and the metabolic changes due to the infection. Pregnancy is associated 
with immunosupression due to reduced cell-mediated immunity and increased systemic levels 
of cortisol which make pregnant women more susceptible to infection. 
Figure 2.1: - Pathogenic mechanisms of malaria in pregnancy. 
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With respect to malaria the loss of previously acquired immunity has been noticed to be 
more pronounced in primigravidae than in multigravidae. The mechanisms are not well 
understood but attempts have been made to explain the phenomenon as follows. 
McGregor first postulated that the placenta is the preferred site for P. falcipanim parasite 
sequestration and development which allows a parity specific immunity to be developed in 
the placenta. This immunity, however, does not protect first pregnancies but is retained in 
the uterus and gets stronger with subsequent pregnancies thus protecting them from placenta 
parasitaemia (McGregor 1984). Duffy and others showed that parasite sequestration in the 
placenta is brought about by distinct site-specific parasite variants or serotypes, which are 
able to adhere to glycosaminoglycans, for example chondroitin sulfate A (CSA) and 
hyaluronic acid (HA) that he the placental blood spaces. The adhesion process is mediated 
by the parasite protein PfEMP1, a variant protein, which is expressed on the surface of 
malaria-infected red blood cells. This leads to the accumulation of parasites and macrophages 
in the intervillous spaces which interfere with oxygen and nutrient supply to the foetus 
(Matteelli et al. 1997; Fried and Duffy 1998; Duffy and Fried 1999; O'Neil-Dunne et al. 2001; 
Duffy 2003). 
Local immunity in the placenta is also thought to be suppressed by increased levels of 
placental oestrogen, which peak in the second trimester, and fall after that. This might explain 
the increased prevalence of malaria in the second trimester (\VVatkinson and Rushton 1983; 
Watkinson et al. 1985). The high circulating cortisol levels in pregnancy is thought to 
contribute to the increased susceptibility of pregnant women to malaria. Cortisol levels are 
highest in the primigravidae which may explain the increased risk and prevalence of malaria 
in primigravidaes (Vleugels et al. 1987; Vleugels et al. 1989; O'Neil-Dunne et al. 2001; Bouyou- 
Akotet et al. 2004). 
44 
Maternal anaemia is thought to be due to haemolysis and phagocytosis of uninfected 
erythrocytes and the increased autoimmune clearance of infected erythrocytes by the spleen 
(Fleming 1989; Mutabing-wa 1994; Shulman et al. 1996). 
The increased demands of the hyper catabolic state of malaria, the presence of a large 
parasite mass; the hypoglycaemic response to starvation and the increased response of 
pancreatic islets to secretory stimuli lead to hyperinsulinaemia and hypoglycaemia in 
pregnancy (Davis et al. 1994). The paroxysms of fever, anaemia, hypoglycaemia and placental 
insufficiency all contribute to the undesirable foetal outcomes of malaria-infected pregnancies 
which include abortion, still birth and low birth weight. 
2.3.3 Clinical features 
P. falciparrrm malaria in pregnancy is associated with deleterious consequences to the mother 
and foetus. Maternal anaemia, fever, hypoglycaemia, maternal and foetal death, abortion, still 
birth, intrauterine growth retardation and low birth weight are known complications of 
falciparum malaria (WHO 1998a). The importance of any of these depends on the local 
transmission profile in the pregnant woman's area of residence. In areas with stable and 
intense transmission, pregnant women generally remain asymptomatic despite sequestration 
of parasitized red blood cells in the placental microcirculation. This results in maternal 
anaemia and low birth weight, particularly in the primigravidae (Brabin 1985; Verhoeff et al. 
1999; Shulman et al. 2001; Steketee et al. 2001). More than 80% of severe pregnancy anaemia 
(Hb < 7g/dl) is associated with malaria parasitaemia (Fleming 1989; Jackson et al 1991; 
Ndyomugyenyi and Magnussen 1999) and 60% of cases of moderate anaemia in pregnancy 
(Hb =7- llg/dl) are also associated with malaria in pregnancy (Fleming et al. 1986). 
Shulman and others showed that in Kenya, falciparum infection in primigravidae was 
strongly associated with moderate and severe anaemia. Severe anaemia was found to be more 
than twice as common in women with peripheral parasitaemia than in those who were not 
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parasitaemic, and parasitaemia was associated with a 2.2g/dl decrease in mean haemoglobin 
level (Shulman et al. 1996; Shulman et a!. 2001). In their review, Guyatt et al (Guyatt and 
Snow 2001) showed that about half a million pregnant women develop severe anaemia as a 
result of infection with malaria in sub-Saharan Africa each year. It has been shown that the 
risk of low birth weight and maternal anaemia is three times higher in malarious zones 
compared to a non-malarious zones (Brabin and Piper 1997). Brabin and Piper (Brabin and 
Piper 1997) estimated that up to 40% of low birth weight babies born in malarious areas are 
attributable to malaria and less than 10% attributable to severe anaemia (Hb < 7.0 g/d). 
Guyatt and other estimate that malaria is responsible for 19% of low birth weight incidence 
in malaria endemic areas (Guyatt and Snow 2004). 
In areas where the transmission is low and unstable, malaria in pregnancy is more 
symptomatic and acute affecting all parities equally. Maternal deaths and abortion may occur 
(Brabin 1985; Shulman et al. 2001; Adam et al. 2005) 
2.3.4 Diagnosis of malaria in pregnaiz y 
Antenatal diagnosis and treatment of malaria is one of the control measures recommended 
for pregnant women (WHO 2004). However, the diagnosis of malaria in pregnancy is a 
challenge in stable transmission areas. This is because antenatal malaria infection is often 
asymptomatic and parasitized red blood cells sequestrated in the placental microcirculation 
may not be detectable in peripheral blood. Anaemia, used as an indicator of malaria in 
pregnancy, may become recognisable only when it is severe (Fleming 1989; Brabin 1991; 
Shulman et al. 1996; Verhoeff et al. 1999; Shulman et al. 2001; Shulman et a!. 2002). Some 
researchers have retrospectively diagnosed malaria in pregnancy from placenta blood or 
biopsy (Rasheed et al. 1992; Bulmer et al. 1993; Bulmer et al. 1993; Rasheed et al. 1993) but this 
is useful only for research studies. 
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In recent times malaria rapid diagnostic tests (RDTs) based on the immunochromatographic 
detection of specific parasite antigens in infected blood, have been developed. The RDTs in 
use currently detect either histidine-rich protein-2 (HRP-2) or plasmodium lactate 
dehydrogenase enzyme (pLDH) (WHO 1999b). Several studies evaluating either the HRP-2 
based RDTs (Kilian et al. 1997; Tjitra et al. 1999; Singh and Valecha 2000; Tarimo et al. 2001; 
Forney et al. 2003) or pLDH based RDTs (Cooke et al. 1999; Piper et al. 1999; Iqbal et al. 
2003; Palmer et al. 2003) have been published. However, only few studies (Leke et al. 1999; 
Mankhambo et al. 2002; Singer et al. 2004) have reported their use to diagnosis malaria at 
delivery and/or the presence of placental malaria. The OptiMAL® antigen test used in the 
present study utilises a dipstick coated with monoclonal antibodies against parasite lactate 
dehydrogenase. It is an intracellular metabolic enzyme and has isoforms which help in 
parasite species differentiation. The pLDH is produced only by live plasmodium parasites 
and so the OptiMAL® dipstick has the ability to differentiate live parasites from dead ones. 
They can distinguish P. falciparum from the non falcipantm species, but cannot distinguish 
between P. tivax, P. ovale and P. malariae. Since it detects circulating antigens, the OptiMAL® 
test may detect placental malaria that may be undetectable by microscopic examination of a 
peripheral blood smear (WHO 1999b). 
On the contrary, diagnosis of malaria in pregnancy in low transmission areas is easier because 
the infection is often symptomatic and parasitaemia is detectable in peripheral blood. 
2.3.5 Malaria control in pregnancy 
Malaria in pregnancy is considered an emergency requiring prompt and effective treatment so 
clinical and parasitological failures are not acceptable (Shulman December, 2001). The 
essence of treating malaria in pregnancy in endemic regions is not only to achieve 
symptomatic relief but also to achieve full peripheral and placental parasite clearance so as to 
avert and/or control maternal anaemia and placental parasite sequestration, both of which 
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have deleterious effects on the foetus (Shulman December, 2001). However, the wide spread 
existence of chloroquine and SP resistance on the African continent makes this a difficult 
task (Schapira 1990). Treatment options now available for the treatment of malaria in 
pregnancy are limited due to safety concerns, affordability and supply. Because of these 
limitations, combinations of different control measures have been recommended by the 
WHO to reduce maternal infection (Shulman 1999; Shulman et al. 1999; Shulman et a!. 2001; 
WHO 2004; Shulman December, 2001). These include, the early diagnosis and treatment of 
malaria, antimalarial intermittent preventive treatment during pregnancy, antimalarial 
chemoprophylaxis and protection from exposure to the bites of the vector (especially the use 
of insecticide treated materials including bed nets) (Garner and Brabin 1994; Shulman 1999; 
Shulman et al. 1999; Garner and Gulmezoglu 2000; Shulman et al. 2001). 
2.3.5.1 Antimalarial chemoprophylaxis 
Routine chemoprophylaxis using locally effective antimalarials has been shown to reduce 
antenatal parasitaemia, prevent the prevalence of severe maternal anaemia and the associated 
adverse pregnancy outcomes (Spencer et a!. 1987; Ogunwande 1991; Cot et al. 1992; Nyirjesy 
et al. 1993; Cot et al. 1995). The beneficial effects of chemoprophylaxis on primigravidae 
appear to be more marked than in multigravidae (Greenwood et al. 1994; Greenwood et al. 
1994; Cot et al. 1995). However, widespread low compliance, low efficacy of chloroquine, 
lack of awareness and adverse drug effects have caused problems for the widespread 
implementation of antimalarial chemoprophylaxis during pregnancy. 
For example, a recent survey of 422 pregnant women in 5 communities in Ghana by the 
National Malarial Control Programme indicated that less than half of pregnant women took 
antimalarial chemoprophylaxis during pregnancy and only 11.6% of them took it 
appropriately (Marfo 2001). The rationale for weekly chloroquine prophylaxis has become 
weak as a result of wide spread resistance to this drug, thus reducing its efficacy. Steketee and 
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his colleagues (Steketee el al. 1996) showed the reduced efficacy of chloroquine on placental 
parasitaemia clearance compared to mefloquine in Malawi. Apart from parasite resistance, the 
adverse effects of chloroquine, such as pruritus, do not encourage prophylaxis with this drug. 
Also studies in Kenya and Nigeria have not found the use of pyrimethamine or 
chlorproguanil as single drugs for malaria prophylaxis in pregnancy to be effective because of 
the high prevalence of resistance (Nguyendinh el al. 1982; Spencer et al. 1986; Watkins et al. 
1987; Nahlen et al. 1989). 
2.3.5.2 Intermittent Preventive Treatment (IPT) 
The WHO has recommended the use of intermittent preventive treatment with SP as one of 
the control measures for malaria in pregnancy in areas with stable malaria transmission and 
increasingly many countries in these regions are changing their national malaria control 
policies accordingly (WHO 2005). Intermittent preventive treatment with SP decreases 
parasitaemia and severe anaemia and improves birth weight in areas where P. falciparum is 
sensitive to this drug (Shulman et al. 1999). It reduced by half the incidence of low birth 
weight in primigravid and multigravid women who had been given two doses compared to 
that seen in subjects who had been given one. However, this effect of SP was greater in 
primigravid women (Verhoeff et al. 1998). In Malawi, Rogerson and others (Rogerson et al. 
2000) showed that in pregnant women who received SP-IPT the prevalence of placenta 
malaria was decreased by a third and the prevalence of low birth weight decreased by a half 
compared to the prevalences in pregnant women who did not receive SP-IPT. In this 
population however, coverage with SP-IPT was only about 30%. The effectiveness of the 
SP-IPT policy therefore depends on P. falcipanml sensitivity to SP and local antenatal 
coverage. The increasing resistance to SP and low local antenatal coverage may limit the 
effectiveness of SP-IPT. Holtz and others showed that in Blantyre, Malawi where utilization 
of antenatal services is near 100%, SP-IPT coverage is under 40% (Holtz et al. 2004). 
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2.3.5.3 Insecticide Impregnated Bed Nets (ITNs) 
Although, the use of ITNs as a vector control measure in pregnancy is recommended (WHO 
2004), results of assessments of the impact of impregnated bed nets are not consistent 
because of the complexity of factors that determine acquisition and continued use of the 
nets. Browne in Ghana (Browne et al. 2001) and Shulman in Kenya (Shulman et al. 1998) did 
not find any effect on malaria and anaemia in pregnancy following the use of insecticide 
impregnated bed nets. Dolan in 1993 however found a reduction in maternal anaemia with 
the use of ITNs in the mesoendemic area of the Thai-Burmese border (Dolan el al. 1993) and 
similarly D'Alessandro in The Gambia suggested that a reduction in percentage of premature 
babies might be due to the use of ITNs (D'Alessandro el al. 1996). Also results from a large, 
cluster randomised control trial in the Kisumu area of Kenya showed that the use of ITNs 
significantly reduced the prevalence of parasitaemia in pregnancy and the incidence of both 
maternal anaemia and low birth weight in the study population. The study showed that the 
use of ITNs had a 25% protective efficacy against peripheral and placenta parasitaemia in 
pregnant women. There was a 0.6g/dl increase in haemoglobin concentration at delivery for 
pregnant women who used ITNs and a significant reduction in the proportion of severe 
anaemia at delivery. Babies born to women who used ITNs weighed about 80 grams more at 
birth compared to the weight of babies born to mothers in the control groups. These 
beneficial impacts of ITNs were, however, significant mainly in women with 4 or less 
gravidities (ter Kuile et al. 2003). 
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2.4 Antimalarial drug use in pregnancy 
Chloroquine and SP appear to be the safest, most readily available and affordable drugs for 
treating or preventing uncomplicated malaria in pregnancy in Africa south of the Sahara. 
2.4.1 Chlomguine (CQ) 
Chloroquine is a 4-aminoquinoline that has a good schizonticidal activity against all 
chloroquine-sensitive plasmodial infections. It is also gametocytocidal against P. vivax, P. 
malariae and P. ovale as well as active against immature gametocytes (stages1-3) of P. falciparum 
(WHO 2000c; Winstanley et al. 2004). Until P. falcipanrm resistance eroded confidence in its 
use (White 1998), chloroquine was the first-line drug of choice for treating uncomplicated 
malaria in most malaria endemic countries including Ghana. Pruritus is the most frequent 
adverse effect reported (Sowunmi et al. 1998; Taylor and Wilhite 2004) for chloroquine which 
may be severe enough to compromise compliance in some patients. Other adverse events 
reported include transient headaches, nausea, vomiting, gastrointestinal symptoms (Steketee 
el al. 1987; Steketee el al. 1996). Attacks of acute porphyria and psoriasis may be precipitated 
in susceptible individuals. Very rare adverse events include leucopoenia, bleaching of the hair 
and, extremely rare adverse events include aplastic blood and neurological disorders, such as 
polyneurids, ototoxicity, seizures and neuromyopathy (Steffen et al. 1990). Lange and others 
did not find any evidence of retinopathy in long term chloroquine users (Lange el al 1994). 
Its use in pregnancy is considered safe (Wolfe and Cordero 1985; Parke 1988; Luzzi and Peto 
1993; Phillips-Howard and Wood 1996) with no increases in abortions, still births and 
congenital abnormality rates when administered at normal therapeutic doses. 
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2.4.2 Amodiaquine (Apj 
Amodiaquine is a 4-aminoquinoline antimalarial drug similar in structure and activity to 
chloroquine with antipyretic and anti-inflammatory properties (WHO 2000c; Winstanley et al. 
2004). 
Olliaro and others, in a review of published and unpublished studies conducted in Africa on 
the treatment of uncomplicated falciparum malaria, showed that amodiaquine is significantly 
more effective than chloroquinc in clearing parasites, with a tendency for faster clinical 
recovery (Olliaro et al. 1996). Other reviews and studies (Muller et al. 1996; Mengesha and 
Makonnen 1999) including those of Brasseur and colleagues (Brasseur et al. 1999) in West 
and Central Africa respectively support this view. Compared to SP, amodiaquine cleared 
fever faster. With respect to parasite clearance, the two drugs were equally effective by day 7 
(Brasseur et al. 1999). 
After oral administration, amodiaquine is rapidly and extensively metabolised to 
desethylamodiaquine, the principal antimalarial entity (Winstanley et al. 2004) and may not be 
detectable after eight hours (Winstanley et al. 1990). Desethylamodiaquine is concentrated in 
erythrocytes and is slowly eliminated with a terminal elimination half-life of up to 18 days. 
The most common adverse reactions to the therapeutic doses of amodiaquine used for 
malaria treatment include nausea, vomiting, abdominal pain, diarrhoea and itching (Brasseur 
et al. 1995; Sowunmi et al 2001) .A 
less common effect is bradycardia (Ngouesse et al. 2001). 
Substantial attention has been focused on the possibility of serious liver toxicity in patients 
taking amodiaquine as chemoprophylaxis. Fortunately, such toxicity appears to be 
uncommon, but national malaria programmes do not recommend amodiaquine prophylaxis. 
It is not clear, according to the current literature, whether serious hepatotoxicity associated 
with amodiaquine is mediated by exacerbation of underlying liver disease or by direct actions 
of amodiaquine on the liver. When used for chemoprophylaxis, amodiaquine caused toxic 
hepatitis and fatal agranulocytosis (Hatton et al. 1986; Neftel et al. 1986). The incidence of 
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serious reactions in UK travellers using amodiaquine for prophylaxis was 1 in 1 700. Blood 
disorders occurred in 1 in 2 200 travellers and serious hepatic disorders in 1 in 15 650. Fatal 
events occurred in 1 in 15 500 travellers (Phillips-Howard and West 1990). The toxicity of 
amodiaquine seems to be related to the immunogenic properties of the quinoneimine 
produced by auto-oxidation of the parent drug (Winstanley 1990). Amodiaquine is therefore 
contraindicated in persons with known hypersensitivity to amodiaquine, in persons with 
hepatic disorders, and for chemoprophylaxis (Keystone 1990; Luzzi and Peto 1993). Jaeger et 
al reported that large doses of amodiaquine produce syncope, spasticity, convulsions and 
involuntary movements (Jaeger 1987). However, amodiaquine has been used extensively in 
Africa, especially in francophone Africa, for the treatment of malaria with few reports of 
serious adverse effects. Amodiaquine at the recommended doses does not have any 
teratogenic effects and there is no other evidence to contraindicate the use of amodiaquine 
for treatment of malaria during pregnancy (WHO 2000c). 
Amodiaquine is administered over 3 days at total doses ranging between 25 mg and 35 mg of 
amodiaquine base per kg in dosage regimens similar to those for chloroquine. A regimen of 
10 mg of amodiaquine base per day for 3 days (total dose 30 mg/kg) is recommended as it 
has the advantage of simplicity (WHO 2000c). 
2.4.3 Sur phadoxine pyrimethamine (SP) 
SP is an antifolate combination drug, which acts by synergism of its two components - 
pyrimethamine and sulphadoxine against the parasite-specific enzymes, dihydropteroate 
synthetase and dihydrofolate reductase (Winstanley et al. 2004). It is an effective blood 
schizonticide against P. falcipanum but less effective against other species of plasmodium. It 
does not show cross-resistance with the 4-aminoquinolines, mefloquine, quinine, halofantrine 
or the artemisinin derivatives (WHO 2000c). It has a long half-life, hence its formulation as a 
single dose drug, which is why compliance with it is high. SP has been used successfully in 
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areas with high P. fakzpanim resistance to chloroquine and during malaria epidemics. 
However, the long half-life of SP provides a potent selective pressure for parasite resistance 
in areas of high transmission. 
There is a theoretical risk of jaundice among premature babies born to mothers given SP late 
in the third trimester. However, there is no evidence of increased risk of kernicterus in the 
newborn, (Anonymous 1983; Phillips-Howard and Wood 1996; Shulman et al. 1999) 
following exposure to antimalarial drugs containing sulphonamides or sulphones prior to 
delivery. The use of SP is also not associated with increased risk of adverse neonatal 
outcomes (Phillips-Howard and Wood 1996; Parise et al. 1998; Verhoeff et al. 1998). 
However, its use in the first trimester may be associated with birth defects (Hernandez-Diaz 
et al. 2000). 
Therapeutic doses of SP for malaria are generally well tolerated. The most serious adverse 
reactions are associated with hypersensitivity to the sulphadoxine component, involving the 
skin and mucous membranes, usually occurring after repeated administration (Miller et al. 
1986). Serious cutaneous reactions following single-dose treatment with SP are rare. 
2.4.4 Amodiaquine/sn phadoxine pyrimethamine (A, Q/SP) Combination 
The simultaneous use of two or more drugs as a chemotherapeutic strategy is already being 
employed in the treatment of leprosy, tuberculosis, cancer, and HIV/AIDS. The objective is 
to improve treatment outcomes and slow down the development of resistance to the 
individual drugs in the combination. Its application in malaria treatment involves the 
simultaneous administration of two or more blood schizonticidal antimalarial drugs either co- 
formulated or co-administered. The drugs should have a synergistic and not antagonistic anti- 
parasite effect when used together, should not interfere with each other's metabolism, should 
have a similar half-life and should not have any new adverse effects (WHO 2001b). Although 
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synergism, is desirable between drugs in combination we are not aware of any 
pharmacokinetic studies of AQ+SP combination therapy in pregnant women or in children. 
However, by combining a shorter acting AQ with a slower acting SP it seems that a fast 
reduction in the parasite burden by AQ occurs which allows SP to act against the remaining 
diminished parasite burden. Hence the effect of AQ+SP on parasite burden may be additive. 
Antimalarial drug combinations have been used mostly in South-East Asia where multi-drug 
resistance is prevalent to improve treatment efficacy and to slow down the development of 
resistance to the component drugs (McGready et al. 1998; McGready et al. 2000; Nosten et al. 
2000; van Vugt et al. 2000; McGready et al. 2001; McGready et al. 2003; McGready et al. 2005). 
In West Africa, a change to AQ+SP is considered a possible option for combination therapy. 
AQ and SP have reasonably similar pharmacokinetic profiles, with varied modes of action on 
different biochemical targets in the parasite and are therefore technically suitable candidates 
for combination therapy. We are not aware of any studies reporting the use of AQ+SP 
combination in pregnant women either for treatment or for chemoprophylaxis. However, its 
use in children has been found to be safe and more efficacious compared to either AQ or SP 
alone (McIntosh and Greenwood 1998). A study in Uganda, reported a 100% adequate 
clinical response and a 99% parasitological success in children who received the AQ+SP 
combination compared to those who received SP alone or SP+CQ combination (Gasasira et 
al. 2003). In a multi-centre trial in Uganda, AQ+SP was found to be superior to CQ+SP 
combination in clearing parasitaemia and resolving symptoms in children (Bakyaita et al. 
2005). Another study in Uganda also showed AQ+SP combination to be superior to AQ or 
SP alone in achieving adequate clinical and parasitological response following treatment 
uncomplicated malaria in children (Staedke et al. 2001). All the studies in Uganda showed the 
AQ+SP combination to be associated with more frequently with minor adverse effects. In 
Tanzanian children, the AQ+SP combination was found to be safe and had greater clinical 
and parasitological efficacy compared to AQ or SP alone (Schellenberg et al. 2002). 
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2.4.5 Mefloquine 
Mefloquine is a 4-quinoline methanol chemically related to quinine. It is a potent long-acting 
blood schizonticide with a long elimination half-life and consequently gives long-lived sub 
therapeutic concentrations in the blood. It is highly active against P. falciparum, P. vivax and, P. 
malariae and most probably P. ovale. It is not gametocytocidal and is not active against the 
hepatic stages of malaria parasites. Mefloquine was used mainly in South East Asia to treat 
malaria resistant to both chloroquine and SP. However, since the late 1980s, resistance of P. 
falciparum to mefloquine has increased to more than 50% in 28 days after treatment with the 
drug. Mefloquine can be used both for therapy and chemoprophylaxis. Mefloquine is 
recommended as a prophylactic drug for travellers to areas with significant risk of 
chloroquine-resistant falciparum malaria. 
The main disadvantage of mefloquine relates to the numerous adverse effects associated with 
its use either for treatment or for prophylaxis. These include dizziness, mild to moderate 
nausea, vomiting, diarrhoea and abdominal pain. In addition its use is associated with 
neuropsychiatric adverse reactions such as affective disorders, anxiety disorders, 
hallucinations, sleep disturbances including nightmares and, in a few people, overt psychosis, 
toxic encephalopathy, convulsions and acute brain syndrome (Corbett et al. 1996). 
Mefloquine use is also associated with bradycardia and sinus arrhythmia in up to 68% of 
patients treated in hospital-based studies. Other adverse reactions reported rarely include 
blood dyscrasias, transient elevation of transaminases, blackwater fever, Stevens Johnson 
syndrome and toxic epidermal necrolysis. Concurrent use of quinine can potentiate dose- 
related adverse reactions to mefloquine and so mefloquine should not be administered within 
12 h of the last dose of quinine. Co-administration of mefloquine with tetracyclines or 
ampicillin also produces higher mefloquine blood concentrations. 
Mefloquine used for both chemoprophylaxis and treatment during the second and third 
trimesters of pregnancy is efficacious and safe (Nosten et al. 1994; Steketee et al. 1996; Adam 
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et al. 2004). However, its use during the first trimester may be associated with increased risk 
of abortion (Phillips-Howard et al. 1998) or stillbirths (Nosten et al. 1999). In non-pregnant 
women of childbearing potential, mefloquine can be prescribed for chemoprophylaxis, but 
pregnancy should preferably be avoided during and for 3 months after completing 
chemoprophylaxis. Mefloquine is excreted in breast milk in small amounts, the activity of 
which is unknown. Circumstantial evidence suggests that adverse effects do not occur in 
breastfed infants whose mothers are taking the drug (Bangchang et al. 1994). 
2.4.6 Artemisinins 
Artemisinin (ginghaosu) is an antimalarial isolated from Arten7isia annna L. Artemisinin is poorly 
soluble in oils or water but the parent compound has yielded dihydroartemisinin, the oil 
soluble derivatives artemether and arteether, and the more water-soluble derivatives sodium 
artesunate and artelinic acid. These derivatives have more potent blood schizonticidal activity 
than the parent compound and are the most rapidly effective antimalarial drugs known. They 
are used for the treatment of severe and uncomplicated malaria. They are not hypnozoiticidal 
but gametocytocidal activity has been observed. The antimalarial activity of artemisinin and 
its derivatives is extremely rapid and most patients show clinical improvement within 1 to 3 
days after treatment. However, like many other antimalarials the recrudescence rate is high 
when the drugs are used as monotherapy (WHO 1998b; WHO 2000c). In response, the 
WHO recommends that treatment policies for falciparum malaria in all countries 
experiencing resistance to monotherapies should be combination therapies, preferably those 
containing an artemisinin derivative (ACT - artemisinin-based combination therapy) (WHO 
2001 b). 
Reports on the use of these drugs during pregnancy are limited. Available data from 124 
pregnancies exposed to artemisinin products in the first trimester and 607 pregnancies 
exposed during the second or third trimester suggest that the use artemisinin in pregnancy 
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might be safe (WHO 2003a). However, experimental studies in animals showed that 
artemisinin compounds caused foetal resorption and morphological deformities in rats 
(WHO 2003a). Therefore the WHO recommends that artemisinin compounds may be used 
in the second and third trimesters when other treatments are considered unsuitable. But its 
use outside this period may be recommended only after careful consideration of the harm 
that could result from untreated malaria during pregnancy against the risk of a teratogenic 
effect that may result from its use (WHO 2003a). 
2.5 Iron and folic acid supplementation 
Malaria, iron deficiency, folate deficiency, haemoglobinopathies and HIV/AIDS have been 
identified by various studies as major causes of anaemia in Africa south of the Sahara. These 
are thought to interact in a vicious cycle of depressed immunity, infection and malnutrition 
(Fleming 1989; Shulman et al. 1996; van den Brock 1996; Mockenhaupt et al. 2000). Thus iron 
and folate supplementation in addition to effective treatment and prevention of malaria are 
recommended in pregnancy. 
There is in vitro evidence (Watkins ei al. 1985) and some clinical evidence (van Hensbrock el 
al. 1995) that folic acid, even in physiological doses, administered concurrently with SP, can 
antagonize the action of SP and thus reduce its efficacy. It was therefore suggested that folic 
acid supplements should be delayed for one week after SP treatment to avoid an inhibitory 
effect on antimalarial efficacy (WHO 1997). However, recent evidence from The Gambia 
showed that folic acid did not inhibit the action of SP used for IPT for in pregnant women 
(Mbaye el al. 2005 submitted). 
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2.6 Evaluating antimalarial drug efficacy and safety in pregnancy 
2.6.1 Therapeutic efficacy indicators 
The search for indicators of antimalarial drugs efficacy and how to measure them have 
engaged the attention of many scientists recently. The importance of any parameters and how 
they are measured vary from stable to unstable endemic regions, often depending on the 
local malaria transmission profiles and the drug resistance situation. The suitability of any of 
these for public health and for research purposes is not clearly defined. Each of these has 
some strengths and weaknesses with respect to the local malaria transmission profile 
(Phillips-Howard 1999). 
In the absence of protocols for specific population groups, various modifications were made 
to the WHO in-vivo test protocol originally developed to assess parasitological and clinical 
efficacy of chloroquine in children (WHO 2001a) to suite the characteristics of other 
populations under study. The current protocol (WHO 2003b) permits these modifications. In 
most in-vivo studies in pregnant women, the level of parasitological failure including or 
excluding new infections was assessed to measure efficacy of treatments under consideration. 
What differed usually is the type of treatment and the follow up schedules. In south East 
Asia where multi-drug parasite resistance is %vide spread and most treatment trials in 
pregnancy have been conducted, follow up schedules vary from 28 to 63 days depending on 
the half life the antimalarial drugs are being assessed (Nosten et al. 1993; McGready et al. 
2000; Bounyasong 2001; McGready et al. 2001; McGready et al. 2001; McGready et al. 2005). 
In Africa, the maximum follow up time was 42 days to assess the efficacies of chloroquine, 
SP, chlorproguanil or dapsone (Steketee et al 1987; Keuter et al. 1990; Sowunmi et al. 1998). 
In contrast haematological recovery, decreased incidence of low birth weight and perinatal 
mortality were used increasingly to assess the clinical efficacy of antimalarials used either 
for chemoprophylaxis or IPT in pregnancy, most of which took place in Africa as shown in 
Table 2.2. Placental parasitaemia was rather often measured to assess its relationship with 
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low birth weight, maternal anaemia at delivery or parity. Sometimes it was used to assess 
the impact of chemoprophylactic or IPT programmes. 
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2.6.2 Safety indicators 
Monitoring the safety of antimalarial drugs in pregnancy depends on the safety profiles of 
individual drugs and may be difficult because some of the post treatment symptoms and 
signs may be related to the underlying parasitaemia or the physiological changes occurring in 
pregnancy. Frequently studies monitored clinical signs and symptoms (Stcketee et al. 1987; 
McGready et al. 2001; Challis et al. 2004; McGready et al. 2005) that emerged or worsened 
relative to pre-treatment baseline or adverse neonatal outcomes (Wolfe and Cordero 1985; 
Parke 1988; Levy et al. 1991; Nosten et al. 1994; McGready et al. 2001; McGready et al. 2005) 
such as teratogenicity, miscarriage rates, still birth rates and perinatal deaths to assess the 
safety of antimalarial drugs in pregnancy. Most clinical symptoms are predictable and dose 
dependent, based on the pharmacology of the drug involved. In contrast, most adverse 
neonatal outcomes cannot be predicted from known pharmacology of the drug involved. But 
the commonest independent predictor of ADRs is the number of concurrent medications 
being taken. Therefore drug interactions with other prescription medications, over-the 
counter preparations or herbal remedies also need to be considered when evaluating an 
adverse drug reaction (Eisenhauer 2002). 
There is however, a paucity of data evaluating biochemical abnormalities due to antimalarial 
drugs in pregnancy. To evaluate the safety of CQ, AQ, SP and AQ+SP combination, 
symptoms and signs and laboratory data need to be monitored post treatment for patterns 
consistent with Steven Johnson's syndrome, hepatitis, haemolysis, anaemia, agranulocytosis, 
neutropaenia, miscarriage and kernicterus. 
The above review has shown that malaria in pregnancy is a major threat to the life of the 
mother and her foetus particularly in the first time mothers. Fortunately, effective tools 
including insecticide treated bed nets, IPT and treatment of malaria illness for the prevention 
and control of the deleterious effects are available. What is worrying is that the utilization of 
these tools is low coupled with the wide spread drug resistant P. falcipanim parasites. A 
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starting point towards addressing this problem is to begin systematic monitoring of 
antimalarial drugs in pregnant women for their efficacy and safety while improving and 
searching for the optimum ways of deploying the intervention tools currently available. 
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CHAPTER THREE 
MATERIALS AND METHODS 
64 
CHAPTER 3 MATERIALS AND METHODS 
3.1 Study overview 
This was a randomised, double blind, prospective, comparative study of chloroquine versus 
amodiaquine and SP alone or their combination in the treatment of malaria infection in 
pregnancy. Prior to enrolment into the study all pregnant women were screened for eligibility 
according set inclusion criteria at the antenatal clinic sessions held at St. Theresa's Hospital 
between March 2003 and September 2004. Pregnant women who met all entry criteria were 
assigned randomly to CQ, AQ, SP or the AQ+SP combination treatment arms on day 0; 
when an enrolled pregnant woman took the first dose of the assigned treatment under direct 
observation by the recruitment team. 
Each enrolled pregnant woman was followed until day 28 following the initial treatment or 
until one or more criteria for withdrawal from study were met as defined in section 3.12. 
Continuation of follow-up beyond day 28 was passive when the woman visited on scheduled 
days as specified in sections 3.7.2 and 3.7.3. The development of any adverse drug effects 
during active follow-up was classified and managed according to the definitions and 
guidelines listed under section 3.11. 
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3.2 Study objectives 
3.2.1 General objective 
To compare the efficacy, safety and tolerance of AQ, SP and the AQ+SP combination with 
those of CQ in the treatment of antenatal falciparum malaria infection in pregnancy. 
3.2.2 Specific Objectives 
Primary 
To determine the effect of AQ, SP and the AQ+SP combination compared with CQ on the 
prevalence of peripheral parasitaemia on day 28 post treatment. 
Secondary 
1. To determine the effect of AQ, SP and the AQ+SP combination compared with CQ 
on the prevalence of peripheral parasitaemia on day 14 post treatment. 
2. To assess the accuracy of the OptiMAL® antigen test for detecting peripheral 
parasitaemia compared to microscopy. 
3. To compare the incidence of adverse events in the treatment groups. 
4. To compare the effect of study drugs on maternal haemoglobin on 14 and 28 days 
post treatment, and at delivery. 
5. To compare the effect of study drugs on peripheral and placental parasite densities at 
delivery. 
6. To compare the effect of study drugs on birth weight at delivery. 
7. To compare overall incidences of adverse pregnancy outcomes (abortion, stillbirth, 
congenital abnormality, prematurity and intrauterine deaths) in the study group to 
local rates obtained from St Theresa's Hospital's records. 
8. To determine the prevalence of different symptoms in parasitaemic women in 
comparison to women without parasitaemia. 
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3.3 Methods 
3.3.1 Study design 
This was a four-arm randomised, double-blinded clinical trial of the efficacy and safety of 
AQ, SP and the AQ+SP combination compared with chloroquine in the treatment of 
pregnant women with malaria parasitaemia. All study pregnant women received daily iron 
and folic acid supplementation. 
3.3.2 Study location 
The study was done at St. Theresa's Hospital in the Nkoranza district of Ghana. The 
Nkoranza district is one of thirteen administrative districts of the Brong Ahafo Region of 
Ghana. It occupies a surface area of 2,300 square kilometres. The district's population was 
145,000 in 2002 with an annual growth rate of 2.6%. The population is a mixture of Brongs, 
Akans and people from other parts of the country. The district lies in the transition zone 
between the rain forest and the savannah regions of Ghana and it is a malaria endemic area. 
Illiteracy is high and, despite brisk commercial activities, poverty levels are also high. There 
are 13 health facilities in the district. These include St. Theresa's Hospital, 2 health centres, 9 
functioning rural clinics and a private maternity home. St. Theresa's Hospital is owned and 
administered by the Catholic diocese of Sunyani. It functions as the district hospital through 
a collaborative arrangement between the diocese and the Ministry of Health of Ghana. It has 
a bed capacity of 80 and provides all basic medical services including adult medicine, 
paediatrics, surgery and obstetrics and gynaecology. It runs two antenatal clinic sessions a 
week and registers an average of 212 new clients per month. The hospital operates the 
government's policy of providing free basic antenatal care for pregnant women. The average 
number of antenatal visits by each pregnant woman is 3. This policy was, however, 
discontinued during the last quarter of 2002 because government severely delayed 
reimbursement of funds to hospitals. This basic care consists of free consultation, free 
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ferrous sulphate and folic acid, free urine protein and haemoglobin level determinations and 
free chloroquine prophylaxis. The prevalence of malaria parasitaemia in children in the 
district and neighbouring districts was found to be 46% (Yeboah Antwi et al. 2001). Malaria, 
for decades, has been the number one outpatient and inpatient diagnosis in the hospital and 
the most frequent cause of mortality in children in the district. Between 1997 and 2001 a total 
of 2135 pregnant women were diagnosed clinically as having malaria with 15% needing 
admission. Malaria is the cause of 21% of maternal admissions to the St. Theresa's Hospital 
and 20% of pregnant women attending the antenatal clinic has P. falcipanrn parasitaemia (H. 
Tagbor, unpublished data, 2002). Chloroquine was the drug of first choice for treatment of 
malaria in pregnancy in the hospital before this trial. Second line drugs used include SP and 
artesunate. The district is the site for the Safe Motherhood Initiative programme run by 
MaterCare International with funding from CIDA and also one of the field sites for the 
Vitamin A project of the Kintampo Health Research Centre. The health centres and clinics in 
the district also provide antenatal services. 
3.3.3 Study population 
The study population comprised pregnant women of all parities with a gestational age of 16 
weeks and above who attended antenatal clinic services at St. Theresa's Hospital's between 
March 2003 and September 2004. 
3.3.4 Pre project activities 
The project was planned to start in November 2002 and run for 18 months but started in 
March 2003 instead. The delay was caused by problems in the production the study drugs by 
Kinapharma Limited. 
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3.3.4.1 Project team 
The PI in collaboration with the hospital management team recruited a core staff shown in 
Table 3.1, with varying educational background for the screening, fieldwork and data 
management activities of the project. In addition the project co-opted hospital staff from the 
laboratory, maternity wing and antenatal clinic of the hospital to help. 
Table 3.1: Core Project Staff 
Name Educational level/Qualification Role on project Duration on project 
Mark Asante Higher National Diploma Field Supervisor 24 months 
Mark Sarkordie Higher National Diploma Data Entry Clerk 18 months 
Godfred Owusu Ansah Senior Sec. School Certificate Data Entry Clerk 24 months 
Ernest Butsorme Higher National Diploma Field Worker 24 months 
Hannah Ampofowaa Senior Sec. School Certificate Field Worker 24 months 
Florence Twumwaa Senior Sec. School Certificate Field Worker 24 months 
Philip Akpagonu Senior Sec. School Certificate Field Worker 18 months 
Kaizer Appiah-Kubi Senior Sec. School Certificate Field Worker 6 months 
William Baffoe Higher National Diploma Field Worker 6 months 
Pius Occlo Higher National Diploma Laboratory Technician 18 months 
Francis Owusu Ansah Higher National Diploma Laboratory Technician 24 months 
3.3.4.2 Project staff trainin 
A one-month practical course in the topics listed below was organised for the field teams and 
data management team in order for them to understand the nature of the project and acquire 
the knowledge and skills needed for their work. Areas covered in training sessions included: 
i. Malaria antigen test with OptiMAL® dipsticks 
ii. Slide preparation and staining 
iii. Venipuncture 
iv. Haemoglobin concentration determination using Hemocue analysers 
v. Detection of chloroquine and SP in urine using ELISA dipsticks 
vi. Filter paper blood spot preparation 
vii. Establishing rapport and interacting with clients 
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viii. Information gathering 
ix. Motor bicycle riding 
x. Basic computing and data entry 
Staff were each assigned roles and responsibilities on the project according to the standard 
operating procedures. A clinician was responsible for performing obstetric ultrasound 
examination on all recruited pregnant women and received and monitored reports of adverse 
effects in the absence of the PI. Midwives were also trained to prepare slides for microscopy 
and determine haemoglobin concentration at delivery and record relevant data for the 
project. Antenatal staff were involved in educating pregnant women on the project during 
clinic sessions and liaised between the screening and recruiting teams during these sessions. 
3.3.4.3 Sourcing test drugs 
A Ghanaian pharmaceutical company Kinapharma Limited was contracted to manufacture 
and pack test drugs according to custom design for the project. The Food and Drugs Board 
of Ghana tested the tablets and confirmed their quality. Furthermore the drugs were also 
assayed at the London School of Hygiene and Tropical Medicine and found to be of 
standard quality. 
3.3.4.4 Data and safety monilorinS board 
A data and safety monitoring board (DSMB) was constituted for the project. It had Prof. 
Bernard Brabin as chairman and Prof. Aggrcy Oloo, Dr. Kalifit Bojang, Dr. Joanna 
Schellenberg, Dr. George Bonsu and Dr. Todd as members. 
The board was responsible for: - 
i. Regular monitoring of the data and safety issues concerned with the study. 
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ii. Reviewing the PI's reports on serious adverse events and making recommendations on 
further progress of the study. 
iii. Reviewing the statistical analysis plan. 
3.3.5 Inclusion and Exclusion Criteria 
3.3.5.1 Inclusion Criteria 
A pregnant woman was eligible for inclusion in the study if: - 
1. Her pregnancy was at least 16 weeks. 
2. She had P. falcipanrm parasitaemia of any density with or without symptoms. 
3. She was willing to participate and complete the test schedule and had given informed 
consent. 
4. She had no known adverse reaction to any of the study drugs. 
5. She was willing to have supervised delivery at any maternity unit in the district. 
6. She lived within the Nkoranza district. 
3.3.5.2 Exclusion Criteria 
A pregnant woman was ineligible for inclusion in the study if. - 
1. She was less than 16 weeks pregnant. 
2. She was not resident in the study area. 
3. She had a past obstetric or medical history that might adversely affect the 
interpretation of outcomes of the trial such as repeated stillbirths and eclampsia. 
4. She declined to participate. 
5. She had a history of severe adverse drug reactions to co-trimoxazole in the past. 
6. She had a haemoglobin concentration below 5.0 g/dl. 
7. She had malaria that was severe enough to require parenteral medication. 
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3.4 Outcome measures 
3.4.1 Primary 
Prevalence of parasitaemia on day 28 post treatment defined as: - 
a) Any level of peripheral parasitaemia by microscopy at day 28 post treatment. 
b) Any level of peripheral parasitaemia by microscopy at day 28 post treatment 
excluding any new infections identified by MSP2 (merozoite surface protein-2) 
genotyping. 
3.4.2 Secondary 
1. Prevalence of parasitaemia on day 14 post treatment. 
a) Any level of peripheral parasitaemia by microscopy at day 14 post treatment 
excluding any new infection identified by h1SP2 genotyping. 
b) Any level of peripheral parasitaemia by microscopy at day 14 post 
treatment. 
2. Sensitivity, specificity, positive and negative predictive values, likelihood ratios, and 
the area under receiver operating characteristic (ROC) curve for the Optih-1AL® 
antigen test. 
3. Incidence of adverse drug events within seven days following treatment. 
4. Proportions of pregnant women withdrawn from the study due to the occurrence of 
adverse drug events (clinical and laboratory) by day 7 following initiation of 
treatment. 
5. Change in maternal haemoglobin concentrations at days 14 and 28 following 
treatment. 
6. Prevalence of peripheral parasitaemia at delivery. 
7. Prevalence of placental parasitaemia at delivery. 
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8. Proportions of abnormal biochemistry and white blood cell values on days 14 and 28 
post treatment. 
9. Incidences of adverse pregnancy outcomes in the study group. 
10. Prevalence of postpartum parasitaemia. 
11. Prevalence of postpartum anaemia. 
3.5 Sample Size Calculation 
The study sample size was based on the need to detect, with 95% confidence and 90% 
power, a reduction in the proportion of parasitological failures on day 28 in AQ, SP and 
AQ+SP versus CQ using the formula below. 
n= [(zl+z2)22P(1-P)] 
(Pl-P2)2 
Where: 
n is the number of study pregnant women required in each treatment arm. 
p, and p2 are estimates of the proportions of failures in parasitological clearance in the 
chloroquine and other groups respectively after treatment. 
P is the average of p, and P2 
Z1 is the 2-sided significance level probability of concluding that there is a significant 
difference in the observed proportions in the two groups when in fact there is no difference 
and corresponds to 1.96 (type I error) 
z2 is the one-sided probability of concluding that there is no significant difference in the 
observed proportions in the two groups when in fact there is a difference and corresponds to 
1.28 (type II error) 
In calculating the sample size, consideration was given to both statistical demands and 
practical feasibility. In the absence of recent local data on the level of falciparum resistance to 
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amodiaquine and SP at the design stage of this study, the sample size was calculated assuming 
various levels of resistance to these drugs, fixing the study power with an estimated failure 
rate of 22% (Marfo 2001) for chloroquine against uncomplicated falciparum malaria. 
It was assumed that parasitological resistance to AQ, SP and AQ+SP combination would 
range between 5% and 15% against uncomplicated falciparum malaria in Ghana. The study 
was not powered to show a difference in efficacy between AQ, SP and the AQ+SP 
combination. 
Table 3.2: Distribution of study sub sample according to treatment arm. 
Fixed study power of 90%, CQ failure rate of 22%. 
AQ, SP or AQ+SP 
failure rate 
5% 
8% 
10% 
12% 
15% 
Sample Size (N) 
CQ/SP CQ/AQ CQ/AQ+SP 
98 98 98 
157 157 157 
225 225 225 
341 341 341 
743 743 743 
1. These figures representing the sample sizes were adjusted to account for a 15% loss 
to follow up. 
2. The study required between 98 and 743 study pregnant women in each treatment 
arm to give it a power of 90% to detect the difference between the 22% failure rate 
anticipated in the chloroquine group and failure rates of AQ, SP and AQ+SP 
combination in the range of 5% tol5%. 
3. Since chloroquine was the comparator drug in the 3 segments, a sample size of 225 
pregnant women was considered adequate in each of the 4 arms giving a total study 
size of 900 pregnant women. This was based on the assumption of a 28-day 
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parasitological clearance of 90% for AQ, SP and AQ+SP combination, and 78% for 
CQ (a = 5% power = 90%). 
3.6 Screening and enrolment procedures 
All study pregnant women were recruited from the antenatal clinic of St. Theresa's Hospital 
over a period of 18 months. The principal investigator (PI), supported by midwives at the 
antenatal clinic conducted the recruitment during clinic hours. The standard operating 
procedures at the clinic were as follows: 
1. All pregnant women who attended the antenatal clinic were screened initially for 
falciparum antigens using the OptiNIAL® individual malaria test kit. Thin and thick 
blood films on the same slide were made at this point from the finger prick blood 
sample for malaria parasite identification and quantification. Women in whom the 
antigen test was positive and who satisfied the inclusion criteria were then taken 
through the next enrolment stages. 
2. Informed consent was obtained from pregnant women who satisfied all inclusion 
criteria. 
3. Pregnant women who tested positive for malaria with the dipstick test were assessed 
clinically and obstetrically with the view to enrolling them into the study. Information 
on their demographic and socio-economic characteristics, age and parity were 
obtained and recorded. Gestational age was confirmed with ultrasound scanning by a 
study clinician or the principal investigator. 
4. Screening staff then obtained 5mls of venous blood from the antecubital vein for 
baseline investigations including haemoglobin level, filter paper blood spots, white 
blood cell counts (total and differential) and liver function tests (total bilirubin, 
alanine aminotransferase, aspartate aminotransferase and gamma-glutamyl 
transferase). 
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5. All antigen positive thin and thick blood films were examined plus 5 randomly 
selected antigen negative slides. 
6. Pregnant women whose antigen tests were negative went through the routine 
antenatal clinic procedures. Those whose were antigen positive but had negative 
microscopy or gametocytes only were treated with chloroquine according to national 
antimalarial treatment policy but not included in the study. 
7. Randomisation and assignment of recruited pregnant women to treatment groups 
then followed. 
3.6.1 OptiA1L® dipstick assay 
The OptiMAL® individual rapid malaria test kits were bought from the manufacturers (Flow 
Inc. ). The rapid malaria diagnostic dipstick assay was used to help to identify potential 
participants quickly as blood films could not be read immediately. The assays were performed 
and interpreted at the ANC by the screening team. Laboratory technicians who read blood 
films were blinded to the results of the assay. The assays were performed according to the 
manufacturer's instructions outlined below. 
Each test kit has a main device constituted by a dipstick, conjugate and wash wells. Also in 
the package is a well cover, a buffer in a dropper, a pipette, and a disinfecting swab. The test 
proceeds, in five simple steps, as follows: - 
Step 1 
The device is positioned on a flat surfaced table. One drop of buffer is added to the 
conjugate well and four drops of the buffer to the wash well and the test allowed to stand for 
a minute. 
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Step 2 
One drop of finger-prick blood (equivalent to 10 micro litre of blood) is added to the 
conjugate well, mixed gently and then allowed to stand for a minute. 
Step 3 
The dipstick is placed in the conjugate well and allowed to stand for 10 minutes. 
Step 4 
The dipstick is transferred to the wash well and allowed to wash for another 10 minutes. 
Step 5 
The reaction bands on the dipsticks are read and interpreted as shown in Figure 3.1. 
" Two test bands and one control band indicate a P. falaparum infection. 
" One test band and one control band indicate a P. vrva-v infection. 
" One control band only at the top of the test strip is regarded as negative. 
Figure 3.1: Reaction bands of OptiMAL® tests 
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Figure 3.2: -A picture of an OptiMAL* dipstick screening session at the antenatal clinic. 
For the purposes of estimating the level of P. filciparum parasitaemia, the intensity of positive 
reaction bands was graded strong, medium and weak as shown Figure 3.3. 
Reaction Band Intensity of OptiMAL 
Positive Tests 
STRONG MEDIUM WEAK 
Nkoranza Antimalarial Drugs Project 
Figure 3.3: Reaction band intensities of positive test. 
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3.6.2 Clinical and obstetric assessment 
On the day of recruitment, a detailed medical history, including obstetric and drug histories 
was obtained from every pregnant woman who had satisfied the inclusion criteria. 
Information on baseline characteristics such as age, height, occupation, educational status, 
marital status and address was obtained and recorded. The address detailed house number, if 
any, landmarks and contact persons to facilitate follow-up. This was followed by a general 
examination to record the axillary temperature to one decimal point in degrees centigrade 
using an electronic thermometer, a check for pallor and measurement of weight in kilogram 
using the ScalaTM weighing scale. An obstetric examination was then conducted to confirm 
pregnancy and predict gestational age by symphysio-fundal height measurements and also by 
taking the last menstrual period into account. An ultrasound examination was performed on 
each woman to confirm gestation, gestational age and the viability of the pregnancy. A case 
recording forms were used to record information on each pregnant woman. These 
assessments were performed on each subsequent antenatal visit until delivery. 
3.6.3 Laboratory tests 
Apart from the biochemistry tests and the polymerase chain reaction assays, all other 
laboratory tests were carried out at the St. Theresa's Hospital. 
3.6.3.1 Microscopic Blood Examination 
Giemsa stain 
A new working Giemsa solution was prepared for each staining session. For each session, 
two separate working solutions at pH of 7.2 were prepared with concentrations of 3% and 
10% respectively. 
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Slide preparation and reading 
Thin and thick blood smears were prepared for each antigen positive pregnant woman during 
each antenatal session. All slides were labelled with the respective identification number using 
a `permanent' glass-writing pen to facilitate identification while ensuring blinding of 
microscopists to treatment allocations. Women who tested antigen positive had their smears 
stained; blood films for 5 randomly selected slides of antigen negative women were stained 
and examined on each clinic day. All slides were air-dried for 30 minutes in a netted box to 
protect them from flies. The slides were then stained for 10-15ninutes with 10% Giemsa 
stain and an initial reading was made to determine the presence or absence of parasitaemia so 
that treatment could be administered. A second examination of each slide was made to count 
the number of parasites per 100 high power fields (HPT). This was used to calculate the 
parasite density (the number of parasites per micro litre of blood). One microscopist at a time 
examined the slides and estimated parasite counts as follows: - 
i. Selection of a part of the thick film where the white blood cells (WBC) were evenly 
distributed and the parasites well stained. 
ii. Systematic counting of 200 or more white blood cells and estimation at the same time 
of the number of asexual parasites in each field using two, hand-tally counters. 
iii. The parasite density was calculated using the formula (WHO 1994; GILLES and 
WARRELL 1996; Cheesborough 1998): 
Parasite Density = Number of parasites x 8000 
Number of white blood cells 
If more than 500 parasites had been counted without having reached 200 leucocytes, the 
count was stopped after completing the reading of the last field, and the parasite count 
calculated according to the formula above. When the number of asexual parasites counted 
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against 200 leucocytes was below 10 parasites, counting was done against 500 or more 
leucocytes. A blood slide was pronounced negative only when examination of 100 HPF of a 
thick film did not show the presence of asexual forms of P. falciparum. 
The same techniques were employed for establishing parasite counts on each of the 
subsequent blood films prepared on subsequent follow-up visits. 
Independent quality assessments 
The Noguchi Memorial Institute of Medical Research (NMIMR) acted as an independent 
agency for parasitological quality assurance assessment of the Nkoranza Antimalarial Drugs 
Project. Five hundred and forty-seven slides from the project were randomly selected and 
submitted for quality assurance testing by a microscopist (Mr. Charles Atiogbe) at NMIMR. 
Interobserver variability in the interpretation of microscopy results by microscopists from the 
St. Theresa's Hospital and Noguchi Memorial Institute of Medical Research respectively were 
generally identical. The details of this are shown in Appendix 15. All the negative slides sent 
were confirmed negative at NMIMR. The day 0 sample included 81 positive slides of women 
recruited into the study but 6 of them were read negative by the microscopist at NMIMR. 
Forty-nine day 7 slides were re-assessed but it was realised later that the sample had only one 
positive slide. 
3.6.3.2 Pol ymerase chain reaction (PCR) assays 
Polymerase Chain Reaction (PCR) assays on filter paper blood spots obtained from the field 
were carried out in the London School of Hygiene and Tropical Medicine by Rosalynn Ord 
and Anna Randall using their laboratory protocols based on methods described for DNA 
extraction from blood spots (Plowe et al. 1995) and msp2 genotyping (Snounou et al. 1999). 
Briefly, the repetitive polymorphic loci, block 3 of msp2 (merozoite surface protein 2), was 
amplified by nested-PCR after DNA had been extracted from filter paper blood spots using 
81 
the chelex extraction method. In the nest 1 reaction, amplification was performed on a total 
reaction volume of 30µl containing 16.8µl of nuclease free water, 3µl of KCl buffer, 3µl of 
dNTPs, 1µl of M2-OF, 1µl of M2-OR, 0.2µl of Taq and 5µl of DNA extract each. The nest 1 
product was then used as the template for the nest 2 reaction. 
In the nest 2 reaction, amplification was performed on a total reaction volume of 320 
containing 21.4 of nuclease free water, 3.2µl of KC1 buffer, 3.20 of dNTPs 1µl of forward 
primer F, 1µl of Reverse primer R' O. 20 of Taq and 2µl of nestl product each. The nest 2 
amplified products were then electrophoresed on a 2.5% agarose gel. Ethidium bromide was 
used to stain the PCR product following electrophoresis on agarose gel in Tris-Borate EDTA 
(TBE) buffer and the results were visualised using ultraviolet light. The number of distinct 
amplification bands for both allelic variants was counted to estimate of the minimum number 
of genotypes present in each sample. The bands were then compared between day 0 and 
treatment failure day pairs. If the bands were the same, the sample was considered a true 
treatment failure. The presence of new alleles indicated new or re-infections. If a band could 
not be classified as above it was labelled indeterminate. 
3.6.3.3 Haemoglobin measurements 
At recruitment the haemoglobin levels were measured using a HemocucTII' analyser for each 
woman according to the manufacturer's instructions. The measurements were repeated on 
days 14 and 28 after treatment and at delivery and six weeks postpartum. 
3.6.3.4 White blood cells counting 
White blood cells for women in the study were counted microscopically using uncoagulated 
whole blood diluted with a WBC diluting fluid (a staining weak acid solution), the Improved 
Neubauer ruled counting chamber and a manual differential tally counter. The total WBC 
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count was obtained by dividing the total number of cells counted by 20 and multiplying the 
result by 109. The individual white cells were expressed as fractions of the total. 
3.6.3.5 Biochemical assessments 
Frozen sera were transported on ice weekly to the Clinical Analysis Laboratory of the 
Biochemistry Department of the University of Science and Technology, Kumasi for all 
biochemistry tests. 
Liver Function Tests 
Commercial reagent test kits were used for the liver function tests. For AST and ALT, 
individual kits manufactured by RANDOM laboratories Ltd (Diamond Road, Crumlin, Co. 
Antrim, UK) were used while kits manufactured by BIOLABO (S. A. France) were used for 
bilirubin and GGT determination. The tests were performed according to the manufacturers' 
instructions detailed below. 
Aspartate aminotran (erase (AST) determination 
In the presence of AST, aspartate is deaminated to form oxaloacetate, which reacts with 2,4- 
dinitrophenyhydrazine (DNPH) a colour reagent to form a brown oxaloacetate hydrazone 
solution, which is measured spectrophotometrically. 
AST 
a-oxoglutarate + L-aspartate L-glutamatc + Oxaloacetate 
Procedure 
The test kit contains two vials; vial 1 contains an already made reagent constituted by 
phosphate buffer, L-aspartate and a-oxoglutarate and vial 2 contains DNPH. Five hundred 
micro litres of the content of vial 1 was pipetted into test tubes labelled "reagent blank" and 
"sample". This was followed by the addition of 100µI, of distilled water into the reagent 
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blank tube and the 100µL of serum into the sample test tube. The resulting solutions were 
well mixed and incubated at 37°C for 30 minutes. 
Five hundred micro litres of DNPH was added into each tube, mixed and allowed to stand 
for exactly 20 minutes at room temperature. Five hundred micro litres of sodium hydroxide 
was then added to each tube and the absorbance of die test sample read at a wavelength of 
546nm against the reagent blank. The concentration of the AST in the serum was obtained 
from Table 3.3. The reference range for this kit is values up to 12 U/L. 
Table 3.3: - Range of absorbance and corresponding AST activity 
Absorbance Range U/L Absorbance Range U/L 
0.020 - 0.029 7 0.100 - 0.109 36 
0.030 - 0.039 10 0.110 - 0.119 41 
0.040 - 0.049 13 0.120 - 0.129 47 
0.050 - 0.059 16 0.130 - 0.139 52 
0.060 - 0.069 19 0.140 - 0.149 59 
0.070 - 0.079 23 0.150 - 0.159 67 
0.080 - 0.089 27 0.160 - 0.169 76 
0.090 - 0.099 31 0.170 - 0.179 89 
Alanine aminolran. fera re (ALT) determination 
In the presence of ALT, alanine is deaminated to form oxaloacetate, which reacts with 
DNPH to form a brown oxaloacetate hydrazone solution, which is measured 
spectrophotometrically. 
ALT 
a-oxoglutarate + L-alaninc L-glutamate + Pyruvate 
Procedure 
The test kit contains two vials; vial 1 contains an already made reagent constituted by 
phosphate buffer, L-alanine and a-oxoglutarate and vial 2 contains DNPH. Five hundred 
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micro litres of the content of vial 1 was pipetted into test tubes labelled "reagent blank" 
and "sample". This was followed by the addition of 100µL of distilled water into the reagent 
blank tube and the 100µL of serum into the sample test tube. The resulting solutions were 
well mixed and incubated at 37°C for 30 minutes. 
Five hundred micro litres of DNPH was added into each tube, mixed and allowed to stand 
for exactly 20 minutes at room temperature. Five hundred micro litres of sodium hydroxide 
was then added to each tube and the absorbance of the test sample read at a wavelength of 
546nm against the reagent blank. The concentration of the ALT in the serum was obtained 
from Table 3.4. The reference range for this kit is values up to 12 U/L. 
Table 3.4: - Range of absorbance and corresponding ALT activity 
Absorbance Range U/L Absorbance Range U/L 
0.025 - 0.049 4 0.275 - 0.299 48 
0.050 - 0.074 8 0.300 - 0.324 52 
0.075 - 0.099 12 0.325 - 0.349 57 
0.100-0.124 17 0.350-0.374 62 
0.125 - 0.149 21 0.375 - 0.399 67 
0.150 - 0.174 25 0.400 - 0.424 72 
0.175 - 0.199 29 0.425 - 0.449 77 
0.200 - 0.224 34 0.450 - 0.474 83 
0.225 - 0.249 39 0.475 - 0.499 88 
0.250 - 0.274 43 0.5 94 
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Gamma glutamyl Iran ferare (GGT) 
In the presence of GGT, glycylglycine reacts with L-gamma-glutamyl-p-nitroanilide to form 
L-gamma-glutamylglycine and the absorbance is determined kinetically. 
L-gamma-glutamyl-p-nitroanilidc + glycylglycinc 
GGT Jr L-gamma-glutamylglycine + p-nitroalanine 
Procedure 
The test kit contains two vials; vial 1 contains an already made reagent constituted by "Tris 
buffer" and glycylglycine and vial 2 contains the substrate containing L-gamma-glutamyl-p- 
nitroanilide. The test reagent was reconstituted by emptying the entire contents of vial 2 into 
vial 1 and mixed gently until complete dissolution. One thousand micro litres of the 
reconstituted reagent was pipetted into a cuvette of 1cm light path and incubated at 37°C. 
This was followed by the addition of 50µL of the serum sample and the absorbance 
measured against air at a wavelength of 405nm at 30 seconds and after 1,2 and 3 minutes 
and the concentration calculated as follows: - 
GGT (N/L) = change in absorbance per minute X 2121 (molar absorptivity of p- 
nitroalanine). The reference range for this kit is values up to 50U/L. 
Bilirnbin 
Bilitubin reacts with diazotized sulphanilic acid (DSA) to form a pink azo compound. The 
absorbance of this compound at 550nm is directly proportional to the bilirubin concentration 
in the test sample. Total bilirubin concentration is measured when this reaction takes place in 
the presence of dimethyl sulphoxide (DMSO) and the direct (conjugated) bilirubin is 
determined when the reaction takes place in the absence of DMSO. Indirect bilirubin = total 
bilirubin - direct bilirubin. 
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Procedure 
The test kit contains three vials; vial 1 for total bilirubin is constituted by sulphanilic acid, 
DMSO and hydrochloric acid, vial 2 for direct bilirubin is constituted by sulphanilic acid and 
hydrochloric acid and vial 3 contains sodium nitrite. The tests for both total and direct 
bilirubin concentrations were run simultaneously. 
To measure total bilirubin, one thousand micro litres of vial 1 was pipetted into test tubes 
labelled sample blank and assay. Then 50µL of distilled water was added to the sample blank 
test tube and 504 of sodium nitrite added to the assay test tube. The contents of both tubes 
were mixed thoroughly and incubated for 5 minutes at 37°C. After this, 100µL of the test 
serum was pipetted into each test tube, mixed and allowed to stand for 5 minutes at room 
temperature. The absorbance of the assay was read against the sample blank at a wavelength 
of 550nm and the concentration calculated as follows: 
µmol/L= absorbance x 195 (a factor given by the manufacturer). The reference range for 
total bilirubin includes values up to 17.1 µmol/L. 
For the measurement of direct bilirubin, the same procedure was used with vial 2 which 
contained no DMSO. The reference range for direct bilirubin includes values up to 3.4 
µmol/L. 
Independent quality assessments 
Internal quality control of biochemistry tests was ensured by using standard control reagents 
kits. In addition, three hundred duplicate sera from the Nkoranza Antimalarial Drugs Project 
were randomly selected and submitted for biochemistry quality assurance testing at NNIIMR. 
At the end of the tests the author detected that more than 50% of bilirubin results came out 
with total bilirubin as zero while the direct and indirect bilirubin were greater than zero. And 
so the tests were rerun using the same reagents used by the study laboratory but the results 
were the same. The author was not satisfied with the results from NMIMR and declined 
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using them as "gold standard". The samples were sent to the Kintampo Health Research 
Centre for another assessment. There was substantial delay in getting the results from 
KHRC. However, the KHCR used different reagents and so again their results were not 
comparable to those of the study laboratory. 
3.6.3.6 Preparation and storage of: filter paper blood . spots 
Filter paper blood spots were prepared for each study pregnant woman on days 0,3,7,14 
and 28. Perkin Elmer Filtermat A, (cat 1205-401) filter paper, desiccant sachets, Manila paper 
and unclotted blood in ED'l'A tube were use for the preparations. 
Following each recruitment session or a field visit the filter paper was cut into blocks of six 
spots and the Manila paper into strips (bins. X 1.5ins. ) in the laboratory according to the 
number of spots that had to be prepared. 
Each filter paper block was stapled onto a Manila paper strip. 
Each filter paper block and Manila paper strip was labelled accurately with the pregnant 
woman's number and the date and day the sample was taken. 
Using a lOuL pipette, three lOul_ spots of the woman's blood collected into the EDTA tubes 
were put on each block of filter paper. The drops were allowed to soak into the filter paper 
until the paper spot was evenly red without spreading to the underlying surface. 
F. ach prepared filter paper blood spots looked as below: 
JL. NBEL 
0 
9 
I 
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After preparation the batch was dried in a hot air oven at 40°C for 15 minutes. 
The dried filters were packed into plastic containers with desiccant in sets according to the 
day of preparation, sealed and stored at room temperature. Spots from days 0,3,7,14 and 28 
were stored separately from each other. The desiccant sachets were replaced every three 
months throughout the project period until PCR analysis was done at the London School of 
Hygiene and Tropical Medicine. 
3.6.3.7 Urine tests 
The enzyme-linked immunosorbent assay (ELISA) (Schwick et al. 1998; Mockenhaupt el al. 
2000) dipstick was used to screen urine samples obtained from study pregnant women for 
chloroquine and pyrimethamine prior to administration of study drugs to estimate current 
drug use among the pregnant women in the study area. The dipsticks were obtained directly 
from the manufacturer, Dr. Teunis Eggelte of the Academic Medical Centre in the 
Netherlands. 
The dipstick test for antimalarial drugs is based on the specific reaction of an antimalarial 
drug with an antibody raised against it. The dipsticks for CQ and pyrimethamine have 3 
bands. The top band shows the reaction between a monoclonal antibody and the enzyme 
peroxidase and the middle and lower bands contain specific drug antibodies for CQ and 
pyrimethamine respectively. The dipstick has detection limits in the range of 120nmol/l for 
CQ and 250nmol/1 for SP. The test can detect CQ for at least 3 months and SP at least 3 
weeks respectively after they have been taken. The top band acted as an internal control. 
When a test was negative 3 coloured bands appeared on the dipstick. When a test was 
positive for CQ, the top and middle bands only were coloured. No tests were positive for 
pyrimethamine or for both CQ and pyrimethamine. If a test had been positive for 
pyrimethamine the top and lower bands only would have been coloured. If the test was 
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positive for both CQ and pyrimethamine the top band alone would be coloured. The assays 
in this project were performed according to the protocol supplied by the manufacturer. 
3.6.3.8 Stool microscopy 
At recruitment, the stools of all pregnant women were examined microscopically to identify 
those with hookworm infestations. Those who were positive were treated with merbendazole 
100mg twice daily for 3 days. 
3.6.4 Randomisation and study drug allocation 
There were four treatment groups: - CQ, SP, AQ or the AQ+SP combination. Treatment 
allocation was done individually and not in groups. Each drug pack had a numeric drug code, 
randomly allocated to it by a statistician, which was unknown to the recruiting team. A list of 
random numbers was computer generated as drug codes and individually linked to 
identification markers assigned by the manufacturer to each drug pack. These were again 
randomly ordered in blocks of sixteen, containing equal numbers of the treatment options, 
into bigger paper envelopes. There were 57 big envelopes, 56 of them had 16 drug packs 
each individually labelled with the appropriate drug code and the 57`h had 4 drug packs. One 
big envelope was made available at each antenatal clinic section. After giving informed 
consent, a participant was assigned the lowest available serial identification number. She was 
then asked by the recruitment team to pick a sealed drug pack from the big envelope and the 
drug code assigned to the pack was recorded. Picking a drug pack constituted entering the 
study, and the drug allocation within it was binding on the recruiting team and the woman at 
this point. Another big envelope was opened only when the contents of the previous one 
was exhausted. The 57`h envelope was the last to be opened. The PI and project staff were 
blinded to the randomisation process and treatment allocation. 
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The test drugs were formulated as film-coated oral tablets and had the same appearance in 
size and colour. They were pre-package in blister packs and strips by the manufacturer. 
All the drugs were manufactured by Kinapharma Limited in Ghana and quality assurance 
tested by the Foods and Drugs Board of Ghana. Their solubility and drug content was 
confirmed by high pressure liquid chromatography at the London School of Hygiene and 
Tropical Medicine by Dr. Harpakash Kaur. 
3.6.5 Treatment Schedule and Dosage 
The test drugs and their dosages and treatment schedules are shown in Table 3.5. 
Table 3.5: Schedule and dosage of test drugs 
TREATMENT ARM DAY 0 DAY 1 DAY 2 
CQ CQ (600mg) CQ (600mg) CQ (300mg) 
PLACEBO 1 
AQ AQ (600mg) AQ (600mg) AQ (400mg) 
PLACEBO 1 
SP S/P (1500mg/75mg) PLACEBO 2 PLACEBO 2 
PLACEBO 2 
AQ+SP AQ (600mg) AQ (600mg) AQ (400mg) 
S/P (1500mg/75mg) 
A drug pack contained a silver strip of three tablets and blister pack of a yellow and two 
pink tablets. A drug pack appeared as below: - 
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Figure 3.4: Contents of individual drug packs 
The silver strip was either an active SP or a placebo and the blister pack of pink and yellow 
tablets was either CQ or AQ monotherapies in which cases the silver strip was a placebo, or 
in the case of the AQ+SP combination, both the silver strip and the blister packs were active 
drugs. 
3.6.6 Drug compliance and accountability 
In addition to directly observing intake of the first dose of antimalarials at the clinic, field 
staff inspected the empty drug packages at home to ensure that the women had taken the 
drugs on their visits. 
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Figure 3.5: - Direct observation of the 
first treatment dose 
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3.7 Follow-up procedures 
3.7.1 Follow-up visits. 
Field workers visited pregnant women in their homes following the initial supervised drug 
administration at the antenatal clinic on days 3,7,14 and 28. To ensure that all study 
pregnant women were identified and followed up by field workers, the following procedures 
were followed. 
1. On the day before a follow up visit the data entry team generated a list of pregnant 
women due to be visited the following day. 
2. The list contained details such as address, contact persons and landmarks to facilitate 
identification of the pregnant women in the communities. 
3. The data entry team supplied the field teams with the appropriate forms for each 
visit. There were separate but similar follow up forms (F-Forms) designed for the 
purpose and kept by the data entry team. 
3.7.1.1 Follow : bon dajs 3 and 7 
1. The field workers located and identified the study pregnant woman in the 
community. 
2. They identified themselves to the woman and her husband or family. 
3. The field workers asked about the health of the woman and recorded any complaints. 
4. They recorded any adverse effects attributable to the ingestion of the test drugs. 
5. In an unthreatening manner, they inspected drug packages to ensure that every tablet 
was accounted for. 
6. They recorded the axillary temperature of the study woman and noted any observable 
external physical changes such as pallor, jaundice or skin rash. 
7. They sought permission and obtained a 2-ml sample of venous blood from the 
woman into a tube containing the anticoagulant ethylene di-amine-tetra-acetic acid 
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(EDTA) to be used for the preparation of thick films, WBC (total and differential), 
and for subsequent filter paper blood spots in the laboratory. 
8. They recorded all follow up information on follow up forms (F Forms). 
9. At the end of each encounter, they checked that all sections of the form were fully 
completed. 
10. The field workers then gave notice for the next visit on days 7,14 and 28 and bid the 
woman and her family good bye. 
11. Back in the laboratory at St. Theresa's Hospital, the field worker prepared the filter 
paper spots and prepared thin and thick blood smears for each woman seen in the 
field. 
12. They accurately labelled all slides and filter papers and completed a separate 
laboratory form (L-Form) for each slide and each filter paper sample. 
13. The field supervisor ensured that all samples expected from the field had been 
collected. 
14. He inspected all samples to ensure that they were properly labelled and all forms fully 
completed. 
15. After verification the field supervisor submitted the samples to the laboratory 
technician for examination. 
16. The laboratory technician, after examining the slides, filled in the results on the L- 
Form and returned them to the field supervisor. 
17. The field supervisor and the field teams then met the PI with the laboratory results 
and records from the field. 
18. The PI checked that no information was carelessly left out by ensuring that each 
woman's F Form 3 was fully completed. 
19. The PI then initialled the forms and submitted them to the data entry team. 
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3.7.1.2 Follow up on days 14 and 28 
The above follow up routine was repeated on each of the subsequent follow-up visits for 
each pregnant woman. However, on days 14 and 28,5-ml samples of venous blood were 
obtained. One ml was added to an EDTA tube to be used for preparing thin and thick films, 
haemoglobin concentration assessment, white blood cell counts (total and differential), and 
for the preparation of filter paper blood spots. The rest was allowed to clot to separate sera 
from the cells and centrifuged to give approximately 2mls of serum. This was divided into 
two portions, one was kept as a duplicate sample and the other was used for the liver 
function tests. Sera were kept frozen at -20°C until analysed. 
3.7.2 Subsequent antenatal visits 
All study women were seen at the antenatal clinic monthly or fortnightly for those with 32 
weeks and above gestation. At these visits, the women were screened actively for peripheral 
parasitaemia using an OptiMAL® dipstick test. If a woman who had already enrolled had a 
positive antigen test confirmed by microscopy, she received another course of the treatment 
to which she had been initially assigned. However, analyses were restricted only to the first 
treatment. 
3.7.3 Delivery and postpartum follow-up 
Midwives were charged with recording all birth weights and placenta weights, and noted any 
stillbirths and perinatal deaths. They prepared thick blood films from cord blood and from 
the maternal surface of the placenta; these were examined for malaria parasites and pigment 
at the laboratory after Giemsa staining. A clinician confirmed any record of congenital 
deformity. All women and babies were followed for six weeks during which their self- 
reported health status was obtained and reports of any neonatal adverse events such as 
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deaths or morbidity ascertained. The women were also advised to continue the nationally 
approved weekly 300mg of chloroquine over 6 weeks postnatal period. 
3.8 Iron and folic acid supplementation 
All study pregnant women received monthly pre-packed supply of prophylactic iron (as 
ferrous sulphate 200mg containing 65mg iron) and folic acid (4mg) tablets. One tablet each 
of these was to be taken daily. 
3.9 Treatment of Maternal Anaemia 
This study defined anaemia according to the WHO criteria as a haemoglobin concentration 
(Hb) below 11g/dl and severe anaemia as an Hb below 7g/dl. Apart from the routine 
administration of iron (200mg ferrous sulphate equivalent to 6Omg elemental iron) and folate 
(400mcg) supplementation during pregnancy, anaemia in any study pregnant women was 
actively managed depending on the level of Hb, presence of symptoms of cardiovascular 
decompensation and gestational age. 
The following regimen was used to actively treat antenatal anaemia (Kwame-Aryee 1998): 
Hb of 5- 7g/dl at less than 36 weeks gestation. 
Asymptomatic 
Oral ferrous sulphate 200mg three times daily on an OPD basis. 
Symptomatic 
Blood transfusion followed by oral ferrous sulphate. 
Identification of any causes of the anaemia and provision of appropriate treatment for the 
underlying condition. 
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After delivery or after the Hb had returned to normal levels oral iron was continued for 3 to 
6 months in order to replenish the iron stores. 
3.10 Escape Medication 
Oral or parenteral' quinine sulphate given as 10mg/kg every 8 hours for 7 days was used as 
an escape medication if. - 
i. There was deterioration in a woman's clinical condition after initiating treatment2. 
ii. The level of parasitaemia on day 3 or 7 was higher than that of day 0. 
iii. Any level of parasitaemia was found on days 14 and 28 after initiating treatment. 
iv. A woman with malaria parasitaemia refused to continue with study medication because 
of adverse effects. 
3.11 Assessment of adverse drug events 
An adverse event was defined as any untoward medical or obstetric occurrence (including 
physical and laboratory occurrences) in a pregnant woman, which may or may not have been 
related to the test drugs and which developed or increased in severity within seven days of 
initiating test treatment. Women were monitored for these signs and symptoms during post- 
treatment home visits or if they self reported an event. The PI or study clinician reviewed the 
information from the field and made judgements about the nature (severity and seriousness) 
of the event and actions to be taken according to the following predefined guidelines. 
' If oral medication was not possible but this did not happen. 
2 This situation did not arise. 
98 
Severity o fa reported adverse event 
1. An event was judged to be mild if it did not interfere with the woman's routine 
chores and required no specific intervention. 
2. An event was judged to be moderate if it interfered with the woman's routine chores 
or compelled the woman to suspend the test treatment or if she required any specific 
intervention. 
3. An event that required a supervised intervention such as admission to hospital was 
judged to be severe. 
Seriousness of adverse events 
An adverse drug event was judged to be serious if the ingestion of a test drug resulted in 
death of the subject or in a life-threatening situation and not serious if it was not life 
threatening and could not cause any damage. 
In the context of this study the occurrence of the following medical and/or obstetric 
outcomes known to be related to the test drugs were classified as serious and monitored 
within 7 days following ingestion of a test drug. 
1. Steven Johnson's syndrome: this is a toxic cutaneous reaction to drugs causing 
painful blistering and sloughing of the skin and mucous membranes including those 
of the mouth and eye. 
2. Hepatitis, as indicated by jaundice and abnormal levels of serum bilirubin and liver 
transaminases, 
3. Leucopoenia as indicated by abnormally low levels of white blood cells (below 2x 
109 /litre). 
4. Miscarriage. 
5. Neonatal jaundice as indicated by yellowish discoloration of the baby with 48 hours 
of delivery 
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Attributing causality 
The relation of the AE to the ingestion of the drug was assessed as: - 
Unlikely 
The event was clearly related to other factors such as concomitant therapy or a woman's 
clinical state, and was unlikely to have been caused by the study drug. 
Possible 
The event followed a reasonable temporal sequence from the time of ingesting study drug 
and/or followed a known response pattern to the study drug, but could have been produced 
by other factors such as the underlying illness or concomitant therapy. 
Probable 
The event followed a reasonable temporal sequence from the time of ingesting study drug 
and/or followed a known response pattern to the study drug, and was unlikely to have been 
produced by other factors such as the underlying illness or concomitant therapy. 
Most probable 
The event followed a reasonable temporal sequence from the time of ingesting study drug 
and/or followed a known response pattern to the study drug, could not have been produced 
by other factors such as the underlying illness or concomitant therapy, and either occurred 
immediately following the study drug ingestion or improved on stopping the drug. 
Actions taken in response to a reported adverse event 
The detection of an AE could lead to the following actions: - 
None 
No action taken and study drug given as normal. 
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Study drag discontinued 
Study woman stopped taking the study drug and was given escape medication or other 
antimalarial drugs to complete full treatment for malaria. 
Other action taken 
This referred only to concomitant therapy (not anti-malarial) or other actions needed to 
manage the adverse event. 
3.12 Withdrawal from study 
Study women were withdrawn from the study for the following reasons: 
" Self-administration of additional antimalarial drugs during follow-up. 
" Emergence of any concomitant febrile illness that might interfere with measurement 
of outcomes. 
" Withdrawal of informed consent. 
" Development of severe malaria or danger signs on day of treatment or after leaving 
the clinic. 
" Termination of pregnancy at term or prematurely. 
3.13 Data handling and analysis 
3.13.1 Data collection and entry 
Information obtained from women was recorded on case record forms for each woman 
enrolled in the study both at the antenatal clinic and during field visits. 
Two data entry clerks entered data from record forms into a Microsoft Access 2000 
computerized database at St. Theresa's Hospital simultaneously and independently each time 
throughout the study period. The "Compare Programme" a Microsoft Access programme 
(B. Beard et al. ) for comparing double entered data was used weekly to verify that records in 
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both databases were the same. Stata (version 8) software was used to clean and validate 
entered data and for performing the main analysis. Prior to analysis the related data files - 
baseline, follow up, laboratory and post delivery data were processed and merged to produce 
the main file for analysis. 
3.13.2 Data analysis 
The principal analyses of primary and secondary outcomes employed the "intention-to-treat" 
approach to include all randomised participants in their randomly assigned treatment group. 
Treatment group assignment was not altered based on the participant's adherence to the 
assigned treatment regimen during the study. All statistical tests performed were two-sided. 
Baseline data 
The background characteristics and baseline measures including age, parity, gestation, 
gravidity, prior chloroquine use, presenting symptoms, bed net availability and usage, spleen 
and liver enlargement, level of education, occupation, residence, ethnicity, religion, and 
haematological and biochemistry data were summarised using descriptive statistics. 
Binary variables were presented with frequencies and percentages, distributions for 
continuous variables will be summarised with means and standard deviations (SD) or 
medians and interquartile range (IQR). 
Post treatment analyses 
Mainly, the post treatment analyses involved the comparison of AQ, SP and AQ + SP to CQ 
with respect to the primary and secondary end points. 
The primary analysis involved comparisons of proportions of parasitological failure for each 
treatment compared to CQ at fixed time points of follow up. A failure was defined as a 
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Plasmodium falcipanrm density on days 3 and 7 follow up which was greater than that observed 
at baseline or any level of parasitaemia on days 14 and 28 following treatment. Bar charts of 
parasitological failures were also displayed to compare the effect of each test treatment versus 
CQ by days 14 and 28 following treatment. Odds ratios, 95% Cl's and corresponding p- 
values were estimated and tabulated for 14 and 28 days after treatment. 
Secondary analyses 
Treatment effect on haemoglobin, liver enzymes, bilirubin and white blood cells was assessed 
by measuring the absolute change from baseline levels over time using paired t-test, analysis 
of variance (ANOVA) and multiple regression analyses. For haemoglobin, the change at 
delivery and postpartum was also assessed. 
Haemoglobin, AST, ALT, GGT, bilirubin and white blood cells levels were also categorised 
based on reference ranges. The number of values in each category was tabulated with the 
corresponding percentage of the total number of values available according to treatment 
group. The overall estimates were presented unless there were any significant differences 
between subgroups in which case estimates were presented for each stratum. 
The experience of an adverse effect by a woman and the incidence of each individual adverse 
effect reported by women during post treatment follow up on days 3,7,14 and 28 were 
tabulated according to treatment group. Estimates of treatment effect using odds ratios and 
their 95% confidence intervals and corresponding P-values were obtained for each event by 
treatment group AQ, SP and AQ+SP versus CQ. Line and bar graphs were used to display 
patterns of adverse events both within and across treatment groups over time. 
It was anticipated that the signs and symptoms relating to the underlying parasitaemia may 
confound these estimations and so estimates were adjusted for baseline variables. In addition, 
clinical information obtained from the parallel screening and follow up of untreated non- 
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parasitaemic pregnant women during the study were compared with those of enrolled 
parasitaemic pregnant women. 
Pregnancy outcomes of women in the study were compared according to treatment group 
using descriptive statistics. Also the overall incidence of adverse pregnancy outcomes in the 
study group was compared to local rates for abortion, stillbirth, congenital abnormality, and 
mean gestation at delivery obtained from St Theresa's Hospital's records. 
3.13.3 Additional Data 
The overall parasitological failure rate of the study drugs in the study population appeared to 
be low during an interim review of the trial progress in February 2004. Even if all the failure 
at the time was from the chloroquine group it was thought not to be consistent with available 
knowledge. This could be due to the parasitological effect of the test drugs being different in 
pregnant women from what is seen in children (from whom most of the available data was 
obtained); or the parasite resistance in the study area being low compared to other parts of 
the country. 
And so an open-label randomised controlled trial was commissioned in which of 203 
children with peripheral parasitaemia were assigned SP or CQ to assess the parasitological 
failure by days 14 and 28 after treatment. Similar methods used for the primary analysis of the 
main study were used to estimate the efficacies of CQ and SP malaria infection in children in 
the study area. The drugs were from the source as in the main study. The CQ came as tablets 
colour coded and pre-packed; the first dose was given at the OPD under supervision. The SP 
came as syrup and was administered as a single dose under observation at the OPD before 
the children left the hospital. The results are shown in Appendix 16. 
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A control group of 220 pregnant women with negative OptiMAL® antigen tests during 
screening were also randomly selected, assessed clinically and followed up over 28 days using 
the same case records forms as for those in the study. The aim was to have a baseline level of 
clinical complaints among pregnant women in the study area. 
3.14 Ethical Approval 
The ethics committees of the Health Research Unit of the Ministry of Health of Ghana and 
the London School of Hygiene and Tropical Medicine gave approval for the study. 
3.15 Protocol Amendments 
No protocol amendments were required. 
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SCREENING AND ENROLMENT 
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CHAPTER 4 SCREENING AND ENROLMENT 
4.1 Introduction 
The first section of this chapter begins with a description of the screening processes that led 
to randomisation of eligible pregnant women into the study. This is followed by a description 
of the demographic and social characteristics of the study women, their clinical and obstetric 
assessments and baseline parasitological and haematological indices. 
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4.2 Screening and enrolment 
A flow diagram of the screening process that led to randomisation and enrolment of 
pregnant women into the study is shown in Figure 4.1. A total of 6370 OptiMALe tests 
were performed on 4500 pregnant women who attended a routine antenatal clinic; 1338 
(21%) were positive and 5032 were negative. Ninety-four of the 1281 positives assessed 
microscopically, were negative. Fifty-seven of the positive slides were not read 
microscopically because the women declined consent before further samples could be taken 
or the screening process completed. Five hundred and fifty-four of the 598 negative dipstick 
tests assessed microscopically were confirmed negative and 44 (7.3%) were positive. Nine 
hundred pregnant women who satisfied the study inclusion criteria were enrolled into the 
study and 438 excluded for the reasons indicated in Figure 4.1. One hundred and eighty- 
eight who were enrolled earlier and successfully completed the initial 28-day follow up tested 
positive during subsequent screening sessions. They did not re-enter the study. 
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Figure 4.1: Flow diagram of the screening process that led to enrolment of pregnant women into the 
study. 
6370 OptiNLAL tests conducted 
5032 negatives 
900 randomised 
1338 positives 
438 excluded 
NEGATIVE SLIDE 94 
DECLINED CONSENT 71 
LIVED OUTSIDE STUDY AREA 28 
: MULTIPLE PREGNANCY 23 
PREGNANCY < 16 WEEKS 20 
FALSE PREGNANCY 6 
SEVERE M AALARIA 5 
ONLY GAMETOCYTES 3 
SECOND M AL. ARIA EPISODE 188 
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4.2.1 Prevalence of peripheral parasitaemia in the study population 
Screening of pregnant women for enrolment into the study began on March 18,2003 and 
continued until October 2004 as shown in Figure 4.2. Over this period, the average 
prevalence of peripheral parasitaemia among antenatal clinic attenders was about 22% with 
monthly variations ranging from 9% to 32% in 2003 and from 16% to 34% in 2004. The 
prevalence peaked in June, July and August in 2003 during the rainy season but did not show 
any clear pattern relating to the dry and wet seasons of the study area during the year of 2004. 
The main parasite species in the study area is Plasmodium fälciparum. No mixed infections were 
detected in the study population either by OptiMAL® test or microscopy. 
Figure 4.2: - Detection of antenatal parasitaemia by OptiMAL® test over study period. 
Prevalence of antenatal parasitaemia 
0 v 
ö 
Vl ('ýý '"li 
' 
N °' I. - cI 
yoý 
+N 
ý 
Q 
ý 
ac) I 
o" 
0 
ýa4, PQýýSaý 3p ý. ýýQ, JOcýýQ pý ýoý I ýJýQ, JO'gýQ oýý 
2003 2004 
Factors associated with a positive dipstick test result at screening are shown in Table 4.1. 
Low parity, gravidity and age were associated significantly with positive dipstick tests 
(p<0.001). 
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Table 4.1: - Univariate analysis of factors associated with a positive OptiMAL® test. 
OptiMAL® test result 
Negative Positive Unadjusted odds ratio 
n (%) n (%) (95% CI) LR test 
Parity 
2 or above 2,609 (51.9) 323 (24.1) 1.0 
1 1,163 (23.1) 281 (21) 2.0 (1.7-2.3) 
0 1,260 (25) 734 (54.9) 4.7 (4.1-5.5) 
Gravidity 
3 or above 2,743 (54.5) 353 (26.4) 1.0 
2 1,167 (23.2) 324 (24.2) 2.2 (1.8-2.5) 
1 1,122 (22.3) 661 (49.4) 4.6 (3.9-5.3) 
Gestation 
3rd trimester 2,833 (56.3) 702 (52.5) 1.0 
2nd trimester 2,176 (43.3) 632 (47.2) 1.2 (1.0-1.3) 
151 trimester 20 (0.4) 4 (0.3) 0.8 (0.3-2.3) 
Mean (SD) 26.6 (6.5) 25.9 (6.4) 
Median (IQR) 28 (12) 26 (12) 
Age 
30+ 1,643 (32.7) 187 (14) 1.0 
25-29 1,384 (27.5) 261 (19.5) 1.7 (1.4-2.0) 
20-24 1,441 (28.6) 496 (37.1) 3.0 (2.5-3.6) 
<20 563 (11.2) 394 (29.4) 6.1 (5.0-7.5) 
Mean (SD) 26.8 (6.3) 23 (5.6) 
Median (IQR) 26 (8) 22 (7) 
P<0.001 
P<0.001 
p=0.03 
P<0.001 
Nulliparous women (OR=4.7; 95% CI, 4.1 to 5.5) and primiparous women (OR=2.0; 95% 
CI, 1.6 to 2.3) respectively were more likely to have positive dipstick tests compared to 
multiparous women in the study population. Similarly primigravidacs (OR=4.6; 95% Cl, 4.0 
to 5.3) and secundigravidaes (OR=2.2; 95% CI, 1.8 to 2.5) respectively were more likely than 
multigravidaes to have positive dipstick results. Pregnant women less than 30 years of age 
were more likely than those 30 years or above to have positive dipstick results as shown in 
Table 4.1. Gestational age at screening was associated significantly with a positive dipstick 
test result (p=0.03); women in their second trimester (OR=1.2; 95% CI, 1.0 to 1.3) were 
more likely to have a positive test result than those screened in their third trimester. 
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4.2.2 Performance of the OptiMAL® antigen test 
The results of parasite detection by the OptiMAL® dipstick and microscopy are shown in 
Tables 4.2 and 4.3. Using microscopy as the gold standard, the OptiMAL® dipstick was 
found to be highly sensitive (100%) and specific (93.3%) for the diagnosis of P. falciparcim 
infection in pregnancy with a negative predictive value of 100% for parasite densities above 
50/1. tL of whole blood. However, the sensitivity of the test was reduced to 57.1% with a 
specificity of 93.3% for parasite density below 50/pL. When the dipstick was compared with 
microscopy results labelled as negative or positive the dipstick had a sensitivity of 96.4% and 
a specificity of 85.5%. 
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4.3 Baseline characteristics 
4.3.3 Demographic and social characteristics 
The baseline demographic and social characteristics of pregnant women in the four treatment 
groups are shown in Table 4.4. The groups were similar with respect to all the characteristics 
recorded. In all the groups more than half of the women were below 25 years of age with an 
overall mean age of 23 years. Seventy percent of the women had received a formal education, 
mainly up to the junior secondary school level (44%). Fifty-seven percent of them were from 
the Brong ethnic group and mainly farmers (40%) or traders (29%). Twenty-five percent of 
the study population households had a bed net but only 14% of the study pregnant women 
slept under a bed net. 
4.3.4 Clinical and obstetric characteristics 
The results of the clinical and obstetric assessments of the women according to treatment 
group are shown in Table 4.5 and Table 4.6 respectively. There were no statistical 
significant differences between groups. Fifty-eight percent of the women admitted to not 
being well in the last 5 days prior to enrolment. Headache, fever, general malaise, dizziness 
and easy fatigability were their main complaints. However, only 7% of them had an axillary 
temperature of 37.5°C or above at enrolment; 4.1% and 0.9% had a palpable spleen and liver 
respectively at enrolment: Thirty-six percent gave a history of a drug reaction in the past, 
mainly itching due to chloroquine. Primigravidaes and nulliparae formed 52% and 55% 
respectively of the study population. 
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Table 4.4: - Demographic and social characteristics of study pregnant women 
CQ AQ SP AQ+SP Total 
(N=225) (N=225) (N=225) (N=225) (N=900) 
n (%) n (%) n (%) n (%) n (%) 
Age [years] 
<20 66 (29.3) 87 (38.7) 74 (32.9) 59 (26.2) 286 (31.8) 
20-24 82 (36.4) 77 (34.2) 82 (36.4) 90 (40) 331 (36.8) 
25-29 46 (20.4) 32 (14.2) 38 (16.9) 46 (20.4) 162 (18) 
30+ 31 (13.8) 29 (12.9) 31 (13.8) 30 (13.3) 121 (13.4) 
Mean (SD) 23.1 (5.6) 22.5 (5.9) 22.6 (5.4) 23.1 (5.3) 22.8 (5.6) 
Median (IQR) 22 (7) 20 (7) 21 (7) 22 (8) 21 (7) 
Educational level reached 
None 66 (29.3) 63 (28) 66 (29.3) 71 (31.6) 266 (29.6) 
Primary 44 (19.6) 46 (20.4) 50 (22.2) 46 (20.4) 186 (20.7) 
JSS 97 (43.1) 105 (46.7) 95 (42.2) 96 (42.7) 393 (43.7) 
SSS 12 (5.3) 11 (4.9) 9 (4) 7 (3.1) 39 (4.3) 
Tertiary 6 (2.7) 0 (0) 5 (2.2) 5 (2.2) 16 (1.8) 
Religion 
None 13 (5.8) 10 (4.4) 12 (5.3) 14 (6.2) 49 (5.4) 
Christian 188 (83.6) 188 (83.6) 192 (85.3) 196 (87.1) 764 (84.9) 
Islam 23 (10.2) 24 (10.7) 21 (9.3) 14 (6.2) 82 (9.1) 
Traditional African 1 (0.4) 3 (1.3) 0 (0) 1 (0.4) 5 (0.6) 
Ethnic Groups 
Akans 7 (3.1) 10 (4.4) 8 (3.6) 9 (4) 34 (3.8) 
Brongs 123 (54.7) 133 (59.1) 125 (55.6) 135 (60) 516 (57.3) 
Dagabas 38 (16.9) 35 (15.6) 43 (19.1) 33 (14.7) 149 (16.6) 
Dagombas 9 (4) 6 (2.7) 1 (0.4) 2 (0.9) 18 (2) 
Frafras 46 (20.4) 37 (16.4) 47 (20.9) 42 (18.7) 172 (19.1) 
Others 2 (0.9) 4 (1.8) 1 (0.4) 4 (1.8) 11 (1.2) 
Occupation 
Farmer 81 (36) 94 (41.8) 104 (46.2) 84 (37.3) 363 (40.3) 
Housewife 30 (13.3) 24 (10.7) 33 (14.7) 35 (15.6) 122 (13.6) 
Salary Worker 9 (4) 3 (1.3) 2 (0.9) 2 (0.9) 16 (1.8) 
Trader 67 (29.8) 71 (31.6) 50 (22.2) 69 (30.7) 257 (28.6) 
Other 38 (16.9) 33 (14.7) 36 (16) 35 (15.6) 142 (15.8) 
Marital Status 
Married 174 (77.3) 176 (78.2) 178 (79.1) 172 (76.4) 700 (77.8) 
Single 51 (22.7) 49 (21.8) 47 (20.9) 53 (23.6) 200 (22.2) 
Mean household size (SD) 6 (3) 6 (3) 6 (3) 6 (3) 6 (3) 
Households with a bed net 63 (28) 47 (20.9) 53 (23.6) 59 (26.2) 222 (24.7) 
Bed net Use 33 (14.7) 30 (13.3) 28 (12.4) 38 (16.9) 129 (14.3) 
No statistical differences between the groups p>0.05. 
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Table 4.5: - Baseline clinical characteristics according to treatment group 
Sick within last 5 days 
No 
Yes 
Fever 
No 
Yes 
Headache 
No 
Yes 
Vomiting 
No 
Yes 
Malaise 
No 
Yes 
Cough 
No 
Yes 
Dizziness 
No 
Yes 
Dysuria 
No 
Yes 
Easily Tired 
No 
Yes 
Chloroquine Allergy 
No 
Yes 
Past Drug Reactions 
No 
Yes 
Enlarged Spleen 
No 
Yes 
Enlarged Liver 
No 
Yes 
CQ AQ SP AQ+SP Total 
n (%) n (%) n (%) n (%) n (%) 
94 (41.8) 93 (41.3) 97 (43.1) 96 (42.7) 380 (42.2) 
131 (58.2) 132 (58.7) 128 (56.9) 129 (57.3) 520 (57.8) 
133 (59.6) 127 (57.2) 126 (56.5) 116 (52) 502 (56.3) 
90 (40.4) 95 (42.8) 97 (43.5) 107 (48) 389 (43.7) 
120 (53.8) 125 (56.1) 123 (55.2) 109 (49.1) 477 (53.5) 
103 (46.2) 98 (43.9) 100 (44.8) 113 (50.9) 414 (46.5) 
193 (86.6) 193 (85.8) 197 (87.6) 196 (88.3) 779 (87) 
30 (13.5) 32 (14.2) 28 (12.4) 26 (11.7) 116 (13) 
141 (62.9) 157 (69.8) 158 (70.2) 151 (68) 607 (67.7) 
83 (37.1) 68 (30.2) 67 (29.8) 71 (32) 289 (32.3) 
201 (90.1) 194 (86.2) 198 (88) 199 (90.1) 792 (88.6) 
22 (9.9) 31 (13.8) 27 (12) 22 (9.9) 102 (11.4) 
175 (78.1) 178 (79.1) 182 (80.9) 170 (76.9) 705 (78.8) 
49 (21.9) 47 (20.9) 43 (19.1) 51 (23.1) 190 (21.2) 
207 (92.4) 208 (92.4) 199 (88.4) 208 (93.7) 822 (91.7) 
17 (7.6) 17 (7.6) 26 (11.6) 14 (6.3) 74 (8.3) 
172 (76.8) 175 (77.8) 180 (80) 172 (77.5) 699 (78) 
52 (23.2) 50 (22.2) 45 (20) 50 (22.5) 197 (22) 
142 (63.1) 147 (65.3) 144 (64) 147 (65.4) 580 (64.4) 
83 (36.9) 78 (34.7) 81 (36) 78 (34.6) 320 (35.6) 
142 (63.1) 145 (64.4) 141 (62.7) 146 (64.9) 574 (63.8) 
83 (36.9) 80 (35.6) 84 (37.3) 79 (35.1) 326 (36.2) 
217 (96.4) 215 (95.6) 215 (95.6) 216 (96) 863 (95.9) 
8 (3.6) 10 (4.4) 10 (4.4) 9 (4) 37 (4.1) 
222 (98.7) 222 (98.7) 225 (100) 223 (99.1) 892 (99.1) 
3 (1.3) 3 (1.3) 0 (0) 2 (0.9) 8 (0.9) 
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Table 4.6: - Baseline obstetric characteristics according to treatment group. 
Gravidity 
1 
2 
3& above 
Parity 
0 
1 
2& above 
Gestation 
2nd trimester 
3rd trimester 
Blood Pressure (mmHg) 
Systolic (Mean (SD)) 
Diastolic (Mean (SD)) 
Temperature 
<37.5 
37.5°C or above 
Mean (SD) 
Height/cm 
Mean (SD) 
Weight/kg 
Mean (SD) 
CQ AQ SP AQ+SP Total 
n (%) n (%) n (%) n (%) n (%) 
126 (56) 121 (53.8) 114 (50.7) 111 (49.3) 472 (52.4) 
48 (21.3) 52 (23.1) 52 (23.1) 55 (24.4) 207 (23) 
51 (22.7) 52 (23.1) 59 (26.2) 59 (26.2) 221 (24.6) 
134 (59.6) 126 (56) 118 (52.4) 116 (51.6) 494 (54.9) 
67 (29.8) 68 (30.2) 77 (34.2) 80 (35.6) 292 (32.4) 
24 (10.7) 31 (13.8) 30 (13.3) 29 (12.9) 114 (12.7) 
96 (42.7) 99 (44) 104 (46.2) 95 (42.2) 394 (43.8) 
129 (57.3) 126 (56) 121 (53.8) 130 (57.8) 506 (56.2) 
104 (8.1) 103 (9.8) 104 (10) 105 (10.4) 104 (9.6) 
63 (5.8) 63 (6.8) 63 (6.8) 63 (7.3) 63 (6.7) 
203 (90.2) 213 (94.7) 211 (93.8) 214 (95.1) 841 (93.4) 
22 (9.8) 12 (5.3) 14 (6.2) 11 (4.9) 59 (6.6) 
36.5 (0.8) 36.5 (0.7) 36.4 (0.7) 36.5 (0.7) 36.5 (0.7) 
158.6 (6.6) 157.3 (6.5) 157.0 (6.2) 157.7 (6.9) 157.7 (6.6) 
56.4 (8.7) 55.4 (6.8) 55.3 (7.5) 56.5 (8.3) 55.9 (7.8) 
4.3.5 Use of chloroquine prior to enrolment 
Fifty-one percent of the study women said that they had taken chloroquine within the eight 
weeks prior to enrolment either for treatment or for prophylaxis as shown in Table 4.7. It 
was not ascertained, however, the proportions who took chloroquine for treatment or for 
prophylaxis. In sixty-eight percent of these women, this was confirmed by an enzyme-linked 
immunosorbent assay (ELISA) dipstick testing of the urine at no dilution and in 58% at 100- 
fold dilution. At zero dilution there was a 58.9% agreement between history and ELISA 
dipstick in detecting chloroquine use in the last 8 weeks prior to enrolment (kappa statistic of 
5.2 and p<0.001). At 100-fold urine dilution there was a 59.8% agreement between history 
and ELISA dipstick in detecting chloroquine use in the last 8 weeks prior to enrolment 
(kappa statistic = 5.9, p<0.001). 
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Muldgravidacs and multiparous women were about one and half times more likely to have 
used chloroquine prior to enrolment than primigravidae or primiparae. 
Table 4.7: - Assessment of chloroquine intake within 8 weeks prior to enrolment. 
Chloroquine detection in urine by ELISA dipstick 
At zero dilution At 100-fold dilution 
History of CQ use Negative Positive Negative Positive 
n (%) n (%) n (%) n (%) 
No 216 (49.3) 222 (50.7) 269 (61.4) 169 (38.6) 
Yes 149 (32.2) 313 (67.8) 193 (41.8) 269 (58.2) 
Total 365 (40.6) 535 (59.4) 462 (48.7) 438 (51.3) 
4.3.6 Para itological and haematological indices 
The distributions of baseline parasitological and haematological indices by treatment group 
are shown in Table 4.8. The groups were generally similar. However, there were more 
women with parasite densities higher than 1000/µl in the CQ group than in the other groups 
(p=0.08). Parasite densities ranged from 32 to 293120 per micro litre of blood. About twenty 
percent of the women had haemoglobin levels below 8g/dl and only 11% had normal 
haemoglobin levels at enrolment. The majority of the women (70%) had haemoglobin levels 
between 8 and 11g/dl. The mean haemoglobin concentration at enrolment was 9.1g/dl. 
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Table 4.8: - Baseline parasite density and haemoglobin levels according to treatment arm. 
CQ AQ SP AQ+SP Total 
(N=225) (N=225) (N=225) (N=225) (N=900) 
n (%) n (%) n (%) n (%) n (%) 
Parasite density/µL 
<1000/ul 108 (48) 128 (56.9) 112 (49.8) 131 (58.2) 479 (53.2) 
1000/ul & above 117 (52) 97 (43.1) 113 (50.2) 94 (41.8) 421 (46.8) 
Geometric Mean 1166 843 1071 842 970 
Range 32 - 293120 32 - 58800 32- 85333 48 - 194640 32 - 293120 
Haemoglobin 
< 8g/dl 44 (19.6) 39 (17.3) 45 (20) 49 (21.8) 177 (19.7) 
8- 10.9g/dl 156 (69.3) 165 (73.3) 156 (69.3) 151 (67.1) 628 (69.8) 
11g/dl & above 25 (11.1) 21 (9.3) 24 (10.7) 25 (11.1) 95 (10.6) 
Mean (SD) 9.1 (1.5) 9.2 (1.4) 9.2 (1.5) 9.1 (1.5) 9.1 (1.5) 
Median (IQR) 9.1 (1.9) 9.1 (1.8) 9.2 (2.1) 9.2 (2) 9.1 (1.9) 
4.3.7 Factors associated with baseline peripheral parasitaemia 
Variables associated with parasitaemia at enrolment are shown in Table 4.9. In a univariate 
analysis, baseline peripheral parasite density was found to be associated significantly with age, 
parity and gravidity (p<0.001). 
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Compared to multiparous women, nulliparous (OR=3.2 95% CI, 2.3 to 4.5) and primiparous 
women (OR=2.1; 95% CI, 1.4 to 3.1) were more likely to have parasite densities of 1000/µL 
or above in the study. Similarly primigravidaes (OR=2.9; 95% CI, 2.1 to 4.0) and 
secundigravidaes (OR=1.7; 95% CI, 1.1 to 2.5) were more likely than multigravidaes to have 
higher parasite densities. In multivariate analysis, only parity (being nulliparae or primiparae) 
remained associated significantly with high baseline parasite density (p<0.001). The effects of 
age and gravidity were confounded by parity. Parity and gravidity are highly correlated with a 
correlation coefficient of 0.97; p<0.001, and when both were included in the same model the 
effect of parity accounted for both variables. Thus, gravidity was dropped due to the co- 
linear effect. 
Pregnant women with higher parasite densities were more likely than those with densities 
below 1000/uI, to have total bilirubin concentrations above normal (OR= 1.7; 95% Cl, 1.2 to 
2.5). Also, solicited history of ill health, fever, headache, vomiting, easy fatigability and 
general malaise were associated significantly with higher parasite densities even after adjusting 
for parity, baseline haemoglobin and age. 
The proportions of clinical histories in a control group of pregnant women who did not have 
peripheral parasitaemia detected are compared with those in the study pregnant women in 
Table 4.10. The proportions of ill health including fever, headache, vomiting, general 
malaise, tiredness and dizziness were significantly lower in pregnant women without 
parasitaernia than in those with parasitaemia. 
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Table 4.10: - Comparisons of proportions of clinical symptoms presented by pregnant women with or 
without P. falciparum parasitaemia. 
Total number of women 
Sick within last 5 days 
Elicited signs & symptoms 
Fever 
Headache 
Vomiting 
Malaise 
Dizziness 
Easily Tired 
Prior CQ use 
Past Drug Reactions 
Chloroquine Allergy 
Temperature 
Patasitaemic 
[N=900] 
n (%) 
520 (57.8) 
389 (43.7) 
414 (46.5) 
116 (13) 
289 (32.3) 
190 (21.2) 
197 (22) 
462 (51.3) 
326 (36.2) 
320 (35.6) 
37.5°C or above 59 
Mean (SD) 36.5 
Enlarged Spleen 37 
Enlarged Liver 8 
11 Fisher's exact p-value 
Non-parasitaemic p- valueit 
[N=223] 
n (%) 
71 (31.8) <0.001 
14 (6.3) <0.001 
31 (13.9) <0.001 
2 (0.9) <0.001 
17 (7.6) <0.001 
7 (3.1) <0.001 
6 (2.7) <0.001 
154 (69.1) <0.001 
93 (41.7) 0.1 
94 (42.1) 0.1 
(6.6) 3 (1.4) 
(0.7) 35.5 (2.6) 
(4.1) 3 (1.4) 0.04 
(0.9) 1 (0.5) <0.001 
4.3.8 Factors associated with baseline haemoglobin concentrations 
Factors associated with baseline haemoglobin concentration are shown in Table 4.11. 
Anaemia at enrolment was associated significantly with younger mothers, nulliparae and 
primigravidaes (p<0.05). Increased serum bilirubin was also associated significantly with 
anaemia at enrolment (p=0.05). Baseline parasite density only had a borderline association 
(p=0.07) with anaemia at enrolment. When adjustments were made for parity and age only 
age and bilirubin remained associated with anaemia at enrolment. 
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CHAPTER FIVE 
TREATMENT OUTCOMES 
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CHAPTER 5 TREATMENT OUTCOMES 
5.1 Introduction 
This chapter presents the parasitological and haematological findings during the initial 28 
days of follow up after the start of treatment. The proportions of parasitological failure in the 
AQ, SP and AQ+SP groups are compared to failures in the CQ group at days 14 and 28 of 
follow up. Mean changes in haemoglobin over enrolment Hb levels at days 14 and 28 are 
compared within and between treatment groups. The chapter also describes the relationships 
between baseline prognostic factors and the parasitological and haematological outcomes of 
treatment. 
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5.2 Participants' flow during 28-day follow up period 
The flow of participants from randomisation through the initial 28-day follow-up period is 
shown in Figure 5.1. Nine hundred women were individually randomised and assigned 
blindly to CQ, AQ, SP or the AQ+SP combination. Thus, there were 225 in each treatment 
arm. The last woman was enrolled on 24 September 2004. After enrolment, each woman was 
followed up on scheduled follow up days. A woman was only excluded from subsequent 
follow ups if she withdrew her consent on a previous follow up visit. During the day 28 
follow up period, a woman who was lost to follow up or had experienced a pregnancy 
outcome was not excluded from subsequent follow ups. However, for women who had 
experienced a pregnancy outcome during this period, their parasitological and haematological 
outcomes were not included in the day 14 and day 28 analyses. They were analysed as part of 
pregnancy outcomes reported in chapter seven. 
At day 3 follow up, three women had parasitological failure, five withdrew consent, 22 were 
lost to follow-up, three of whom were not found on subsequent follow ups; and five had a 
pregnancy outcome. At day 7 follow up, four withdrew consent, two had parasitological 
failure, 21 were lost to follow up, four of whom were not found on subsequent follow ups; 
and four had a pregnancy outcome. At day 14 follow up, five withdrew consent, 24 had 
parasitological failure, 20 were lost to follow up, two of whom were not found on subsequent 
follow ups; and nine had a pregnancy outcome. At day 28 follow up, one withdrew consent, 
15 were lost to follow up, 88 had parasitological failure, five had a pregnancy outcome and 
721 of the women did not have parasitaemia. In all, there were 24 losses to follow-up, 23 
pregnancy outcomes, 15 withdrawals of consent, 117 parasitological failures and 721 
treatment successes by the end of the initial 28-day follow-up period. 
One hundred and eighty-eight women repeated their treatments after the initial 28-day 
follow-up period when malaria parasites were detected during screening at subsequent 
antenatal visits. The outcome of pregnancy in this subset of women is analysed separately. 
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5.3 Parasitological outcomes 
The cumulative incidence of parasitological failure by days 14 and 28 after treatment 
uncorrected and corrected by msp-2 genotyping are shown in Tables 5.1. 
Table 5.1: - Parasitological failure by days 14 and 28 after the start of treatment 
Uncorrected parasitological response Corrected parasitological response 
Success Failure Total Success Failure Total 
n (%) n (%) Nn (%) n (%) N 
DAY 14 
CQ 197 (92.9) 15 (7.1) 212 199 (96.6) 7 (3.4) 206 
SP 200 (95.2) 10 (4.8) 210 202 (97.6) 5 (2.4) 207 
AQ 212 (98.6) 3 (1.4) 215 213 (99.5) 1 (0.5) 214 
AQ+SP 210 (99.5) 1 (0.5) 211 210 (100) 0 (0) 210 
Total 819 (96.6) 29 (3.4) 848 824 (98.4) 13 (1.6) 837 
DAY 28 
CQ 146 (70.2) 62 (29.8) 208 157 (84) 30 (16) 187 
SP 174 (83.6) 34 (16.4) 208 178 (89) 22 (11) 200 
AQ 196 (92.5) 16 (7.5) 212 200 (97.1) 6 (2.9) 206 
AQ+SP 205 (97.6) 5 (2.4) 210 205 (99) 2 (1.0) 207 
Total 721 (86) 117 (14) 838 740 (92.5) 60 (7.5) 800 
The primary analyses compared outcomes in each treatment group to the outcome in the CQ 
group. As shown in Table 5.1, the cumulative incidence of asexual P. falcipanml parasitaemia 
were 0.5%, 1.4%, 4.8% and 7.1% respectively for the AQ+SP combination, AQ, SP and CQ 
groups by day 14. By day 28 the cumulative incidence of parasitaemia was 2.4%, 7.5%, 16.4% 
and 29.8% respectively for the AQ+SP, AQ, SP and CQ groups. After correction by msp-2 
genotyping, 0%, 0.5%, 2.4% and 3.4% were classified as true failures for the AQ+SP, AQ, 
SP and CQ groups respectively on day 14. At day 28,1.0%, 2.9%, 11 % and 16% for the 
AQ+SP, AQ, SP and CQ groups respectively were classified as true failures. A total 38 
samples were classified as undetermined because the PCR gcnotyping failed. The prevalence 
of parasitological failure by days 14 and 28 according to treatment groups are shown in 
Figures 5.2 and 5.2 respectively. 
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Figure 5.2: - Uncorrected parasitological failure by days 14 and 28 according to treatment group. 
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Figure 5.3: PCR-corrected parasitological failure at days 14 and 28 according to treatment group. 
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"1'hc proportions of parasitological failure by day 14 and 28 when PCR classified re-infections 
and unclassified results are regarded as withdrawals as recommended by the WHO (WHO 
2003b), are shown in Table 5.2 and Figure 5.4. The proportions are generally similar to 
those shown in Table 5.1 when re-infections were classified as treatment successes. 
Table 5.2: - PCR-corrected parasitological failure at days 14 and 28 excluding re-infections. 
Corrected parasitological response 
Success Failure Total 
n (%) n (%) N 
DAY 14 
CQ 197 (96.6) 7 (3.4) 204 
SP 200 (97.6) 5 (2.4) 205 
AQ 212 (99.5) 1 (0.5) 213 
AQ+SP 210 (100) 0 (0) 210 
Total 819 (98.4) 13 (1.6) 832 
DAY 28 
CQ 146 (82.9) 30 (17.1) 176 
SP 174 (88.8) 22 (11.2) 196 
AQ 196 (97) 6 (3) 202 
AQ+SP 205 (99) 2 (1) 207 
Total 721 (92.3) 60 (7.7) 781 
Figure 5.4: - PCR-corrected parasitological failure at days 14 and 28 excluding re-infections. 
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The odds of parasitological failure in the treatment groups compared to the CQ group by 
days 14 and 28 are shown in Table 5.3. 
Table 5.3: The odds of parasitological failure at days 14 and 28. 
Unadjusted odds ratio p-value Adjusted odds ratio p-value 
(95% CI) (95% Cl) 
DAY 14 
Uncorrected Failure 
CQ 1.0 1.0 
SP 0.7 (0.3-1.5) 0.3 0.7 (0.3-1.6) 0.4 
AQ 0.2 (0.1-0.7) 0.01 0.2 (0.1-0.7) 0.01 
AQ+SP 0.1 (0.01 -0. ) 0.01 0.1 (0.01-0.5) 0.01 
Corrected Failure 
CQ 1.0 1.0 
SP 0.7 (0.2-2.3) 0.6 0.8 (0.2-2.8) 0.7 
AQ 0.1 (0.02-1.1) 0.06 0.2 (0.02-1.5) 0.10 
AQ+SP 
------ 
DAY 28 
Uncorrected Failure 
CQ 
SP 
AQ 
AQ+SP 
Corrected Failure 
CQ 
SP 
AQ 
AQ+SP 
1.0 1.0 
0.5 (0.3-0.8) 0.002 0.5 (0.3-0.8) 0.002 
0.2 (0.1-0.3) < 0.001 0.2 (0.1-0.4) < 0.001 
0.1 (0.02-0.1) < 0.001 0.1 (0.02-0.1) < 0.001 
1.0 1.0 
0.5 (0.3-0.9) 0.02 0.7 (0.4-1.3) 0.20 
0.2 (0.1-0.4) < 0.001 0.2 (0.1-0.4) < 0.001 
0.1 (0.02-0.2) < 0.001 0.1 (0.01-0.2) < 0.001 
SP compared to CQ decreased the risk of uncorrected parasitological failure in the study 
women by 30% on day 14 (0R=0.7; 95% CI 0.3 to 1.5) and by 50% on day 28 (OR=0.5; 
95% CI, 0.3 to 0.8). The ORs after adjusting for baseline parasite density, baseline Hb, parity, 
gravidity, and prior ill health did not change. After correcting for new infections, SP 
compared to CQ decreased the risk of parasitological failure in the study women again by 
30% on day 14 (OR=0.7; 95% CI 0.2 to 2.3) and by 50% on day 28 (OR=0.4; 95% CI, 0.1 to 
1.4). The corrected day 14 OR did not change after adjusting for baseline parasite density, 
baseline Hb, parity, gravidity, and prior ill health however, the day 28 adjusted OR increased 
but was no longer significant. 
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AQ compared to CQ decreased the risk of uncorrected parasitological failure in the study 
women by 80% on day 14 (OR=0.2; 95% Cl, 0.1 to 0.7) and by a similar margin on day 28 
(OR=0.2; 95% Cl, 0.1 to 0.3). The ORs were 0.2 (95% Cl, 0.1 to 0.7) on day 14 and 0.2 
(95% Cl, 0.1 to 0.4) on day 28 after adjusting for baseline parasite density, baseline Hb, parity 
or prior ill health. After correcting for new infections, AQ compared to CQ, decreased the 
risk of parasitological failure in the study women by 90% on day 14 (OR=0.1; 95% CI, 0.02 
to 1.1) and by 80% on day 28 (OR=0.2; 95% Cl, 0.01 to 0.4). The corrected ORs were 0.2 
(95% Cl, 0.02 to 1.5) on day 14 and 0.2 (95% CI, 0.01 to 0.4) on day 28 after adjusting for 
baseline parasite density, baseline Hb, parity or prior ill health. 
The AQ+SP combination compared to CQ decreased the risk of uncorrected parasitological 
failure in the study women by more than 90% on day 14 (OR=0.1; 95% Cl, 0.01 to 0.5) and 
by similar margin on day 28 (OR=0.1; 95% CI, 0.02 to 0.1). These did not change after 
adjusting for baseline parasite density, baseline Hb, parity, and prior ill health. There were no 
true parasitological failures on day 14 in the AQ+SP combination group. After correcting for 
new infections, the AQ+SP combination decreased the risk of parasitological failure by 90% 
on day 28 (OR=0.1; 95% CI, 0.02 to 0.2). This did not change after adjusting for baseline 
parasite density, baseline Hb, parity, and prior ill health. 
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5.3.1 Risk factors forpararitological failure 
The unadjusted and adjusted estimates of the association between baseline factors and 
parasitological failure at day 28 independent of treatment are shown in Table 5.4. 
As shown in Table 5.4, higher parasite densities at enrolment increased the risk of 
parasitological failure at day 28 (p<0.001). Women with parasite densities of 1000/ d or 
above at enrolment were three times more likely to have parasitological failure by day 28 
(OR=3.0; 95% Cl, 2.0 to 4.5) compared to women who had parasite densities less than 
1000/0 at enrolment. After adjusting for parity, gravidity, baseline Hb and age, women with 
parasite densities of 1000/0 or above at enrolment were about two and half times more 
likely to have parasitological failure by day 28 (OR=2.4; 95% CI; 1.6 to 3.8). 
Parity was associated significantly with parasitological failure at day 28, (p<0.001). Compared 
to multiparous women, nulliparous and primiparous women respectively were about 8 times 
(OR=7.7; 95% CI, 3.3 to 17.9) and 3 times (OR=3.1; 95% CI, 1.2 to 8.1) more likely to 
experience parasitological failure at day 28. After adjusting for baseline parasite density, 
baseline Hb and age, nulliparous women (OR=8.1; 95% Cl, 2.9 to 9.3) and primiparous 
women (OR=3.2; 95% Cl, 1.1 to 9.3) were still more likely to experience parasitological 
failure at day 28 compared to multiparous women. 
Gravidity was associated significantly with parasitological failure at day 28, p<0.001. 
Compared to multigravid women, primigravidaes and secundigravidaes respectively, were 
about 6 times (OR=6.2; 95% CI, 2.6 to 14.6) and two and half (OR=2.4; 95% CI, 0.9 to 6.3) 
times more likely to experience parasitological failure at day 28. When both parity and 
gravidity are included in the same model the effect of gravidity is completely suppressed and 
that of parity increased. Parity and gravidity are highly correlated with a correlation 
coefficient of 0.98; p<0.001 and so gravidity was not included in the final model. 
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Baseline haemoglobin was associated significantly with parasitological failure at day 28, 
p=0.01. Compared to women who had Hb of 11g/dl or above, women with baseline Hb 
concentrations below 8g/dl were about 4 times (OR=3.7; 95% CI, 1.4 to 9.9) and those with 
an Hb concentration of 8 to 10.9g/dl, were about 3 times (OR=2.7; 95% CI, 1.1 to 6.9) more 
likely to experience parasitological failure at day 28. When adjustment is made for baseline 
parasite density, parity and age, having an Hb concentration below 11g/dl was no longer 
associated with parasitological failure at day 28 (p=0.1). When the women were categorised 
as those with an Hb concentrations 5 to 10.9g/dl or, 11g/dl or above, women with baseline 
Hb concentrations 5 to 10.9g/dl were about 3 times more likely to experience parasitological 
failure compared to those with an Hb concentration of 11g/dl or above at enrolment 
(OR=2.9; 95% CI, 1.2 to 7.3 p<0.02). 
Younger mothers were more likely to experience parasitological failure at 28 (p=0.01) but 
after adjusting for baseline parasite density, baseline Hb and parity age was no longer 
associated with parasitological failure at day 28 (p=0.1). 
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The unadjusted and adjusted estimates of the association between baseline factors and 
parasitological failure at day 14 independent of treatment are shown in Table 5.5. 
By day 14, baseline parasite density was associated significantly with parasitological failure 
(p<0.001) as shown in Table 5.5. Women with parasite densities of 1000/1d or above at 
enrolment were more likely to fail treatment at day 14 compared to women who had parasite 
densities less than 1000/µl at enrolment (OR=7.6; 95% CI, 2.6 to 22.1). After adjustments 
were made for baseline Hb, parity and age high enrolment parasite density was still associated 
significantly with parasitological failure at day 14 (<0.001). In the univariate analysis, parity 
and gravidity were associated significantly with parasitological failure at day 14 but not after 
adjustments were made for age. Age and baseline Hb were not associated with parasitological 
failure at day 14 (p>0.1). 
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5.4 Haematological outcomes 
The effect of treatment on haemoglobin was assessed by determining the absolute change 
from baseline over time using ANOVA and multiple regression analysis. The proportions of 
pregnant women with 3 categories of haemoglobin concentrations at days 14 and 28 after the 
start of treatment are shown in Table 5.6. 
Table 5.6: - Haemoglobin concentrations at days 14 and 28 after start of treatment. 
CQ SP AQ AQ+SP Total 
n (%) n (%) n (%) n (%) N (%) 
DAY 14 
< 8g/dl 21 (10.1) 38 (18.1) 18 (8.5) 31 (14.7) 108 (12.8) 
8- 10.9g/dl 153 (73.2) 143 (68.1) 167 (78.8) 145 (68.7) 608 (72.2) 
11g/dI or above 35 (16.8) 29 (13.8) 27 (12.7) 35 (16.6) 126 (15) 
Mean (SD) 9.7 (1.3) 9.4 (1.4) 9.6 (1.3) 9.6 (1.6) 9.6 (1.4) 
Median (IQR) 9.7 (1.6) 9.5 (1.9) 9.8 (1.6) 9.6 (1.9) 9.6 (1.8) 
DAY 28 
< 8g/dl 26 (12.7) 17 (8.3) 7 (3.3) 10 (4.8) 60 (7.2) 
8- 10.9g/dl 130 (63.4) 133 (64.9) 150 (70.1) 141 (67.8) 554 (66.6) 
11g/dl or above 49 (23.9) 55 (26.8) 57 (26.6) 57 (27.4) 218 (26.2) 
Mean (SD) 9.8 (1.7) 10.0 (1.6) 10.2 (1.4) 10.2 (1.4) 10.1 (1.5) 
Median (IQR) 9.8 (2.1) 9.9 (2) 10.0 (1.9) 10.1 (2) 10.0 (2) 
As shown in Table 5.6 and Figure 5.5, there was a general improvement in Hb levels within 
all treatment groups over the follow up period after treatment. The overall proportions of 
women with Hb below 8g/dl had decreased from about 20% on day 0 to 13% and 7% on 
days 14 and 28 respectively while the proportions of women with an Hb of 11g/dl or above 
had increased from 11% on day 0 to 15% and 26% on days 14 and 28 respectively. Also 
within all the treatment groups mean haemoglobin concentrations increased by days 14 and 
28 respectively compared to the means at enrolment as shown in Figure 5.6. 
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Figure 5.5: - Improvements in haemoglobin concentrations following treatment. 
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Figure 5.6: - Mean Hb concentrations according to treatment group during the day 28 follow up period 
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The mean changes in haemoglobin concentrations within and between the treatment groups 
over time are shown in Table 5.7 and Figure 5.7 
Table 5.7: - Comparison of mean haemoglobin changes by AQ, SP and AQ+SP with CQ. 
Mean change (SD) Range Mean difference p- value F-statistic 
(min to max) compared to CQ (p - value) 
(95% CI) 
DAY 14 
C(2 0.6 (1.4) (-4.0 to 5.6) 
SP 0.3 (1.3) (-4.4 to 4.6) -0.3 (-0.6 to -0.1) 0.02 
AQ 0.5 (1.4) (-6.4 to 4.9) -0.1 (-0.4 to 0.2) 0.5 
AQ+SP 0.4 (1.4) (5.0 to 6.6) -0.1 (-0.4 to 0.1) 0.3 
DAY 28 
C(2 0.7 (1.6) (-3.1 to 6.0) 
SP 0.9 (1.4) (-4.5 to 6.5) 0.2 (-0.1 to 0.5) 0.2 
AQ 1.0 (1.4) (-6.0 to 5.4) 0.3 (0.1 to 0.6) 0.02 
AQ+SP 1.0 (1.5) (-5.8 to 7.7 0.3 (0.1 to 0.6) 0.02 
1.9 (0.1) 
2.5(0.06) 
Figure 5.7: - Change in haemoglobin levels over 28 days follow up period after start of treatment. 
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There was an overall mean increase of 0.4g/dl (95% CI; 0.3 to 0.5) p<0.001 in Hb concentration 
at day 14 relative to the baseline mean concentrations. The mean changes were 0.6,0.3,0.5 and 
0.4g/dl respectively for CQ, SP, AQ and AQ+SP combination groups over the initial 14 days 
following enrolment. There was a mean increase in haemoglobin concentration of about 0.1g/dl 
more in the CQ group than in the AQ and AQ+SP groups respectively and about 0.3g/dl more 
in the CQ group than in the SP group. However, the differences between the CQ and AQ and 
the AQ+SP groups were not statistically significant while the difference for the SP group was 
significant (p = 0.02). The absolute mean changes were statistically not different at day 14 (F- 
statistic 1.9; p=0.1) 
At day 28, the overall mean increase in Hb concentration was 0.9g/dl (95% CI; 0.8 to 1.0) 
p<0.001 relative to the baseline mean concentrations. The mean changes were 0.7,0.9,1.0 and 
1.0g/dl respectively for CQ, SP, AQ and AQ+SP combination groups at day 28. The mean 
haemoglobin increase was about 0.3g/dl less in the CQ group compared to the AQ and AQ+SP 
groups respectively and about 0.2g/dl less in the CQ group than in the SP group. These 
differences were statistically significant for the CQ versus AQ and AQ+SP comparisons (p = 
0.02) but not significant in the case of CQ versus SP (p = 0.2). The mean changes in 
haemoglobin remained unchanged when baseline parasite density, parity, gravidity or age were 
included in the regression model. As shown in Figure 5.7, within each treatment group, the 
change at day 28 tended to be higher than would have occurred by day 14. 
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CHAPTER 6 SAFETY AND TOLERANCE 
6.1 Introduction 
This chapter presents the results of the safety and tolerance observations made among the study 
pregnant women over the 28-day follow up period after the start of treatment. The first section 
describes the types and incidence of adverse effects reported by women during post treatment 
follow up at days 3,7,14 and 28 and makes comparisons between treatment groups. A 
comparison is also made of the incidences of complaints obtained from a sample of untreated 
non-parasitaemic pregnant women screened at the same clinic and who received the same 
number of follow up visits with those of enrolled parasitaemic pregnant women. The second 
section describes the levels of liver enzymes and bilirubin at days 0,14 and 28 and compares: - 
" The proportions of women within predefined categories within treatment groups and in 
all treatment groups compared with CQ. 
" The absolute mean changes at days 14 and 28 over baseline levels within treatment 
groups and in all treatment groups compared with CQ. 
" The baseline liver enzymes and bilirubin levels in the study pregnant women with values 
obtained from a random sample of pregnant women who had negative OptiMAL® 
dipstick tests at screening. 
This section also compares the white blood cell counts at days 0,3,7,14 and 28 based on a 
reference range of 4.0 - 11.0 x 109/L within treatment groups and in all treatment groups 
compared with the CQ group. 
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6.2 Incidence of drug adverse events 
The proportions of treated pregnant women who reported an adverse effect at days 3,7,14 and 
28 of follow up are shown in Figure 6.1. 
Figure 6.1: - Reports of a adverse effect on follow up days according to treatment group 
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Overall, seventy-five percent of women at follow up day 3 reported an adverse effect. As shown 
in Figure 6.1 and Table 6.1, adverse effects were reported by 76%, 86% and 90% of women in 
the CQ, AQ and AQ+SP groups respectively compared to 48% by women in the SP group. 
General weakness, dizziness, vomiting, itching and nausea were the five most frequently reported 
adverse effects. The reports of weakness, vomiting, dizziness and nausea were highest in the AQ 
and AQ+SP groups and least in the SP groups. The reports of itching were highest in the CQ 
group and least in the SP group. A total of 75 women at day 3 had not completed the last dose 
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of their treatment; 40(53%) claimed they had forgotten to take the last dose and 35(47%) 
attributed their inability to finish their treatment to adverse effects. 
Table 6.1: - Reports of adverse effects by study pregnant women at day 3 after the start of treatment. 
CQ AQ SP AQ+SP Total p-value 
n (%) n (%) n (%) n (%) n (%) 
Report of a adverse effect 
No 52 (24.2) 31 (14.1) 113 (52.1) 21 (9.7) 217 (25) 
Yes 163 (75.8) 189 (85.9) 104 (47.9) 196 (90.3) 652 (75) <0.001 
General weakness 
No 109 (50.7) 35 (15.9) 153 (70.5) 35 (16.1) 332 (38.2) 
Yes 106 (49.3) 185 (84.1) 64 (29.5) 182 (83.9) 537 (61.8) <0.001 
Dizziness 
No 118 (54.9) 93 (42.3) 184 (84.2) 95 (43.8) 490 (56.4) 
Yes 97 (45.1) 127 (57.7) 33 (15.2) 122 (56.2) 379 (43.6) <0.001 
Vomiting 
No 145 (67.4) 119 (54.1) 185 (85.3) 86 (39.6) 535 (61.6) 
Yes 70 (32.6) 101 (45.9) 32 (14.7) 131 (60.4) 334 (38.4) <0.001 
Itching 
No 127 (59.1) 149 (67.7) 182 (83.9) 161 (74.2) 619 (71.2) 
Yes 88 (40.9) 71 (32.3) 35 (16.1) 56 (25.8) 250 (28.8) <0.001 
Nausea 
No 165 (76.7) 163 (74.1) 191 (88) 135 (62.2) 654 (75.3) 
Yes 50 (23.3) 57 (25.9) 26 (12) 82 (37.8) 215 (24.7) <0.001 
Headache 
No 169 (78.6) 172 (78.2) 172 (79.3) 163 (75.1) 676 (77.8) 
Yes 46 (21.4) 48 (21.8) 45 (20.7) 54 (24.9) 193 (22.2) 0.74 
Completed treatment 
No 22 (10.2) 15 (6.8) 13 (6) 25 (11.5) 75 (8.6) 
Yes 193 (89.8) 205 (93.2) 204 (94) 192 (88.5) 794 (91.4) 0.12 
Why treatment not completed 
Forgot 9 (40.9) 9 (60) 12 (100) 10 (38.5) 40 (53.3) 
Adverse effects 13 (59.1) 6 (40) 0 (0) 16 (61.5) 35 (46.7) 0.002 
Routine activities interfered 
No 189 (87.9) 133 (60.4) 208 (95.8) 124 (57.1) 654 (75.3) 
Yes 26 (12.1) 87 (39.6) 9 (4.2) 93 (42.9) 215 (24.7) <0.001 
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For women in the SP group, the active drugs were taken on day 0 supervised so the drug pack 
they took home contained only placebo. However, no woman in the SP group who had not 
finished taking the contents of this pack attributed it to adverse effects. Twenty-five percent of 
the women at day 3 claimed their routine activities had been inhibited by the effects of the study 
drugs. This was reported by 43%, 40%, 12% and 4% of women in the AQ+SP, AQ, CQ and SP 
groups respectively. 
A comparison of the SP, AQ and AQ+SP groups with the CQ group with respect to the 
incidence of common adverse effects among the study group is shown in Table 6.2. 
The odds of reporting an adverse effect following treatment with AQ were two times higher 
compared with those treated with CQ; (OR= 1.9,95% CI, 1.7 - 3.2 p=0.01). Those who received 
the AQ+SP combination were 3 times more likely to report an adverse effect (OR=3.0; 95% CI, 
1.7 - 5.1 p<0.001) compared to the CQ group. Reports of an adverse effect were 70% less 
frequently from those who took SP (OR=0.3; 95% CI, 0.19 - 0.44 p<0.001) compared with 
those who took CQ. 
Reports of general weakness were 5 times more frequent from the AQ (OR=5.4; 95% Cl, 3.5 to 
8.5 p<0.001) and AQ+SP (OR=5.3; 95% CI, 3.5 to 8.4 p<0.001) groups respectively and about 
60% less frequent from the SP group (OR=0.4; 95% CI, 0.3 to 0.6 p<0.001) compared with the 
CQ group. Reports of vomiting were more frequent from the AQ (OR= 1.8; 95% CI, 1.2 to 2.6 
p<0.001) and AQ+SP (OR=3.2; 95% CI, 2.1 to 4.7) groups respectively and 65% less frequent 
from the SP group (OR=0.3; 95% CI, 0.3 to 0.7 p<0.001) compared with the CQ group. AQ 
alone was not associated with nausea (p=0.5) however, reports of nausea were 2 times more 
frequent in the AQ+SP combination group (OR=2.0; 95% CI, 1.3 to 3.0 p=0.001) and about 
50% less frequent in the SP group (OR=0.5; 95% CI, 0.3 to 0.8 p=0.002) compared with the CQ 
group. Reports of dizziness were about one and half times more frequent in the AQ (OR=1.7; 
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95% Cl, 1.1 to 2.4 p=0.01) and AQ+SP (OR=1.6; 95% CI, 1.1 to 2.3 p=0.02) groups 
respectively; and about 80% less frequent in the SP group (OR=0.2; 95% Cl, 0.1 to 0.4 
p<0.001). Itching was most frequently reported by those in the CQ group and least frequent in 
the SP group (OR=0.3; 95% CI, 0.2 to 0.4 p<0.001). Reports of inability to perform routine 
chores following treatment were five times more likely to come from women who took AQ 
(OR=4.8; 95% CI, 2.9 to 7.8 p<0.001) and AQ+SP (OR=5.5; 95% CI, 3.3 to 8.9 p<0.001) 
respectively and about 70% less frequent from those who took SP (OR=0.3; 95% CI, 0.1 to 0.7 
p=0.004) compared to taking CQ. The frequency of reports of headache were similar in all the 
treatment groups (p>0.1). When adjustments were made for baseline parasite density, baseline 
Hb, parity, gestation, age and prior ill health, the odds ratios were similar to the unadjusted 
estimates. 
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Table 6.3: - Reports of adverse effects by study pregnant women at day 7 after the start of treatment. 
CQ AQ SP AQ+SP Total p-value 
n (%) n (%) n (%) n (%) n (%) 
Report of an adverse effect 
No 152 (69.4) 145 (66.5) 145 (66.5) 130 (60.2) 572 (65.7) 
Yes 67 (30.6) 73 (33.5) 73 (33.5) 86 (39.8) 299 (34.3) 0.2 
General weakness 
No 170 (77.6) 146 (67) 165 (75.7) 132 (61.1) 613 (70.4) 
Yes 49 (22.4) 72 (33) 53 (24.3) 84 (38.9) 258 (29.6) <0.001 
Dizziness 
No 185 (84.5) 186 (85.3) 194 (89) 171 (79.2) 736 (84.5) 
Yes 34 (15.5) 32 (14.7) 24 (11) 45 (20.8) 135 (15.5) 0.04 
Vomiting 
No 188 (85.8) 190 (87.2) 201 (92.2) 176 (81.5) 755 (86.7) 
Yes 31 (14.2) 28 (12.8) 17 (7.8) 40 (18.5) 116 (13.3) 0.01 
Itching 
No 201 (91.8) 191 (87.6) 190 (87.2) 193 (89.3) 775 (89) 
Yes 18 (8.2) 27 (12.4) 28 (12.8) 23 (10.7) 96 (11) 0.4 
Nausea 
No 186 (84.9) 195 (89.4) 198 (90.8) 183 (84.7) 762 (87.5) 
Yes 33 (15.1) 23 (10.6) 20 (9.2) 33 (15.3) 109 (12.5) 0.1 
Headache 
No 185 (84.5) 189 (86.7) 176 (80.7) 183 (84.7) 733 (84.2) 
Yes 34 (15.5) 29 (13.3) 42 (19.3) 33 (15.3) 138 (15.8) 0.4 
Routine activities interfered 
No 4 (1.8) 16 (7.3) 2 (0.9) 16 (7.4) 38 (4.4) 
Yes 215 (98.2) 202 (92.7) 216 (99.1) 200 (92.6) 833 (95.6) <0.001 
Overall, thirty-four percent of women at follow up day 7 reported an adverse effect. As shown in 
Figure 6.1 and Table 6.3, the frequencies of reports of an adverse effect, itching, nausea and 
headache similar in all the treatment groups (p<0.1). General weakness was more frequently 
reported by women in the AQ (33%) and AQ+SP (39%) groups than by women in the CQ 
(22%) and SP (24%) groups. Dizziness was reported most frequently by women in the AQ+SP 
(21%) compared to 16%, 15% and 11% of women in the CQ, AQ and SP the groups 
respectively. Vomiting was reported less frequently by women in the SP (8%) group compared to 
14%, 13% and 19% of women in the CQ, AQ and AQ+SP groups respectively. Four percent of 
the women at day 7 claimed their routine activities had been inhibited by the effects of the study 
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drugs. This was reported more frequently by women in the AQ (7%) and AQ+SP (7%) groups 
compared to 2% andl% of women in the CQ and SP respectively. 
A comparison of the SP, AQ and AQ+SP groups with the CQ group with respect to the 
incidence of common adverse effects reported on day 7 was made using logistic regression. 
Compared to the CQ group, women in the AQ+SP combination group were one and half times 
more likely (OR=1.5; 95% CI, 1.0 to 2.2 p=0.04) to report an adverse effect on day 7 but the 
AQ and SP groups respectively, were not different from the CQ (OR= 1.1; 95% Cl, 0.8 to 1.7 
p=0.5). Reports of general weakness on day 7 were more frequent from the AQ (OR=1.7; 95% 
CI, 1.1 to 2.6 p<0.01) and AQ+SP (OR=2.2; 95% CI, 1.5 to 3.6 p<0.001) groups respectively 
compared with the CQ group but the SP group was not different from the CQ group (OR=1.1; 
95% Cl, 0.7 to 1.7 p<0.6). Compared to the CQ group, those in the SP group were 50% less 
likely to report vomiting on day 7 (OR=0.5; 95% CI, 0.3 to 1.0 p=0.03) but there was no 
statistical difference in incidence in the AQ and AQ+SP groups respectively compared to the 
CQ group (p>0.1). Although the distribution of reports of dizziness on day 7 according to 
treatment groups was significantly different (p=0.04), they were not when all the groups were 
compared to the CQ group (p>0.1). Reports of inability to perform routine chores on day 7 
were four times more likely to come from women in the AQ (OR=4.3; 95% Cl, 1.4 to 13.0 p=0. 
01) and AQ+SP (OR=4.3; 95% CI, 1.4 to 13.1 p<0.01) groups respectively and about 50% less 
frequent from those in the SP group (OR=0.5; 95% CI, 0.1 to 2.7 p=0.4) compared to those in 
the CQ group. When adjustments were made for baseline parasite density, baseline Hb, parity, 
gestation, age and prior ill health, the odds ratios were similar to the unadjusted estimates. 
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Table 6.4: - Reports of adverse effects by study pregnant women at day 14 after the start of treatment. 
Report of a side effect 
No 
Yes 
CQ AQ SP AQ+SP Total p-value 
n (%) n (%) n (%) n (%) n (%) 
151 (69.9) 165 (75) 157 (73) 159 (74.3) 632 (73.1) 
65 (30.1) 55 (25) 58 (27) 55 (25.7) 233 (26.9) 0.6 
General weakness 
No 181 (83.8) 188 (85.4) 171 (79.5) 175 (81.8) 715 (82.7) 
Yes 35 (16.2) 32 (14.6) 44 (20.5) 39 (18.2) 150 (17.3) 0.4 
Dizziness 
No 192 (88.9) 199 (90.4) 193 (89.8) 192 (89.7) 776 (89.7) 
Yes 24 (11.1) 21 (9.6) 22 (10.2) 22 (10.3) 89 (10.3) 0.9 
Vomiting 
No 
Yes 
Itching 
No 
Yes 
Nausea 
No 
Yes 
Headache 
No 
Yes 
197 (91.2) 200 (90.9) 206 (95.8) 200 (93.5) 803 (92.8) 
19 (8.8) 20 (9.1) 9 (4.2) 14 (6.5) 62 (7.2) 0.2 
205 (94.9) 213 (96.8) 191 (88.8) 207 (96.7) 816 (94.3) 
11 (5.1) 7 (3.2) 24 (11.2) 7 (3.3) 49 (5.7) 0.001 
195 (90.3) 202 (91.8) 206 (95.8) 196 (91.6) 799 (92.4) 
21 (9.7) 18 (8.2) 9 (4.2) 18 (8.4) 66 (7.6) 0.2 
179 (82.9) 183 (83.2) 189 (87.9) 183 (85.5) 734 (84.9) 
37 (17.1) 37 (16.8) 26 (12.1) 31 (14.5) 131 (15.1) 0.4 
Routine activities interfered 
No 3 (1.4) 5 (2.3) 4 (1.9) 2 (0.9) 14 (1.6) 
Yes 213 (98.6) 215 (97.7) 211 (98.1) 212 (99.1) 851 (98.4) 0.7 
Overall, twenty-seven percent of women at follow up day 14 reported an adverse effect. As 
shown in Figure 6.1 and Table 6.4, the frequencies of reports of an adverse effect, general 
weakness, vomiting, nausea, headache and inhibition of performance of household chores were 
similar in all the treatment groups (p<0.1). Itching was reported most frequently by women in 
the SP (11%) group compared to 5%, 3% and 3% of women in the CQ, AQ and AQ+SP 
groups respectively and this difference was significant p=0.001. Compared to the CQ group, 
women in the SP group were about twice likely to report itching on day 14 (OR=2.3; 95% CI, 
1.1 to 4.9 p=0.02) but there was no statistical difference in incidence in the AQ and AQ+SP 
groups respectively compared to the CQ group (p>0.1). 
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Table 6.5: - Reports of adverse effects by study pregnant women at day 28 after the start of treatment. 
CQ 
n% 
AQ SP AQ+SP Total p-value 
n (%) n (%) n (%) n (%) 
Report of a side effect 
No 129 (62.6) 168 (78.1) 142 (68.3) 153 (71.8) 592 (70.3) 
Yes 77 (37.4) 47 (21.9) 66 (31.7) 60 (28.2) 250 (29.7) 0.01 
General weakness 
No 150 (72.8) 174 (80.9) 163 (78.4) 169 (79.3) 656 (77.9) 
Yes 56 (27.2) 41 (19.1) 45 (21.6) 44 (20.7) 186 (22.1) 0.2 
Dizziness 
No 177 (85.9) 197 (91.6) 185 (88.9) 186 (87.3) 745 (88.5) 
Yes 29 (14.1) 18 (8.4) 23 (11.1) 27 (12.7) 97 (11.5) 0.3 
Vomiting 
No 186 (90.3) 196 (91.2) 190 (91.3) 187 (87.8) 759 (90.1) 
Yes 20 (9.7) 19 (8.8) 18 (8.7) 26 (12.2) 83 (9.9) 0.6 
Itching 
No 186 (90.3) 199 (92.6) 187 (89.9) 196 (92) 768 (91.2) 
Yes 20 (9.7) 16 (7.4) 21 (10.1) 17 (8) 74 (8.8) 0.7 
Nausea 
No 178 (86.4) 200 (93) 186 (89.4) 193 (90.6) 757 (89.9) 
Yes 28 (13.6) 15 (7) 22 (10.6) 20 (9.4) 85 (10.1) 0.2 
Headache 
No 150 (72.8) 181 (84.2) 166 (79.8) 181 (85) 678 (80.5) 
Yes 56 (27.2) 34 (15.8) 42 (20.2) 32 (15) 164 (19.5) 0.01 
Routine activities interfered 
No 4 (1.9) 8 (3.7) 2 (1) 8 (3.8) 22 (2.6) 
Yes 202 (98.1) 207 (96.3) 206 (99) 205 (96.2) 820 (97.4) 0.2 
Overall, thirty percent of women at follow up day 28 reported an adverse effect. As shown in 
Figure 6.1 and Table 6.5, the reports of adverse effects from women were more frequent in 
the CQ (37%) and SP (32%) groups compared to 22% and 28% in the AQ and AQ+SP 
groups respectively and this difference was significant p=0.01. Headache was reported more 
frequently in the CQ (27%) and SP (20%) groups compared to 16% and 15% in the AQ and 
AQ+SP groups respectively and this difference was significant p=0.01. The frequencies of 
reports of general weakness, dizziness vomiting, nausea, itching and inhibition of performance 
of household chores were similar in all the treatment groups (p<0.1). Compared to the CQ 
group, women in the AQ (OR=0.5; 95% CI, 0.3 to 0.7 p<0.001) and AQ+SP combination 
(OR=0.7; 95% CI, 0.4 - 1.0 p=0.05) groups respectively, were less likely to report an adverse 
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effect; but reports of an adverse effect by women in the SP group (OR=0.8; 95% Cl; 0.5 - 1.2 
p=0.2) were no more different from the CQ group. 
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The incidence of skin rash among the study women after the start of treatment is shown in 
Table 6.6. 
Table 6.6: - Incidence of skin rash among study women after the start of treatment. 
Incidence of skin rash at follow up days 
DAY3 DAY7 DAY 14 DAY 28 
Nn (%) Nn (%) Nn (%) Nn (%) 
Treatment 
CQ 215 5 (2.3) 219 3 (1.4) 216 2 (0.9) 206 4 (1.9) 
AQ 220 1 (0.5) 218 3 (1.4) 220 3 (1.4) 215 4 (1.9) 
SP 217 3 (1.4) 218 6 (2.8) 215 5 (2.3) 208 3 (1.4) 
AQ+SP 217 4 (1.8) 216 4 (1.9) 214 4 (1.9) 213 2 (0.9) 
Total 869 13 (1.5) 871 16 (1.8) 865 14 (1.6) 842 13 (1.5) 
p-value 0.4 0.7 0.7 0.8 
As shown in Table 6.6,13 (1.5%) of the study women reported diffuse skin rashes on day 3. 
The rashes looked coarse and prickly resembling heat rashes and in 11 of the women they were 
itchy. The highest incidence was in the CQ group followed by the AQ+SP combination group 
and the SP and AQ groups but there was no statistical difference between the groups. The 
mucous membranes were not affected nor were there other clinical manifestations of severe 
cutaneous adverse reactions (SCAR). The women did not need any medical attention for the skin 
rash. By day 7, only in one of these women did the rash persist but cleared before day 14. The 
timing of the rashes makes it possible for them to be related to the test drugs, but they could also 
have occurred by chance or been produced by interactions between the test drugs and 
concomitant drugs unknown to the investigators. 
By day 7,15 new case of skin rashes similar in appearance to those described above were 
reported and investigated. But in two of the women, the skin rashes were diffuse maculo-papular 
non-vesicular rashes, itchy and slightly hyperpigmented. There were no manifestations of SCAR 
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but the rashes could be related to the test drugs. The pictures of the skin rashes in the two 
Figure 6.2: - Skin rashes reported at 
day 7 after treatment with SP. 
Figure 6.3: - Sldn rash reported at day 
7 after treatment with AQ+SP. 
The women did not have any other complaints and did not require any treatment. The rashes 
disappeared before day 14. 
Fourteen and thirteen new reports of skin rashes were received and investigated on days 14 and 
28 respectively. In ten of the cases (4 on day 14 and 6 on day 28) fungal skin infections were 
diagnosed and treated accordingly. There were no manifestations of SCAR in the rest of the 
cases. In almost all the rest the reported rashes, were more like lichenifications resulting from 
excessive scratching as they also reported itching. None of these rashes could be associated with 
the test drugs. 
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6.2.1 Prevalence of clinical complaints among study population 
A comparison between a random sample of pregnant women with negative OptiMAL® antigen 
tests during screening and the study pregnant women with respect to complaints made by them 
during 28 days follow up is shown in Figure 6.4. On day 3 after treatment, 75% of pregnant 
women in the study group reported a clinical complaint compared to 39% in the control group. 
By day 7, the proportion of women with complaints in the study group had reduced to almost 
half of the day 3 proportions and remained almost stabilized throughout the follow up period. 
Apart from day 3, the prevalence of clinical complaints in the study group were comparable to 
those made by pregnant women who were not treated. 
Figure 6.4: Comparison of incidence of complaints by treated and untreated pregnant women over a 28- 
day follow up period after screening. 
Day 3 Day 7 Day 14 
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Day 28 
6.3 Baseline biochemistry measurements 
The pre-medication levels of bilirubin, AST, ALT and GGT of the study women in the four 
treatment groups are shown in Table 6.7. There were no significant statistical differences 
between the groups with respect to these parameters. 
Table 6.7: - Baseline biochemistry values according to treatment groups 
CQ AQ SP AQ+SP Total 
11 (%) rn (%) il (%) n (%) n (%) 
AST 
Up to 12 U/L 129 (59.5) 127 (58.5) 124 (57.7) 134 (60.4) 514 (59) 
13 to 24 U/L 61 (28.1) 65 (29.9) 69 (32.1) 67 (30.2) 262 (30.1) 
=/> 25 U/L 27 (12.4) 25 (11.5) 22 (10.2) 21 (9.5) 95 (10.9) 
Mean (SD) 13.9 (10.6) 14.2 (11.6) 14.0 (11) 13.4 (10.1) 13.9 (10.8) 
Median (IQR) 10 (9) 10 (9) 10 (9) 10 (9) 10 (9) 
ALT 
Up to 12 U/L 184 (85.2) 184 (84.8) 188 (87.4) 199 (89.6) 755 (86.8) 
13 to 24 U/L 23 (10.6) 19 (8.8) 17 (7.9) 18 (8.1) 77 (8.8) 
=/> 25 U/L 9 (4.2) 14 (6.4) 10 (4.7) 5 (2.3) 38 (4.4) 
Mean (SD) 7.5 (6.6) 7.8 (8.3) 7.8 (8.6) 7.0 (7.4) 7.5 (7.8) 
Median (IQR) 4 (4) 4 (4) 4 (4) 4 (4) 4 (4) 
GGT 
Up to 50 U/L 212 (99.5) 213 (99.1) 212 (99.5) 218 (100) 855 (99.5) 
51 to 100 U/L 1 (0.5) 2 (0.9) 0 (0) 0 (0) 3 (0.4) 
=/> 101 U/L 0 (0) 0 (0) 1 (0.5) 0 (0) 1 (0.1) 
Mean (SD) 9.4 (8) 10.4 (10.2) 10.4 (11.6) 9.3 (6.6) 9.9 (9.3) 
Median (IQR) 7 (6) 8 (7) 8 (7) 8 (7) 8 (7) 
Total Bilirubin (pmol/L) 
Up to 17.1 p. mo1/L 176 (81.1) 173 (79.7) 171 (79.5) 193 (86.9) 713 (81.9) 
17.2 to 34.4 µmol/L 29 (13.4) 34 (15.7) 31 (14.4) 23 (10.4) 117 (13.4) 
_/> 34.5 pmol/L 12 (5.5) 10 (4.6) 13 (6.1) 6 (2.7) 41 (4.7) 
Mean (SD) 12.6 (17.6) 12.3 (11.5) 12.6 (12.4) 11.0 (11) 12.1 (13.4) 
Median (IQR) 8 (9) 9 (10) 8 (10) 788 (9) 
Direct Bilirubin (pmol/L) 
Up to 3.4 . tmol/L 119 (54.8) 119 (54.8) 127 (59.1) 141 (63.5) 506 (58.1) 
3.5 to 6.8 pmol/L 51 (23.5) 57 (26.3) 46 (21.4) 51 (23) 205 (23.5) 
_/> 6.9. tmol/L 47 (21.7) 41 (18.9) 42 (19.5) 30 (13.5) 160 (18.4) 
Mean (SD) 5.2 (6.6) 5.0 (5.6) 5.0 (5.8) 4.3 (5.5) 4.9 (5.9) 
Median (IQR) 3 (4) 3 (4) 3 (4) 2.6 (3) 3 (4) 
Indirect Bilirubin (pmol/L) 
Up to 13.7pmol/L 192 (88.5) 191 (88) 187 (87) 205 (92.3) 775 (89) 
13.8 to 27.4 pmol/L 22 (10.1) 20 (9.2) 21 (9.8) 14 (6.3) 77 (8.8) 
_/> 27.5 pmol/L 3 (1.4) 6 (2.8) 7 (3.3) 3 (1.4) 19 (2.2) 
Mean (SD) 7.4 (11.9) 7.3 (7.3) 7.6 (8) 6.6 (6.9) 7.2 (8.7) 
Median (IQR) 5 (5) 5 (6) 5 (6) 5 (5) 5 (6) 
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As shown in Table 6.7, apart from AST and direct bilirubin, all the other parameters had their 
baseline mean values within normal ranges. At baseline, 59% of the women had AST levels 
within the normal range, 30% were above the normal range but within 2 times the upper limit 
and 11% had values 2 times above the upper limit of the normal range. The overall mean of AST 
level was 13.9 U/L at enrolment. Eighty-seven percent of women had ALT levels within the 
normal range, 9% were above the normal range but within 2 times the upper limit and 4% were 
2 times above the upper limit of the normal range. The overall baseline mean of ALT level was 
9.9 U/L. At baseline, 99.5% of the women had GGT levels within the normal range with an 
overall mean level of 9.9 U/L. Eighty-two percent of the women had total bilirubin levels within 
the normal range, 13% were above the normal range but within 2 times the upper limit and 5% 
were 2 times above the upper limit of the normal range. The overall baseline mean of total 
bilirubin level was 12.1µmol/L. Fifty-eight percent of the women had direct bilirubin levels 
within the normal range, 24% were above the normal range but within 2 times the upper limit 
and 18% were 2 times above the upper limit of the normal range. The overall baseline mean of 
direct bilirubin level was 4.9 tmo1/L. Urea and creatinine levels were determined on a subset of 
samples only. Ninety-five percent and 76% of the women respectively had urea and creatinine 
levels within normal range at enrolment. 
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6.4 Post treatment biochemistry measurements 
6.4.1 Aspartate aminotransferase (AST) 
The distribution of pregnant women according to treatment groups within predefined levels of 
AST at days 14 and 28 after the start of treatment are shown in Table 6.8 and Figure 6.5 
respectively. 
Table 6.8: AST levels at days 14 and 28 after treatment according to treatment group. 
CQ AQ SP AQ+SP Total 
n (%) n (%) n (%) n (%) n (%) 
DAY 14 
Up to 12 U/L 86 (43.2) 99 (49) 90 (43.9) 98 (49) 373 (46.3) 
13 to 24 U/L 86 (43.2) 70 (34.7) 85 (41.5) 75 (37.5) 316 (39.2) 
=/> 25 U/L 27 (13.6) 33 (16.3) 30 (14.6) 27 (13.5) 117 (14.5) 
Mean (SD) 15.3 (9.8) 17.5 (15.7) 16.2 (12.7) 16.0 (13) 16.2 (13) 
Median (IQR) 13 (12) 13 (12) 13 (12) 13 (12) 13 (12) 
DAY 28 
Up to 12 U/L 100 (52.9) 114 (54) 106 (54.6) 115 (58.4) 435 (55) 
13 to 24 U/L 63 (33.3) 82 (38.9) 69 (35.6) 66 (33.5) 280 (35.4) 
=/> 25 U/L 26 (13.8) 15 (7.1) 19 (9.8) 16 (8.1) 76 (9.6) 
Mean (SD) 15.1 (12.5) 13.2 (9.4) 14.3 (12) 13.2 (10.5) 13.9 (11.1) 
Median (IQR) 10.0 (11) 10.0 (9) 10.0 (12) 10.0 (9) 10.0 (9) 
As shown in Table 6.8 and Figure 6.6, there was a general increase in AST levels within 
treatment groups over the follow up period after treatment. The proportions of women within 
the normal range decreased to 46% on day 14 and then increased again to 55% at day 28 
compared to 59% at enrolment. The pattern was the same across the treatment groups and a 
comparison of proportions did not show any significant statistical differences between them. 
Also within all the treatment groups mean AST levels increased at day 14 but decreased to 
baseline means at day 28 as shown in Figure 6.6. 
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Figure 6.5: - Levels of AST at enrolment and days 14 and 28 according to treatment groups 
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Figure 6.6: - Mean AST levels at enrolment and at days 14 and 28 after start of treatment according to 
treatment group. 
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The mean changes in AST activity at days 14 and 28 after the start of treatment relative to 
baseline values according to treatment groups are shown in Table 6.9. 
Table 6.9: - Mean changes in AST activity at days 14 and 28 after treatment according to treatment 
group. 
Mean change (SD) Range Mean difference p- value F-statistic 
(min to max) compared to CQ (p-value) 
(95% Cl) 
DAY 14 
CQ 1.5 (10.4) (-34 to 38) 
11Q 2.9 (16.8) (-51 to 82) 1.4 (-1.4 to 4.2) 0.32 
SP 2.4 (14.9) (48 to 82) 0.9 (-1.9 to 3.7) 0.52 
AQ+SP 2.7 (13.4) (-39 to 82) 1.2 (-1.6 to 4) 0.40 
DAY 28 
CQ 1.6 (13.3) (42 to 73) 
AQ -1.3 (11.9) (-51 to 61) -2.9 (5.5 to -0.2) 0.04 
SP 0.8 (13.7) (-57 to 82) -0.8 (3.5 to 1.9) 0.56 
AQ+SP 0.2 (14.4) (45 to 79) -1.3 (-4 to 1.3) 0.33 
0.4(0.8) 
1.6(0.2) 
There was an overall mean increase of 2.4 U/L (95% Cl; 1.4 to 3.4 p<0.001) in AST activity at 
day 14 relative to baseline mean values. As shown in Table 6.9, there is no association between 
this increase and the type of treatment received (F-statistic = 0.4; p=0.8). A comparison of the 
test drugs with CQ showed that the mean AST change was 1.4,0.9 and 1.2 U/L more in the 
AQ, SP and AQ+SP groups respectively compared to the CQ group but these differences are 
not statistically significant. At day 28, the overall mean increase in AST activity was 0.3 U/L 
(95% CI; -0.6 to 1.2 p=0.6) over baseline values and showed no association with treatment 
received (F-statistic = 1.6 and p=0.2). The mean changes were about 2.9,0.8 and 1.3 units 
respectively less in the AQ, SP and AQ+SP groups compare to the CQ group. The differences 
were statistically not significant for the CQ versus SP and AQ+SP comparisons but significant in 
the case of CQ versus AQ (p - value =0.04). Overall the differences between the groups were 
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not statistically significant. The mean changes in AST activity remained unchanged when baseline 
parasite density, parity or gravidity were included in the regression model. 
6.4.2 Alanine aminolran (erase (ALT) 
The distribution of pregnant women according to treatment groups within predefined levels of 
ALT at days 14 and 28 after the start of treatment are shown in Table 6.10 and Figure 6.7 
respectively. 
Table 6.10: - ALT levels at days 14 and 28 after treatment according to treatment group. 
CQ AQ SP AQ+SP Total 
n (%) n (%) n (%) n (%) n (%) 
DAY 14 
Up to 12 U/L 175 (88) 171 (84.7) 175 (85.4) 176 (88) 697 (86.5) 
13 to 24 U/L 12 (6) 25 (12.4) 19 (9.3) 16 (8) 72 (8.9) 
=/> 25 U/L 12 (6) 6 (2.9) 11 (5.3) 8 (4) 37 (4.6) 
Mean (SD) 8.0 (8.3) 7.5 (6.8) 8.2 (8.8) 7.7 (8.5) 7.9 (8.1) 
Median (IQR) 4 (4) 4 (4) 4 (4) 4 (4) 4 (4) 
DAY 28 
Up to 12 U/L 167 (88.4) 186 (88.2) 171 (88.1) 177 (89.9) 701 (88.6) 
13 to 24 U/L 17 (9) 23 (10.9) 18 (9.3) 15 (7.6) 73 (9.2) 
=/> 25 U/L 5 (2.6) 2 (0.9) 5 (2.6) 5 (2.5) 17 (2.2) 
Mean (SD) 7.2 (5.6) 6.7 (5) 7.0 (5.6) 6.7 (6.4) 6.9 (5.6) 
Median (IQR) 4.0 (4) 4.0 (4) 4.0 (4) 4.0 (4) 4.0 (4) 
As shown in Table 6.10and Figure 6.8, the overall proportion of women with a normal range 
of ALT activity was similar at enrolment and on days 14 and 28 after treatment. The mean ALT 
levels increased at day 14 for CQ, SP and AQ+SP but decreased to baseline means at day 28 as 
shown in Figure 7.8. In the AQ group the mean ALT activity decreased at the follow up times 
compared to enrolments. 
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Figure 6.7: - Levels of ALT activity at enrolment and days 14 and 28 according to treatment groups 
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Figure 6.8: - Mean ALT levels at enrolment and at days 14 and 28 after start of treatment according to 
treatment group. 
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The mean changes in ALT activity at days 14 and 28 after the start of treatment relative to 
baseline values according to treatment groups are shown in Table 6.11. 
Table 6.11: - Mean changes in ALT activity at days 14 and 28 after treatment according to treatment 
group. 
Mean change (SD) Range Mean difference p- value F-statistic 
(min to max) compared to CQ (p-value) 
(95% CI) 
DAY 14 
CQ 0.5 (8) (-24 to 44) 
AQ 0.0 (8.1) (-53 to 28) -0.5 (-2.3 to 1.3) 0.57 
SP 0.6 (9.8) (-45 to 59) 0.1 (1.7 to 1.9) 0.88 
AQ+SP 0.7 (9.8) (-61 to 43) 0.2 (-1.6 to 2) 0.81 
DAY 28 
CQ -0.2 (7.1) (26 to 25) 
AQ -1.3 (7.2) (52 to 13) -1.0 (2.7 to 0.6) 0.21 
SP -0.6 (9.1) (49 to 29) -0.4 (2.2 to 1.3) 0.64 
AQ+SP -0.1 (9.1) (-67 to 54) 0.1 (-1.5 to 1.8) 0.87 
0.3(0.9) 
0.8(0.5) 
Overall, there was no significant difference between mean ALT activity at day 14 and at 
enrolment but a difference of borderline significance (p = 0.06) was noted at day 28. 
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6.4.3 Gamma glutamy! trap f rare (GGT) 
The distribution of pregnant women according to treatment groups within predefined levels of 
GGT at days 14 and 28 after the start of treatment are shown in Table 6.12 and Figure 6.9 
respectively. 
Table 6.12: - GGT levels at days 14 and 28 after treatment according to treatment group. 
CQ AQ SP AQ+SP Total 
n (%) 
DAY 14 
Up to 50 U/L 197 (92) 201 (94.4) 203 (93.6) 199 (92.6) 800 (93.1) 
51 to 100 U/L 1 (0.5) 0 (0) 2 (0.9) 1 (0.5) 4 (0.5) 
=/> 101 U/L 16 (7.5) 12 (5.6) 12 (5.5) 15 (6.9) 55 (6.4) 
Mean (SD) 15.9 (25) 14.8 (22) 15.4 (22.8) 15.7 (24.6) 15.4 (23.6) 
Median (IQR) 8 (8) 9 (8) 8 (8) 8 (9) 8 (8) 
DAY 28 
Up to 50 U/L 188 (86.6) 210 (94.6) 192 (89.3) 194 (88.6) 784 (89.8) 
51 to 100 U/L 0 (0) 1 (0.5) 1 (0.5) 2 (0.9) 4 (0.5) 
=/> 101 U/L 29 (13.4) 11 (4.9) 22 (10.2) 23 (10.5) 85 (9.7) 
Mean (SD) 21.6 (32) 13.9 (21.5) 18.6 (28.6) 19.0 (29.2) 18.2 (28.1) 
Median (IQR) 9.0 (10) 8.0 (7) 9.0 (7) 8.0 (8) 8.0 (8) 
Overall, the proportion of women with GGT activity outside the normal range increased on day 
14 with a further increase on day 28 as shown in Figures 6.9. 
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Figure 6.9: - Levels of GGT activity at enrolment and days 14 and 28 according to treatment groups 
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Figure 6.10: - Mean GGT levels at enrolment and at days 14 and 28 after start of treatment according to 
treatment group. 
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The mean changes in GGT activity at days 14 and 28 after the start of treatment relative to 
baseline values according to treatment groups are shown in Table 6.13. 
Table 6.13: - Mean changes in GGT activity at days 14 and 28 after treatment according to treatment 
group. 
Mean change (SD) Range Mean difference p- value F-statistic 
(min to max) compared to CQ (p-value) 
(95% Cl) 
DAY 14 
CQ 5.6 (24.1) (-44 to 99) 
AQ 4.8 (22.4) (-38 to 98) -0.8 (-5.4 to 3.8) 0.74 
SP 4.8 (22.8) (-59 to 97) -0.8 (5.4 to 3.8) 0.73 
AQ+SP 6.7 (25.4) (44 to 98) 1.1 (3.5 to 5.7) 0.64 
DAY 28 
CQ 11.5 (31.4) (-42 to 98) 
AQ 4.0 (22.2) (-53 to 95) -7.5 (12.9 to -2.1) 0.01 
SP 8.3 (28.5) (-39 to 99) -3.2 (-8.7 to 2.2) 0.25 
AQ+SP 10.0 (29.7) (-46 to 98) -1.5 (-6.9 to 3.9) 0.59 
0.3(0.8) 
2.8(0.04) 
The overall mean increase in GGT activity at day 14 was 5.5 U/L (95% Cl; 3.8 to 7.1 p<0.001) 
over the baseline mean but this increase was not related to the type of treatment (F-statistic = 0.3 
and p=0.8). At day 28, the overall mean increase in GGT activity was about 8.4 U/L (95% Cl; 
6.5 to 10.4 p<0.001) over the baseline mean and the increase was associated with the type of 
treatment (F-statistic = 2.8 and p=0.04). The increase was significantly less in the AQ group 
(p=0.01). The mean increase in the CQ group was 7.5,3.2 and 1.5 U/L more than in the AQ, SP 
and AQ+SP groups respectively as shown in Table 6.13. The mean changes in GGT activity 
remained unchanged when baseline parasite density, parity or gravidity were included in the 
regression model. 
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6.4.4 Overall bilirubin concentrations 
The distribution of pregnant women according to treatment groups within predefined levels of 
bilirubin concentrations at days 14 and 28 after the start of treatment are shown in Tables 6.14, 
6.15 and 6.16 and Figures 6.11,6.12 and 6.13 respectively. 
The proportion of women within the normal range for overall bilirubin concentration increased 
over enrolment at days 14 and 28 after the start of treatment. Eighty-two percent of the women 
had normal total bilirubin levels at enrolment; this increased to 91% at day 14 and 92% at day 28. 
The proportion of women with a normal direct bilirubin increased from 58% at enrolment to 
77% at day 14 and 75% at day 28. The proportion with a normal indirect bilirubin also increased 
from 89% at enrolment to 97% at day 14 and day 28. This pattern was similar in all the treatment 
groups over the follow up periods as illustrated by Figures 6.11,6.12 and 6.13 and did not differ 
significantly between treatment groups. 
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Table 6.14: - Total bilirubin levels at days 14 and 28 after treatment according to treatment group. 
DAY 14 
Up to 17.1 pmol/L 
17.2 to 34.4 pmol/L 
=/> 34.5 µmol/L 
Mean (SD) 
Median (IQR) 
n 
CQ AQ SP AQ+SP Total 
oý a 01 n n ý%ý (%) n% 
178 (89.5) 180 (89.1) 191 (93.2) 185 (92.5) 734 (91.1) 
14 (7) 21 (10.4) 11 (5.4) 9 (4.5) 55 (6.8) 
7 (3.5) 1 (0.5) 3 (1.4) 6 (3) 17 (2.1) 
9.4 (10.9) 8.6 (7.1) 7.5 (6.4) 8.2 (7.8) 8.4 (8.2) 
6 (5) 6 (6) 5 (4) 5 (4) 6 (5) 
DAY 28 
Up to 17.1 µmol/L 175 (92.6) 192 (91) 175 (90.2) 183 (92.9) 725 (91.7) 
17.2 to 34.4 µmo1/L 9 (4.8) 16 (7.6) 14 (7.2) 10 (5.1) 49 (6.2) 
_/> 34.5 µmol/L 5 (2.6) 3 (1.4) 5 (2.6) 4 (2) 17 (2.1) 
: Mean (SD) 8.2 (7) 8.3 (7.3) 8.6 (7.9) 8.1 (6.9) 8.3 (7.3) 
Median (IQR) 6.0 (5) 6.0 (5) 6.0 (5) 6.0 (5) 6.0 (5) 
Figure 6.11: - Total bilirubin levels at enrolment and days 14 and 28 according to treatment groups 
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Table 6.15: - Direct bilirubin levels at days 14 and 28 after treatment according to treatment group. 
DAY 14 
Up to 3.4 µmol/L 
3.5 to 6.8 pmol/L 
6.9 µmol/L 
Mean (SD) 
Median (IQR) 
n 
CQ 
(%) 
AQ 
n% 
SP 
n ý°ý 
AQ+SP 
n () n 
Total 
(%) 
147 (73.9) 152 (75.2) 159 (77.6) 161 (80.5) 619 (76.8) 
26 (13.1) 27 (13.4) 27 (13.2) 17 (8.5) 97 (12) 
26 (13) 23 (11.4) 19 (9.3) 22 (11) 90 (11.2) 
3.7 (4.9) 3.4 (3.6) 3.2 (3.6) 3.3 (4.2) 3.4 (4.1) 
2 (2) 2 (1.1) 2 (2) 2 (1.5) 2 (1) 
DAY 28 
Up to 3.4. tmo1/L 137 (72.5) 158 (74.9) 146 (75.3) 153 (77.7) 594 (75.1) 
3.5 to 6.8 . unol/L 33 
(17.5) 31 (14.7) 29 (14.9) 24 (12.2) 117 (14.8) 
_/> 6.9 µmo1/L 19 (10) 22 (10.4) 19 (9.8) 20 (10.1) 80 (10.1) 
Mean (SD) 3.6 (4) 3.4 (3.8) 3.3 (4.1) 3.2 (3.8) 3.4 (3.9) 
Median (IQR) 2.0 (2) 2.0 (3) 2.0 (1) 2.0 (1) 2.0 (1.2) 
Figure 6.12: - Direct bilirubin levels at enrolment and days 14 and 28 according to treatment groups 
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Table 6.16: - Indirect bilirubin levels at enrolment and days 14 and 28 according to treatment groups 
DAY 14 
Up to 13.7pmol/L 
13.8 to 27.4 µmol/L 
=/> 27.5 µmol/L 
Mean (SD) 
Median (IQR) 
DAY 28 
Up to 13.7Eunol/L 181 (95.8) 204 (96.7) 190 (98) 190 (96.5) 765 (96.7) 
13.8 to 27.4 µmol/L 7 (3.7) 7 (3.3) 2 (1) 6 (3) 22 (2.8) 
=/> 27.5 µmol/L 1 (0.5) 002 (1) 1 (0.5) 4 (0.5) 
Mean (SD) 4.6 (3.9) 5.0 (4.4) 5.2 (5) 4.9 (3.8) 4.9 (4.3) 
Median (IQR) 4.0 (4) 3.7 (4) 4.0 (4) 4.0 (4) 4.0 (4) 
Figure 6.13: - Indirect bilirubin levels at enrolment and days 14 and 28 according to treatment groups 
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The overall mean changes in bilirubin concentrations at days 14 and 28 after the start of 
treatment relative to baseline values according to treatment groups are shown in Tables 6.17, 
6.18 and 6.19 and Figures 6.14,6.15 and 6.16. 
The overall mean decrease in total bilirubin level at day 14 was 3.6 pmol/L (95% CI; 2.7 to 4.6 
p<0.001) over the baseline mean but was not associated with the type of treatment received (F- 
statistic = 0.7and p=0.6) as shown in Table 6.17. At day 28, the overall mean decrease in total 
bilirubin was 3.5 µmol/L (95% CI; 2.5 to 4.5 p<0.001) over the baseline level and not associated 
with the type of treatment received (F-statistic = 0.9 and p=0.4). Similarly, the mean decreases in 
both the direct and indirect bilirubin concentrations over the baseline were significant on days 14 
and 28 but were not associated with the type of treatment received. The mean changes in the 
direct and indirect bilirubin concentrations at days 14 and 28 after the start of treatment relative 
to baseline values according to treatment groups are shown in Tables 6.18 and 6.19. The mean 
changes in bilirubin remained unchanged when baseline parasite density, parity or gravidity were 
included in the regression model. 
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Table 6.17: - Mean changes in total bilirubin concentrations at days 14 and 28 after treatment according 
to treatment group. 
Mean change (SD) Mean difference 
(min to max) compared to CQ 
(95% CI) 
Range p- value 
DAY 14 
CQ -3.7 (18.4) (-207 to 78.6) 
AQ -3.4 (10.8) (-64 to 45) 0.3 (-2.4 to 2.9) 0.84 
SP -4.7 (11.6) (-70.8 to 25.2) -1.0 (-3.6 to 1.6) 0.45 
AQ+SP -2.8 (10.3) (-78.9 to 28.2) 0.9 (-1.8 to 3.5) 0.52 
DAY 28 
CQ -4.6 (18.4) (-218 to 29.4) 
AQ -3.7 (12.2) (-72 to 39) 0.9 (1.9 to 3.7) 0.54 
SP -3.6 (13.6) (-79.8 to 37.6) 1.0 (1.9 to 3.8) 0.51 
AQ+SP -2.3 (10.9) (-93 to 33.6) 2.3 (-0.6 to 5.1) 0.12 
F-statistic 
(p-value) 
0.7(0.6) 
0.8(0.5) 
Figure 6.14: - Mean total bilirubin levels at enrolment and at days 14 and 28 after start of treatment 
according to treatment group. 
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Table 6.18: - Mean changes in direct bilirubin concentrations at days 14 and 28 after treatment according 
to treatment group. 
DAY 14 
CQ 
SP 
AQ+SP 
Mean change (SD) Range Mean difference p- value F-statistic 
(min to max) compared to CQ (p-value) 
(95% Cl) 
-1.7 (6.6) (-61 to 41.3) 
-1.6 (5.3) (-33 to 12.6) 0.1 (-1 to 1.2) 0.91 
-1.6 (5.1) (-35.8 to 16.9) 0.1 (-1 to 1.2) 0.88 
-0.9 (5.1) (-38.3 to 19.2) 0.8 (0.3 to 1.2) 0.16 
0.9(0.4) 
DAY 28 
CQ -1.6 (6.9) (-68 to 24.2) 
A(2 -1.5 (6.1) (-33 to 20.4) 0.1 (-1.2 to 1.4) 0.88 
SP -1.4 (6.6) (-39.8 to 33.9) 0.2 (-1.1 to 1.4) 0.81 
AQ+SP -0.7 (5.4) (-42.3 to 28.8) 0.9 (-0.4 to 2.2) 0.17 
0.8(0.5) 
Figure 6.15: - Mean direct bilirubin levels at enrolment and at days 14 and 28 after start of treatment 
according to treatment group. 
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Table 6.19: - Mean changes in indirect bilirubin concentrations at days 14 and 28 after treatment 
according to treatment group. 
Mean change (SD) Range Mean difference p- value F-statistic 
(min to max) compared to CQ (p-value) 
(95% Cl) 
DAY 14 
CQ -1.9 (12.9) (-146 to 42.2) 
_-iQ -1.7 
(7.7) (-35 to 37.1) 0.2 (-1.6 to 2) 0.81 
SP -3.0 (7.7) (-43 to 13.2) -1.1 (-2.9 to 0.7) 0.24 
AQ+SP -1.9 (7.2) (-56 to 22.3) 0.1 (-1.7 to 1.9) 0.93 
DAY 28 
C(2 -2.9 (12.7) (-150 to 28.4) 
AQ -2.1 (7.8) (-43 to 23.9) 0.8 (-1 to 2.7) 0.38 
SP -2.1 (9.2) (-58.5 to 31.9) 0.8 (-1.1 to 2.7) 0.41 
AQ+SP -1.5 (7.1) (-67.3 to 16.6) 1.4 (-0.5 to 3.3) 0.15 
0.9(0.5) 
0.7(0.6) 
Figure 6.16: - Mean indirect bilirubin levels at enrolment and at days 14 and 28 after start of treatment 
according to treatment group. 
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6.5 White blood cell (WBC) counts 
The levels of total white cell counts at enrolment and at follow up time points after treatment are 
shown in Table 6.20. At baseline about 31% of the women had total white cell counts below 4x 
109/L but this proportion increased slightly at all the follow up days apart from at day 7. 
However, there were no associations between these changes and the treatment groups. The 
lowest WBC count in the study women after treatment was 1.6 x 109/L on day 3 in the CQ 
group. The lowest WBC count in women in the AQ group was 1.8 x 109/L on day 14 after 
treatment. 
The overall changes in white cell counts after the start of treatment were investigated using 
paired t-test. Applying the nonparametric signed-rank test yielded the same conclusions and 
ANOVA was used to test for differences in the means of treatment groups. The overall mean 
changes in the total and differential white cell counts at days 3,7,14 and 28 after the start of 
treatment relative to baseline counts, are shown in Tables 6.21. The total white cell counts 
decreased relative to baseline levels on days 3,14 and 28. The neutrophil counts increased while 
lymphocyte counts decreased after the start of treatment relative to baseline levels at all follow up 
days. Monocytes and eosinophils also showed a general decrease relative to baseline counts. 
However, as shown Table 6.22, the post treatment means are similar in all the treatment groups 
and the overall changes observed were not associated with the type of treatment received. 
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Table 6.21: - Mean changes in differential white cell counts at follow up after the start of treatment. 
Overall mean 
N difference (SD) 95% CI p-value 
Total WBC 
DAY 3 867 -0.1 (1.7) (-0.2 to -0.01) 0.03 
DAY 7 855 0.1 (1.8) (0.01 to 0.2) 0.08 
DAY 14 856 -0.1 (1.8) (-0.3 to -0.03) 0.02 
DAY 28 832 -0.2 (1.8) (-0.3 to -0.1) <0.001 
Neutrophil 
DAY 3 867 0.6 (8.7) (-0.01 to 1.1) 0.05 
DAY 7 856 1.3 (9.5) (0.7 to 1.9) <0.001 
DAY 14 856 1.4 (9.5) (0.8 to 2.0) <0.001 
DAY 28 832 1.7 (8.8) (1.1 to 2.3) <0.001 
Lymphocytes 
DAY 3 867 -0.5 (8.9) (-1.1 to 0.1) 0.1 
DAY 7 856 -1.1 (9.6) (-1.8 to -0.5) <0.001 
DAY 14 856 -1.1 (9.1) (-1.7 to -0.5) <0.001 
DAY 28 832 -1.3 (8.9) (-1.9 to -0.7) <0.001 
Monocytes 
DAY 3 867 -0.02 (0.6) (-0.1 to 0.01) 0.3 
DAY 7 856 -0.01 (0.6) (0.04 to 0.03) 0.7 
DAY 14 856 0.03 (1.5) (-0.06 to 0.1) 0.5 
DAY 28 832 -0.01 (0.6) (-0.1 to 0.03) 0.5 
Eosinophils+Basophils 
DAY 3 867 0.02 (2.6) (-0.2 to 0.2) 0.8 
DAY 7 856 -0.1 (2.7) (-0.3 to 0.1) 0.4 
DAY 14 856 -0.2 (2.7) (-0.4 to -0.02) 0.03 
DAY 28 832 -0.3 (2.4) (0.5 to -0.2) <0.001 
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Table 6.22: - Mean differential white cell counts expressed as the percentage of total WBC (%WBC) 
Neutrophils Lymphocytes Eosinophils plus Monocytes 
Basophils 
N %WBC (SD) %WBC (SD) %WBC (SD) % WBC (SD) 
DAY 0 
CQ 225 62.3 (6.6) 35.6 (6.5) 2.1 (2.1) 0.1 (0.4) 
AQ 225 62.7 (7.5) 34.5 (7.6) 2.1 (1.9) 0.2 (0.5) 
SP 225 61.9 (6.6) 36.1 (6.5) 1.9 (1.8) 0.1 (0.4) 
AQ+SP 225 63.4 (6.5) 34.6 (6.5) 2.0 (2.0) 0.1 (0.3) 
Total 900 62.6 (6.8) 35.2 (6.8) 2.0 (1.9) 0.1 (0.4) 
p-value 0.1 0.04 0.3 0.05 
DAY 3 
CQ 214 63.4 (7.3) 34.4 (7.1) 2.1 (2.1) 0.1 (0.3) 
AQ 218 62.7 (7.1) 35.3 (6.9) 1.9 (1.8) 0.1 (0.5) 
SP 217 62.4 (7.6) 35.3 (7.2) 2.2 (2.4) 0.1 (0.4) 
AQ+SP 218 63.8 (6.3) 34.1 (6.5) 2.0 (1.8) 0.1 (0.3) 
Total 867 63.1 (7.1) 34.8 (7) 2.0 (2.0) 0.1 (0.4) 
p-value 0.2 0.2 0.3 0.2 
DAY 7 
CQ 215 63.7 (8.2) 34.2 (8.1) 1.9 (1.8) 0.1 (0.4) 
AQ 214 63.9 (8) 34.1 (7.9) 2.0 (2.3) 0.1 (0.3) 
SP 214 63.6 (7.5) 34.2 (6.8) 2.0 (2.2) 0.1 (0.4) 
AQ+SP 213 63.9 (7.2) 34.1 (7.2) 1.9 (2.1) 0.1 (0.5) 
Total 856 63.8 (7.7) 34.1 (7.5) 1.9 (2.1) 0.1 (0.4) 
p-value 0.9 0.9 0.3 0.2 
DAY 14 
CQ 213 64.4 (7.6) 33.5 (7.3) 2.0 (2.1) 0.1 (0.4) 
AQ 217 63.9 (6.7) 34.2 (6.8) 1.8 (1.8) 0.3 (2.7) 
SP 212 64.0 (7.4) 34.3 (7.4) 1.7 (1.7) 0.1 (0.4) 
AQ+SP 214 63.4 (8.5) 34.5 (6.9) 1.7 (2.3) 0.1 (0.4) 
Total 856 63.9 (7.6) 34.1 (7.1) 1.8 (2.0) 0.1 (1.4) 
p-value 0.6 0.5 0.9 0.5 
DAY 28 
CQ 205 63.7 (7.4) 34.5 (7.2) 1.7 (1.9) 0.1 (0.5) 
AQ 214 64.4 (7.2) 33.9 (6.9) 1.6 (1.6) 0.1 (0.3) 
SP 205 63.9 (6.6) 34.3 (6.7) 1.7 (1.8) 0.1 (0.3) 
AQ+SP 208 65.0 (6.7) 33.1 (6.5) 1.8 (1.9) 0.1 (0.4) 
Total 832 64.3 (7) 33.9 (6.8) 1.7 (1.8) 0.1 (0.4) 
p-value 0.2 0.2 0.7 0.7 
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CHAPTER SEVEN 
PREGNANCY OUTCOME 
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CHAPTER 7 PREGNANCY OUTCOME 
7.1 Introduction 
This chapter presents results on the parasitological and haematological outcomes at delivery and 
post partum in the study women. These outcomes are presented initially as the estimates of 
treatment effect and then as overall effect compared to baseline levels. 
The chapter also includes a descriptive analysis of birth outcomes by treatment group. The 
overall incidences of adverse pregnancy outcomes in the study group are compared to local rates 
for abortion, stillbirth, congenital abnormality, and mean gestation at delivery obtained from St 
Theresa's Hospital's records. 
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7.2 Follow up at delivery and postpartum 
A total of 827 women who completed treatment were expected to have supervised deliveries at a 
clinic, health centre or at the hospital. Records of deliveries conducted at various sites were 
obtained for 711 of those women (86%). There were 66 home deliveries assisted by relatives, 107 
home deliveries assisted by traditional birth attendants, 114 deliveries at health centres and clinics 
and 422 deliveries at hospital. The distribution of these is similar between the treatment groups. 
The flow of participants after the initial day 28 follow up, through delivery to postpartum is 
shown in Figure 7.1. Delivery records are not available for 116 women who completed 
treatment; 41,48,51 and 49 in the CQ, AQ, SP and the AQ+SP combination groups 
respectively. Losses to follow up at delivery or postpartum were mainly due to migration outside 
the study area. Most of them claimed they needed the support of their families who lived outside 
the study area to care for them at delivery and/or at postpartum, and so travelled to be with their 
families before delivery. 
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7.3 Parasitological outcomes at delivery and postpartum 
The prevalence of asexual P. falcipanim in peripheral blood, placental blood and placental 
impression smears at delivery and in peripheral blood post partum according to treatment group 
are shown in Table 7.1. 
Table 7.1: - Parasite prevalence at delivery and postpartum according to treatment group. 
Parasite prevalence Unadjusted odds ratio p-value Adjusted odds ratiott p-value 
Nn (%) (95% Cl) (95% Cl) 
AT DELIVERY 
Peripheral blood 
CQ 133 13 (9.8) 1.0 1.0 
AQ 125 10 (8) 0.8 (0.3-1.9) 0.6 0.9 (0.4-2.3) 0.9 
SP 133 6 (4.5) 0.4 (0.2-1.2) 0.1 0.4 (0.1-1.1) 0.1 
AQ+SP 124 3 (2.4) 0.2 (0.1-0.8) 0.02 0.3 (0.1-1.0) 0.06 
Total 515 32 (6.2) 
Placental blood 
CQ 133 24 (18.1) 1.0 1.0 
AQ 125 12 (9.6) 0.5 (0.2-1.0) 0.05 0.5 (0.2-1.0) 0.06 
SP 133 10 (7.5) 0.4 (0.2-0.8) 0.01 0.4 (0.2-0.8) 0.01 
AQ+SP 124 13 (10.5) 0.5 (0.3-1.1) 0.1 0.5 (0.3-1.1) 0.1 
Total 515 59 (11.5) 
Placental 
impression smear 
CQ 133 26 (19.6) 1.0 1.0 
AQ 125 16 (12.8) 0.6 (0.3-1.2) 0.2 0.6 (0.3-1.2) 0.2 
SP 133 16 (12) 0.6 (0.3-1.1) 0.1 0.5 (0.3-1.0) 0.1 
AQ+SP 124 18 (14.5) 0.7 (0.4-1.3) 0.3 0.7 (0.4-1.4) 0.4 
Total 515 76 (14.8) 
AT POSTPARTUM 
CQ 152 5 (3.3) 1.0 1.0 
AQ 145 4 (2.8) 0.8 (0.2-3.2) 0.8 0.9 (0.2-3.5) 0.9 
SP 138 10 (7.3) 2.3 (0.8-6.9) 0.1 2.5 (0.8-7.7) 0.1 
AQ+SP 144 6 (4.2) 1.3 (0.4-4.3) 0.7 1.4 (0.4-4.7) 0.6 
Total 579 25 (4.3) 
tt Odd ratios adjusted for parity, age, gestation at enrolment and duration between enrolment and delivery. 
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7.3.1 Parasite prevalence at delivery 
These analyses compared parasite prevalence at delivery in peripheral blood, placental blood and 
placental impression smear in the AQ, SP and AQ+SP combination groups with that in the CQ 
group in each sample. 
Peripheral blood parasitaemia 
As shown in Table 7.1, the prevalences of asexual P. falciparnm parasitaemia were 9.8%, 8%, 
4.5% and 2.4% for the CQ, AQ, SP and the AQ+SP combination groups respectively in the 
peripheral blood. The ORs of parasitaemia was 0.8 (95% CI; 0.3 to 1.9 p=0.6) in the AQ group, 
0.4 (0.2 to 1.2 p=0.1) in the SP group and 0.2 (95% CI; 0.1 to 0.8 p=0.02) in the AQ+SP 
combination group compared to the CQ group. The ORs did not change significantly after 
adjustments were made for baseline parasite density, gestation at enrolment, duration between 
enrolment and delivery, parity and age. Thus all the test drugs have greater protective efficacy 
against parasitaemia at delivery compared to CQ, but it is only in the AQ+SP combination group 
that the effect was statistically significant. Peripheral blood parasitaemia was significantly 
associated with baseline parasite density. The unadjusted ORs were 3.2 (95% CI; 1.5 to 7.1 
p=0.004) and 2.9 (95% CI 1.3 to 6.5 p=0.01) after adjustment were for gestation at enrolment, 
duration between enrolment and delivery, parity and age. 
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Placental blood parasitaemia 
As shown in Table 7.1, the prevalences of asexual P. falcipanlm parasitaemia were 18.1%, 9.6%, 
7.5% and 10.5% for the CQ, AQ, SP and the AQ+SP combination groups respectively in the 
placental blood. The ORs of parasitaemia was 0.5 (95% CI; 0.2 to 1.0 p=0.05) in the AQ group, 
0.4 (0.2 to 0.8 p=0.01) in the SP group and 0.5 (95% CI; 0.3 to 1.1 p=0.09) in the AQ+SP 
combination group compared to the CQ group. The ORs did not change significantly after 
adjustments for baseline parasite density, gestation at enrolment, duration between enrolment 
and delivery, parity and age. Thus the protective efficacy against placental blood parasitaemia at 
delivery was significantly greater in the AQ and SP groups compared to CQ, but only of 
borderline significance in the AQ+SP combination group. Placental blood parasitaemia was not 
associated with baseline parasite density, gestation at enrolment, duration between enrolment and 
delivery, parity or age. 
Placental impression smear 
As shown in Table 7.1, the prevalences of asexual P. falciparum parasitaemia were 19.6%, 12.8%, 
12% and 14.5% for the CQ, AQ, SP and the AQ+SP combination groups respectively in the 
placental impression smear. The ORs of parasite prevalence was 0.6 (95% Cl; 0.3 to 1.2 p=0.2) 
in the AQ group, 0.6 (95% Cl; 0.3 to 1.1 p=0.1) in the SP group and 0.7 (95% CI; 0.4 to 1.3 
p=0.3) in the AQ+SP combination group compared to the CQ group. The ORs did not change 
after adjustments for baseline parasite density, gestation at enrolment, duration between 
enrolment and delivery, parity and age. Thus using the placental impression smear, the protective 
effects of the test drugs against placental parasitaemia were not significantly different from that 
of CQ. Placental parasitaemia by impression smear was not associated with baseline parasite 
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density unadjusted and when adjusted for gestation at enrolment, duration between enrolment 
and delivery, parity and age. 
7.3.2 Postpartum parasite prevalence 
As shown in Table 7.1, the prevalences of asexual P. falciparnm parasitaemia were 3.3%, 2.8%, 
7.3% and 4.2% for the CQ, AQ, SP and the AQ+SP combination groups respectively at 
postpartum. The ORs of parasitaemia was 0.8 (95% CI; 0.2 to 3.2 p=0.8) in the AQ group, 2.3 
(95% CI; 0.8 to 6.9 p=0.1) in the SP group and 1.3 (95% CI; 0.4 to 4.3 p=0.7) in the AQ+SP 
combination group compared to the CQ group. The ORs did not change significantly after 
adjustments for baseline parasite density, gestation at enrolment, duration between enrolment 
and delivery, parity and age. Thus the protective effects of the test drugs against postpartum 
parasitaemia were not significantly different from that of CQ. Postpartum parasitaemia was not 
associated with baseline parasite density unadjusted and when adjusted for gestation at 
enrolment, duration between enrolment and delivery, parity and age. 
187 
7.4 Haematological outcomes at delivery and postpartum 
The proportions of study pregnant women in 3 categories of haemoglobin concentrations at 
delivery and postpartum are shown in Table 7.2. There is a significant improvement in Hb levels 
within all treatment groups at delivery and postpartum treatment as illustrated by Figure 7.2. 
The proportions of women with Hb equal to 11g/dl or above had increased from about 10% at 
enrolment to 42% and 77% at delivery and postpartum respectively while the proportions of 
those with Hb below 8g/dl decreased over the period. There was a 1.1g/dl (0.9 - 1.3) p<0.001 
increase in Hb over baseline level at delivery but has no apparent association with the type of 
treatment (F-statistic = 1.5; p=0.2). At postpartum, the increase over baseline mean Hb was 
2.4g/dl (2.3 - 2.6) p<0.001 with a borderline association with the mean changes between the 
groups (F-statistic = 2.5; p=0.0G). The change in mean Hb at postpartum tends to be higher than 
would have been at delivery within the treatment groups as shown in Figure 7.3. 
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Table 7.2: - Haemoglobin concentrations at delivery and at six weeks postpartum. 
CQ 
n ("ýu) 
AQ 
n (%) n 
SP 
(%) 
AQ+SP Total 
tl (%) n (°/a) 
DELIVERY Hb 
< 8g/dl 17 (15.0) 15 (14.9) 14 (13.0) 15 (15.1) 61 (14.5) 
8- 10.98/dl 57 (50.4) 40 (39.6) 50 (46.3) 37 (37.4) 184 (43.7) 
11g/dl or above 39 (34.5) 46 (45.5) 44 (40.7) 47 (47.5) 176 (41.8) 
: Mean (SD) 10.1 (2.2) 10.4 (2.1) 10.2 (1.9) 10.4 (2.1) 10.3 (2.1) 
Median (IQR) 10.3 (3.0) 10.7 (2.9) 10.5 (2.6) 10.7 (2.9) 10.5 (2.9) 
POSTPARTUM Hb 
< 8g/dl 1 (0.6) 1 (0.7) 0 (0) 0 (0) 2 (0.3) 
8- 10.9g/dl 43 (28.5) 34 (23.6) 31 (22.5) 24 (16.7) 132 (22.9) 
11g/dl or above 107 (70.9) 109 (75.7) 107 (77.5) 120 (83.3) 443 (76.8) 
Mean (SD) 11.6 (1.6) 11.5 (1.5) 11.8 (1.6) 11.8 (1.3) 11.7 (1.5) 
Median (IQR) 12.0 (3) 12.0 (1) 12.0 (2) 12.0 (1.5) 12.0 (2) 
Figure 7.2: - Comparison of delivery and postpartum haemoglobin concentrations to baseline levels 
according to treatment group. 
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Table 7.3: - Mean changes in Hb concentrations at delivery and postpartum relative to baseline 
concentrations. 
Mean change (SD) Range Mean difference p- value F-statistic 
(min to max) compared to CQ (p-value) 
(95% Cl) 
DELIVERY 
CQ 0.8 (2.2) (-5.4-6.4) 
. -\Q 1.3 (2.0) (3.8-7) 0.6 (-0.01 - 1.1) 0.06 
SP 1.2 (2.0) (-3.8-5.9) 0.4 (-0.1 -1.0) 0.1 
AQ+SP 1.2 (2.3) (-5.4-7.4) 0.5 (-0.1 - 1.0) 0.1 
POSTPARTUM 
CQ 2.2 (1.8) (-2.4-7.9) 
AQ 2.3 (1.7) (-2.3-8) 0.15 (0.3-0.6) 0.47 
SP 2.7 (1.9) (-2.3-7.6) 0.51 (0.1-0.9) 0.02 
AQ+SP 2.5 (1.7) (-1.1-8) 0.35 (-0.06 - 0.8) 0.09 
1.5(0.2) 
2.3(0.08) 
Figure 7.3: - Mean Hb increase over baseline according to treatment group at delivery and postpartum. 
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7.5 Birth weights 
Birth weight records were available for 101 and 420 deliveries conducted at health centres and 
the hospital respectively. Overall the incidence of low birth weight was 12.7% as shown in Table 
7.4. The mean birth weigh was 2898g ranging from 1000 to 4300g for women who were treated 
only once. It was 2846g ranging from 1000 to 4000g in those who had retreatment. In separate 
analyses of data in women treated for single and double episodes of malaria, no differences were 
found. The results of the overall incidence of low birth weights according to treatment groups 
are shown in Table 7.4. 
Table 7.4: - Birth weights of babies bom to study pregnant women according to treatment group. 
BIRTH WEIGHT 
>/=2500 g <2500 g Mean (SD) Median (IQR) Range 
n (%) n (%) (min to max) 
TREATMENT 
CQ 117 (86.7) 18 (13.3) 2919 (495) 3000 (500) (1000 - 4200) 
AQ 104 (83.2) 21 (16.8) 2866 (579) 3000 (400) (1000 - 4000) 
SP 118 (88.1) 16 (11.9) 2874 (479) 3000 (600) (1300 - 4000) 
. 1Q+SP 116 (91.3) 11 (8.7) 2931 (480) 3000 (600) (1000 - 4300) 
Total 455 (87.3) 66 (12.7) 2898 (508) 3000 (500) (1000 - 4300) 
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7.6 Pregnancy outcomes 
No maternal deaths were recorded. The numbers of known neonatal outcomes according to 
treatment groups are shown in Table 7.5. 
Table 7.5: - Neonatal outcomes according to treatment groups. 
CQ AQ SP AQ+SP Total 
Neonatal Outcomes n (%) n (%) n (%) n (%) n (%) 
Abortions 1 (0.5) 0 (0) 2 (1.2) 0 (0) 3 (0.4) 
Still births 2 (1.1) 1 (0.6) 2 (1.2) 1 (0.6) 6 (0.8) 
Perinatal deaths 2 (1.1) 3 (1.7) 4 (2.3) 1 (0.6) 10 (1.4) 
Neonatal deaths 3 (1.6) 2 (1.1) 1 (0.6) 2 (1.1) 8 (1.1) 
Alive 176 (95.7) 171 (96.6) 165 (94.8) 172 (97.7) 684 (96.2) 
7.6.1 Abortions 
As shown in Table 7.5, two abortions were recorded by midwives. The first event was in a 19 
year old primigravid enrolled on 8/7/03 at 18 weeks gestation who received SP. A TBA reported 
she aborted on 21/7/03. Her parasite density at enrolment was 720/µL. The second event was 
in 18 year old primigravid enrolled on 27.01/04 at 19 weeks gestation who received CQ. Her 
baseline parasite density was 15200/µL. She aborted at the St. Theresa's Hospital on 3/2/04. 
Another woman's outcome was recorded as still birth but by the study definitions should have 
been recorded as an abortion. She was a 41 year old with parity of 6 and enrolled on 10/02/04 at 
20 weeks gestation who received SP. Her baseline parasite density was 1240/µL. She aborted at 
the St. Theresa's Hospital on 23/2/04. 
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7.6.2 Still births 
As shown in Table 7.5, there were six still births; 2 in the CQ group, 1 each in the AQ and 
AQ+SP groups and 2 in the SP group. 
7.6.3 Preterm deliveries 
There are records of 97 preterm deliveries; 27 (14.7%), 30 (17%), 18 (10.3%) and 22 (12.5%) in 
the CQ, AQ, SP and AQ+SP groups respectively. The groups were not statistically different. 
Two of the preterm babies died at birth. 
7.6.4 Perinatal deaths 
There were records of ten perinatal deaths; 2,3,4 and 1 in the CQ, AQ, SP and AQ+SP groups 
respectively as shown in Table 7.5. Two of these were home deliveries, 3 occurred at health 
centres and 6 at St. Theresa's hospital. Midwives reported they all needed resuscitation at birth. 
They all had birth weights 3kg or above apart from one preterm baby. 
7.6.5 Neonatal deaths 
There were eight neonatal deaths recorded between one and four weeks of the postpartum 
period. These include 3 (1.6%), 2 (1.1%), 1 (0.6%), and 2 (1.1%) in the CQ, AQ, SP and AQ+SP 
groups respectively as shown in Table 7.5. The groups were not statistically different. 
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7.6.6 Abnormalities 
There are records of 8 abnormalities. Seven of the babies had extra digits and one shown in 
Figure 7.4 below had a malformed ear. 
Figure 7.4: -A new born with malformed left ear. 
This baby was born to a 25 year old primigravid and a teacher. She received CQ at 22 weeks of 
gestation. She was delivered by caesarean section due to pre-eclampsia. No other abnormality 
was detected on the baby. The ear has since been reconstructed. 
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DISCUSSION AND CONCLUSION 
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CHAPTER 8 DISCUSSION AND CONCLUSION 
8.1 Introduction 
The present study was conducted in a routine antenatal clinic setting to compare the efficacy, 
safety and tolerability of AQ and SP as single or combination therapies with CQ in the treatment 
of P. falcipanim infection in pregnancy. The key findings on epidemiology of malaria during 
pregnancy, performance of screening for malaria parasitaemia at routine antenatal clinics, and the 
efficacy, safety and tolerance of the study drugs are discussed in this chapter. Also discussed, are 
the implications of the findings for research, policy and practice. 
8.2 Local epidemiology of malaria in pregnancy 
The prevalence of antenatal malaria detected by OptiMAL® antigen testing in the study area was 
about 21% with no significant seasonal variation. The main parasite species found was P. 
falciparum. Antenatal malaria was significantly associated with young age, nulliparity or primiparity 
and anaemia (Hb below 11g/dl). These features are consistent with the epidemiologic patterns of 
malaria in pregnancy found in other malaria endemic regions with perennial malaria transmission 
(Nair and Nair 1993; Steketee et al 2001; Zhou et al. 2002; Bouyou Akotet et al. 2003). This 
pattern was very similar among the study women when the association between their baseline 
parasite densities and parity, age and gravidity were examined. This is expected since the study 
sample came from the same population. Among the study women, the younger, nulliparous or 
primiparous women had significantly higher parasite densities and lower haemoglobin levels than 
older or multiparous women. About 90% of the study women had anaemia (Hb < 11g/dl) and a 
fifth of them had severe anaemia (Hb < 7g/dl). Anaemia was associated significantly with 
parasite density, age and parity. These findings agree with those from earlier studies that have 
investigated the causes of anaemia in pregnancy (Matteelli et al. 1994; Shulman et al. 1996; 
196 
Ndyomugyenyi and Magnussen 1999; Mockenhaupt et al. 2000). Anaemia in the present study 
was also associated with high levels of bilirubin (direct and indirect) suggesting haemolysis as the 
mechanism. Previous studies have linked hypohaptoglobinaemia in pregnant women with 
malaria indicating haemolysis as a cause of maternal anaemia in pregnancy (Gilles et al. 1969; 
Rougemont et al 1988; Yerly et al. 1990). Many other studies have attributed maternal anaemia in 
pregnancy to other factors such as iron, folate, vitamin A, vitamin B12 deficiencies, HIV/AIDS, 
haemoglobinopathies and hookworm infestations (Liljestrand el al. 1986; Fleming 1989; van den 
Broek 1996; van den Broek 1998; Verhoeff el al. 1999). In the present study, anaemia was not 
associated with prior chloroquine use, hookworm infestation or hepatosplenomegaly. The other 
causes of anaemia in pregnancy including iron and folate deficiencies, HIV/AIDS and 
haemoglobinopathies were not investigated. However, Mockenhaupt and others showed that 
apart from homozygous alpha thalassaemia, iron deficiency and haemoglobinopathies did not 
have significant associations with anaemia in Ghanaian pregnant women (Mockenhaupt et al. 
2000). 
8.3 Performance of the OptiMAL® antigen test 
These are the first data describing the performance characteristics of the dipstick for routine use 
during antenatal clinic sessions. A potential limiting factor in assessing the performance of the 
antigen test was the choice of slide microscopy as the "gold standard" as its performance 
depends heavily on the expertise of the microscopist. This study increased the chances of reliable 
microscopy by employing the services of an experienced microscopist. In addition, an 
independent assessor blindly assessed random samples throughout the study period. Both 
microscopists were blinded to the dipstick results. Only a limited sample of the negative dipstick 
slides were assessed microscopically as it was logistically impossible to test all of them. The 
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results of the present study indicate that in the study population the OptiMAL® dipstick was able 
to identify more than 90% of pregnant women with malaria infection and correctly labelled 
about 85% non parasitaemic pregnant women. The high positive and negative predictive values 
and the corresponding likelihood ratios of a positive or negative test indicate that not many 
pregnant women were incorrectly diagnosed. However, the test performed poorly if parasite 
densities were below 50/4L. 
Few studies have reported the use of rapid diagnostic tests in pregnant women but mainly for 
the purpose of diagnosing placental malaria at delivery (Leke et a!. 1999; Mankhambo et a!. 2002; 
Singer et a1.2004). All these studies reported the tests as having good diagnostic features apart 
from one (Mankhambo et a!. 2002), which doubts the sensitivity of the OptiMAL® test to 
adequately diagnose placental malaria. A recently published study reporting the of use 
OptiMAL® dipsticks in the diagnosis of malaria in pregnant women attending antenatal clinics in 
Nigeria (Vanderjagt et a!. 2005) found the test to be insensitive compared to microscopy and 
PCR. However, it is not possible to compare this result to our study because the authors did not 
report the sensitivity, specificity, predictive values or likelihood ratios. 
The OptiMAL® dipstick test is expected to produce similar results in all environments if the test 
is conducted according to the manufacturer's instructions. However, in our experience during 
the dry months of the year, the wash well dried up too soon if the manufacturer's instruction of 
filling this well at the beginning of the test process was followed. Under these conditions, the 
optimum results were obtained when the wash well was filled just before the dipstick was 
transferred into it. 
The screening process with the OptiMAL® dipsticks fitted well within the routines of the 
antenatal clinic schedule. It did not cause any disruptions to the flow of work at the clinic 
throughout the study period. The high cost of RDT kits ranging between (US$1.00 to US$3.50) 
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per test compared to the cost (US$0.40) of using microscopy (Hanson et al. 2004) coupled with 
the relatively cheap and sensitive CQ and SP supported the argument that RDT use in moderate 
to high transmission areas may not be cost effective (Wongsrichanalai 2001; Fernando et al. 2004; 
Hanson et al. 2004). However, in Ghana the average cost of microscopic diagnosis of malaria are 
10,000 and 15,000 cedis in public and mission hospitals respectively. At an exchange rate of 
US$1.00 to 9,120 Ghanaian cedis, the cost of microscopy per test is more than US$1.00, which 
was the cost of the OptiMALe dipstick per test used in the present study. So cost may no longer 
be an issue limiting the wider use of RDTs in routine health care in Ghana. RDTs not being 
quantitative is a limiting factor (\Vongsrichanalai 2001) but since peripheral parasite density in 
pregnancy may not correlate with placental parasitaemia, the use of OptiMAL® dipsticks to 
detect circulating pLDH may be of public health significance. Antenatal RDT screening and 
treatment of only those with positive results would mean that: - 
i. Therapeutic judgements would be based on accurate diagnosis and so minimise wrongful 
antimalarial drugs prescription. The reduction of the excess and unnecessary antimalarial 
drugs prescription and use would save cost to offset the cost of using rapid diagnostic tests 
(Hanson et a!. 2004). 
ii. Accurate diagnosis and rational drug use are most likely to reduce drug pressure, which is 
implicated in the spread of parasite resistance to antimalarial drugs (\Vernsdorfer 1994; 
Wongsrichanalai 2001). 
iii. Pregnant women would benefit from early diagnosis and treatment of antenatal malaria 
which is likely to reduce the complications associated with malaria infection in pregnancy. 
iv. Exposure of pregnant women to the newer and more expensive antimalarial treatment 
options being recommended for national policies but whose safety remains largely untested 
in pregnant women will minimise. 
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8.4 Clinical presentation of malaria in the study women 
Fifty-eight percent of the women admitted to not being well in the last 5 days prior to enrolment 
and headache, fever, general malaise, dizziness and easy fatigability were their main complaints. 
However, only 7% of them had an axillary temperature of 37.5°C or above at enrolment. The 
symptoms were associated significantly with higher baseline peripheral parasite density. The 
symptoms were solicited from the women and so their responses depended on their 
understanding of the questions posed to them and their recall of the occurrence of the 
symptoms. To reduce any bias this limitation might introduce, the same set of questions were 
posed to all the study women who were parasitaemic and a control group of non-parasitaemic 
pregnant women, and the time of recall limited to the last five days prior to screening and 
enrolment. In the control group of pregnant women without parasitaemia, the proportions of ill 
health including fever, headache, vomiting, general malaise, tiredness and dizziness were 
significantly lower than in those with parasitaemia. 
In stable malaria transmission areas, malaria in pregnancy is known to be frequently 
asymptomatic with maternal anaemia and low birth weight being the main features (Brabin 1983; 
Brabin 1985; Verhoeff et al. 1999; Shulman et al. 2001; Steketee et al 2001; WHO 2004). 
McDermott and others reported that none of 19 Malawian pregnant women in their study who 
had parasitaemia at enrolment had a history of fever or symptoms related to malaria (McDermott 
et al. 1988). Similarly, Steketee and others did not observe any difference in the frequency of 
history of fever between parasitaemic and non-parasitaemic Malawian pregnant women (Steketee 
et al. 1996). In our study population malaria in pregnancy is often symptomatic. This is new and 
contrary to what is known to be the clinical manifestations of malaria in pregnancy in areas with 
stable malaria transmission such as our study area. These symptoms mimic pregnancy related 
symptoms but because they are associated significantly with parasite density, they must be 
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seriously considered. Possible explanations as to why this has not been noted earlier are given 
below. 
The first explanation is that, services provided at antenatal clinics do not include screening for 
malaria infection in pregnancy although the clinics are used to promote malaria control measures. 
A review of the antenatal records and the record capture forms used at the clinic in Nkoranza 
suggests that the only screening (clinical or laboratory) that goes on at the clinic is aimed at 
detecting pre-eclampsia and anaemia. This is the practice in the rest of Ghana 
(GSS/NMIMR/ORC 2004). The midwives monitor blood pressure and test for protein in the 
urine to help detect pre-eclampsia, estimate haemoglobin to help detect anaemia and prescribe 
haematinics and malaria chemoprophylaxis. Symptoms are only noted at antenatal clinics when 
the pregnant woman reported them. The midwives, for example, are able to make a connection 
between headache, high blood pressure and urine protein to mean pre-eclampsia; and dizziness, 
low Hb concentration and obvious pallor to mean anaemia. Although pregnant women may give 
complaints similar to those in this study no possible connection is made between the symptoms 
and malaria. Malaria chemoprophylaxis and haematinics are prescribed only as a routine practice 
at the antenatal clinics. 
Secondly, the presenting symptoms may be mild, unspecific, and self limiting which is typical of 
adult malaria (WHO 2000a). The pregnant woman may not report them if not asked. In the 
present study, the symptoms were solicited. 
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8.5 The liver and malaria during pregnancy 
Pregnancy rarely causes alterations in the levels of AST, ALT, GGT or bilirubin (Knox and 
Olans 1996; Riely 1999). Thus, any elevation in these parameters is abnormal. In the present 
study, these parameters were raised above normal in a proportion of study women at enrolment. 
The differential diagnosis of these apparent abnormal tests at baseline is not clear. It could have 
resulted from defects in sampling which could cause samples to haemolyse or defects in methods 
used to assess these parameters but the consistent pattern seen make this possibility very 
unlikely. Liver disease conditions in pregnancy that may cause abnormal laboratory tests include 
hyperemesis gravidarum, cholestasis of pregnancy, acute fatty liver of pregnancy (AFLP), 
HELLP (haemolysis, elevated liver tests and low platelet) syndrome, drug induced hepatoxicity, 
preeclampsia and eclampsia (Knox and Olans 1996; Riely 1999). The clinical assessments at 
enrolment did not suggest any of the above conditions. Apart from drug toxicity and probably 
viral hepatitis, these conditions are related to gestational age. However, in the present study, 
gestational age did not have a significant association with the abnormal laboratory tests. Blood 
pressures for all the study women were normal at enrolment and remained so throughout the 
day 28 follow up period. Platelet counts were not assessed in this study nor was it determined if 
there were pre-existing liver diseases by other means such as ultrasonography. However, it is 
known that the prevalence of hepatitis C virus infection is very high in some populations in 
Ghana (Wansbrough Jones et a!. 1998). 
Severe malaria in adults has been associated with hepatic dysfunction with increased AST, ALT, 
GGT and total bilirubin concentrations and may indicate poor prognosis (WHO 2000a). It is 
most likely that malaria parasites were responsible for the abnormal liver function tests at 
enrolment in the present study. The argument for this is that a control group of non- 
parasitaemic pregnant women who donated blood samples for liver functions tests rarely had 
elevated liver enzymes or bilirubin. Secondly, following treatment, total bilirubin and its fractions 
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returned to normal. Thus malaria in pregnancy although it may present with mild unspecific 
symptoms is actually dangerous and may have fatal consequences. 
8.6 Treatment efficacy 
Treatment efficacy in this study expressed as parasitological failure and haematological recovery 
at day 28 after starting treatment was assessed along the lines of the WHO protocol for 
monitoring antimalarial drug-resistance (WHO 2001a). However, responses to treatment in 
clinically ill children, for whom the WHO protocol was designed, may be different from adult 
pregnant women who are often asymptomatic. And so the emphasis in this study was on 
monitoring parasitological response following treatment. Women were not followed up on days 
one and two after initial treatment to supervise the second and third doses of the treatment. This 
means that adherence to the treatment regimes may not have been 100% but it was expected that 
it would be higher than it would be in the routine health care delivery system. Colour coding and 
pre-packaging increased the chances that a full course of treatment would be taken appropriately. 
Thus within the spectrum of an efficacy or effectiveness study, this one is nearer to the efficacy 
end of the spectrum. Ninety-three percent and 94% of all randomised study women completed 
the day 28 and day 14 follow ups respectively and so the study sample size retained its power to 
detect any differences in proportions of parasitological failure between CQ and the test drugs. 
The individual randomisation and the double blind design of the study ensured that confounding 
and selection bias was substantially limited if not totally eliminated. 
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8.6.1 Para itological outcomes 
The study showed that the proportion of treatment failures in pregnant women was low. AQ 
alone and its combination with SP performed better than to CQ in clearing peripheral 
parasitaemia at both days 14 and 28. The parasite prevalence corrected for new infections by 
msp-2 genotyping was 0% at day 14 in the AQ+SP combination group and one percent at day 
28. The results of 33 samples could not be determined by PCR genotyping. In 21 samples the 
PCR failed in the follow up day pairs, in 4 samples it failed in the day 0 pairs and in 7 samples it 
failed in both day 0 and follow up day pairs. The reasons could be due to suboptimal storage 
conditions of the filter paper samples, or ineffective DNA extraction. However, it is also known 
that parasite genotypes detected in one sample may not often be present in a matching sample in 
pregnant women suggesting a differential sequestration of different genotypes (Kamwendo et al. 
2002). It has been found in children (Bruce et al. 2000) and in pregnant women (Kamwendo et al. 
2002) that an infection is composed of different parasite genotypes such that at any time some 
genotypes may be sequestrated and others circulating. However in the present study we took 
only one sample per women on day 0 and on follow up days and so one can only speculate that 
the above explanations account partly for our findings. 
We are unaware of any previous publication reporting the efficacy of AQ or its combination with 
SP in the treatment of malaria infection in pregnancy. However, the efficacy of AQ alone or its 
combination with SP or artesunate against CQ has been studied in children. In Ghana, recent 
studies in children have shown that AQ or its combination with SP or artesunate were better at 
clearing parasitaemia compared to chloroquine (Mockenhaupt et al. 2005; Oduro et al. 2005). 
Similar studies in children in other places have confirmed the superiority of AQ alone or in 
combination with SP or artesunate over CQ (Brasseur et al. 1999; Staedke et al. 2001; Basco et al. 
2002; Dorsey et al. 2002; Abacassamo et a!. 2004). Olliaro and colleagues in a systematic review in 
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1996 (Olliaro et al. 1996) compared the efficacy of AQ with CQ or SP. Their review showed that 
AQ was superior to CQ at clearing peripheral parasitaemia at day 7 and 14 post treatment while 
SP was superior to AQ at clearing parasitaemia at days 14 and 28 post treatment. 
As expected, the combination of AQ and SP performed best suggesting that this combination 
could be a useful option in the treatment of malaria in pregnant women in other parts of Ghana 
or in other areas where the antimalarial drug resistance levels and malaria transmission conditions 
are similar to those of the study area. This would not be the case in areas where resistance to CQ, 
AQ or SP is high like in East Africa and south-east Asia. 
Parasitological failure by day 28 occurred most frequently in those with high baseline parasite 
densities (1000/µL or more), Hb below 11g/dl and prior ill health; and in the primigravidae, 
nulliparae and primiparae. Nulliparous, primigravid women had the highest risk of parasitological 
failure. This agrees with the findings reported by Keuter and others in Kenya (Keuter et al. 1990). 
However, high baseline parasite density was not a predictor of treatment response in women 
who received the AQ+SP combination because there was only 1% true failure. 
8.6.2 Haematological response 
There was a general and progressive improvement in Hb concentrations during the follow up 
with a decrease in the proportions of anaemic pregnant women in all the treatment groups. 
These changes in haemoglobin were not related to the baseline parasite density, baseline Hb, 
parity, gravidity or age. AQ alone or in combination with SP was associated with higher increases 
in Hb at day 28 follow up after the start of treatment compared to CQ and SP. Similar 
improvements in haemoglobin concentrations have been observed in studies in which 
antimalarial drugs were used either for prophylaxis (Spencer et al. 1987; Greenwood et al. 1989; 
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Cot et al. 1998) or IPT (Parise et al. 1998; Shulman et al. 1999) or treatment (Steketee et al. 1987; 
Keuter et al. 1990; McGready et al 2000; McGready et al. 2001; McGready et al. 2005) in pregnant. 
The increase in haemoglobin concentrations correlated with the decrease in parasite prevalence 
seen at follow up suggesting that falciparum parasitaemia was responsible for the anaemia in the 
pregnant women. Also associated with the increases in haemoglobin concentration in the present 
study, were significant decreases in the concentrations of total bilirubin and its fractions 
suggesting that the antimalarials had stopped the haemolysis. Therefore post treatment 
monitoring of haemoglobin concentrations can be used to indicate clinical efficacy of 
antimalarial treatment in pregnant women. Iron and folate supplementation and the treatment of 
hookworm infestation in those infested may also contribute to the improvements in 
haemoglobin concentrations as shown by (Shulman et al 1996; Dreyfuss et al. 2000). Their 
contributions could not be assessed in the present study as all women received iron and folate 
supplements but they are known to be helpful for improving anaemia in pregnant women 
(Fleming 1989; Menendez et al. 1994; Msolla and Kinabo 1997; Verhoeff et al. 1998; Huddle et al. 
1999; Mockenhaupt et al 2000). 
8.7 Safety and tolerance 
The safety of antimalarial drugs used either for chemoprophylaxis, IPT or case management in 
the control of malaria in pregnancy has been the subject of debate and concern over the years. 
The incidence of symptoms and signs, and laboratory indicators associated with the test drugs 
reported in the present study are discussed in the following sections of this chapter. 
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8.7.1 Symptoms and signs 
Seventy-five percent of women at day 3 follow up reported an adverse effect. General weakness, 
dizziness, vomiting, itching and nausea were the 5 most frequent adverse effects reported by the 
women. As expected, women who took SP had the least number of complaints while about 90% 
of the complaints came from women in the AQ and the AQ+SP combination groups. Notably 
the reports of weakness, vomiting, dizziness and nausea were highest in the AQ and AQ+SP 
groups and least in the SP groups. These complaints were not associated with age, baseline Hb, 
baseline parasite density, parity, gestation or prior ill health. The incidence of these complaints 
was higher than those reported by pregnant women who were non-parasitaemic and were not 
treated. Therefore it is most probable that the high incidence of complaints on day 3 was caused 
by the test drugs. Because many of the adverse effects noted are similar to the symptoms caused 
by pregnancy itself, the inclusion of a control group of non-infected pregnant women, a novel 
feature of this study, was very helpful in ascertaining the proportion of complaints that could be 
attributed to the drugs. Despite the symptoms related to treatment with AQ or AQ+SP, 
compliance was high. More than 90% of the study women completed their day 3 follow up. 
About five percent of the study women did not finish their full course of treatment due to the 
adverse effects. About 32% of those who reported adverse effects claimed that performance of 
their routine household chores had been inhibited after the start of treatment; compared to 
about 24% of untreated non-parasitaemic control group who also claimed that they could not 
perform their household chores on day 3 after screening. It is possible that the study women 
tolerated the adverse effects and complied with the treatment because they understood that they 
had malaria and were aware of what might happen if they did not comply. Women in the present 
study probably felt involved when they saw the positive reaction bands of the OptiMAL® 
dipsticks and understood what they meant. Compliance with AQ or AQ+SP might not be so 
good if these drugs were used for IPTp. Olliaro and colleagues in their review of trials involving 
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the use of AQ, SP or CQ for prophylaxis or treatment reported similar adverse effects as in this 
study but did not find any significant differences in incidence among the treatment groups 
(Olliaro et al. 1996). 
Two cases of non-life threatening skin rash were thought to be probably related to the test drugs. 
They were reported on day 7 after the start of treatment and disappeared within a week. One 
woman took SP alone and the other took the AQ+SP combination. No other conditions were 
associated with the rash and the women did not receive any specific interventions. SP is known 
to be associated with rare but severe cutaneous reactions which could be life threatening such as 
Stevens Johnson syndrome (Phillips-Howard and `'Vest 1990; Steffen et al. 1990; Luzzi and Peto 
1993; Sturchler et al. 1993) but the lesions seen in this study were not of this type. Reactions 
similar to the one reported in this study were reported by David and others in Sierra Leone in 
children who took Maloprim for prophylaxis fortnightly for 3 or more months (David el al. 
1997). 
8.7.2 Liver enUmes 
There was a general rise in AST activity at day 14 particularly in the AQ group compared to 
baseline activities. The mean AST levels returned to baseline levels at day 28. This is similar to 
what was found by Sturchler and others in travellers who used AQ, SP or CQ for prophylaxis. 
They found an association between AQ and male SP users and increased AST activity but which 
was significant only in the AQ group (Sturchler et al. 1987). The rise in AST activity in the 
present study could be considered as a transient derangement associated with the antimalarials. 
They were not associated with any clinical manifestations of hepatitis. 
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The more liver-specific ALT showed a similar pattern but contrary to expectation the mean ALT 
levels in the AQ group decreased steadily throughout the follow up period to below baseline 
levels at day 28. 
The pattern of change in the GGT was different. The mean GGT values increased throughout 
the follow up period in all the treatment groups but were all within the normal range. It is not 
clear what was responsible for this pattern. Although GGT cannot help in discriminating 
between liver diseases, it is considered the most sensitive enzymatic indicator of liver disease; 
high values are rare in the absence of liver disease (Riely 1999). GGT may be elevated in 
response to toxic effects of drugs on liver cells (Lee 2003). It may also be raised in patients with 
liver cancer, heavy alcohol drinkers or patients with alcohol cirrhosis and in patients receiving 
anticonvulsants such as phenytoin or phenobarbital (Knox and Olans 1996; Riely 1999; Lee 
2003). However, these conditions cannot explain the consistent pattern of increase in all the 
treatment groups throughout the follow up. It seems plausible that all the drugs used in the 
present study had some effect on the hepatobiliary system to cause elevations in GGT. 
Interactions of the test drugs with other unprescribed agents like drugs or herbal concoctions 
may also be responsible. Pregnancy itself increases the risk of drug induced hepatoxicity. 
In healthy, non pregnant expatriate workers and their families in Nigeria, who were receiving 
long term prophylaxis with mefloquine plus SP combination or CQ, Kollaritsch and others 
observed irregular deviations of AST, ALT and GGT levels from normal levels at baseline and 
during chemoprophylaxis and so did not relate them to the drugs (Kollaritsch et al. 1988). In a 
female volunteer, they observed a six-fold increase in GGT levels at the end of an 18 months 
follow up period. They attributed the abnormal levels in AST, ALT and GGT to chronic 
alcoholism in some of the volunteers. 
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8.7.3 Bilirubin 
Bilirubin levels declined after the start of treatment to below baseline levels at both day 14 and 
day 28. The possible explanation for this is cessation of the haemolysis caused by the malaria 
parasites as indicated in section 8.6.2. Also it is the only biochemical test that was significantly 
associated with Hb and parasite density at enrolment. 
8.7.4 IY/hite blood cells 
Leucopoenia is the most feared adverse effect from AQ treatment. Earlier studies have 
associated the prophylactic use of AQ to leucopoenia due to neutropaenia (Hatton et al 1986; 
Neftel et al. 1986; Rhodes et al. 1986; Phillips-Howard and West 1990) or to lymphopoenia 
(Sturchler et al. 1987). Sturchler and others did not find a significant difference in the degree of 
leucopoenia caused by AQ, SP or CQ (Sturchler et al. 1987). In the present study, the 
proportions of neutrophils increased after the start of treatment without any significant 
differences in the treatment groups during the follow up period. The same pattern was shown 
when all granulocytes (neutrophils, basophils and eosinophils) were considered, apparently 
because the neutrophils form about 80% of the granulocyte population. There was a non 
significant decrease in the overall average lymphocyte count on day 3 follow up compared to 
baseline counts. On days 7,14 and 28 the overall mean decreases in lymphocyte counts relative 
to baseline counts were significant but unrelated to the type of treatment received. The mean 
total white cell count decreased significantly on day 3 but unrelated to the type of treatment 
received. Subsequently, there were overall mean increases in the total white cell counts but again 
not related to the type of treatment received. The present study did not find any significant 
differences in the post treatment total and differential white cell counts of the treatment groups 
as did earlier studies. Apart from the post treatment lymphopoenia noted, there was no decrease 
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in the total white cell counts and neutrophils but rather an increase. Possible explanations for this 
are that total white cell counts are generally increased in pregnancy and although malaria is a 
cause of leucopoenia (Mckenzie et al. 2005) severe malaria is also associated with leucocytosis 
(Modiano et al. 2001). The mean decrease on day 3 was probably due to the combined effects of 
the drugs and the parasite loads. Besides, the earlier findings were in those who used 
amodiaquine for prophylaxes and so barring any differences in gender, age, race and 
methodology, a clear pattern may not emerge after a one off treatment dose. 
8.8 Pregnancy outcome 
The parasitological and haematological outcomes at delivery and at six weeks postpartum, 
incidence of low birth weight and the incidence of adverse neonatal outcomes are discussed in 
the following sections of this chapter. The analyses of pregnancy outcomes are limited by the 
large numbers of women who were lost to follow up at delivery and postpartum. Those lost to 
follow up at delivery migrated outside the study area before delivery to be with their parents or 
families. If we expected pregnancy outcome records on at least 90% of those who completed the 
day 28 follow up, then the data available for the analyses was only 50% for delivery Hb, 62% for 
parasite prevalence, 58% for birth weight and 70% for postpartum Hb and parasite prevalence 
analyses. Thus the power to detect any differences in treatment was reduced. 
8.8.1 Parasitological outcomes 
A placenta blood smear or impression smear was more sensitive in detecting parasitaemia at 
delivery than peripheral blood smear. Compared to CQ, the test drugs appeared to have some 
protective effect against peripheral parasitaemia but this was only significant in women who 
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received the AQ+SP combination therapy. Compared to CQ, SP appeared to have the most 
protective effect against placenta parasitaemia. Nulliparity and high baseline parasite density were 
both significantly associated with peripheral parasitaemia at delivery. Nulliparity alone was 
associated with placental parasitaemia detected by impression smear and not the placental blood 
smear whilst a high baseline parasite density was associated significantly with placental 
parasitaemia detected by placenta blood smear and not by placenta impression smear. Gestation 
at enrolment however, did not have an association with either peripheral or placenta parasitaemia 
at delivery. 
At six weeks postpartum, the prevalence of peripheral parasitaemia was less than 5% indicating 
that a significant clearance of parasitaemia occurs after delivery. This finding is similar to the 
finding in some earlier studies (Ladner el al. 2002). A plausible reason for this is the fact that 
delivery removes the immunosupression and hence susceptibility to malaria (Nguyen-Dinh et al. 
1988). On the contrary Steketee and others did not find any differences in parasite prevalence at 
antenatal, delivery and within 6 months of postpartum in both non-HIV and HIV Malawian 
women (Steketee et al. 1996) and Diagne and others found an increase in malaria episodes within 
2 months postpartum in Senegalese women (Diagne el al. 2000). 
8.8.2 Maternal haemoglobin at delivery 
Nulliparity and teenage pregnancy were associated significantly with maternal I-Ib at delivery. The 
mean maternal Hb at delivery was higher than the mean during the day 28 follow up. Compared 
to CQ, the test drugs appeared to have some protective effect against maternal anaemia but this 
was significant only in study women who received the AQ+SP combination therapy. For study 
women who had retreatment prior to delivery, AQ and AQ+SP had very significant protective 
effects against maternal anaemia at delivery. This is expected because as discussed in section 
212 
8.6.2, antimalarial drug interventions either for prophylaxis or treatment and iron and folate 
supplementation, lead to improvements in maternal Hb concentrations. 
At 6 weeks postpartum, only two of the study women had an Hb below 8g/dl while more than 
75% had Hb of 11g/dl or above. While the reduction in falciparum parasitaemia may partly 
explain this, an improvement in nutrition may also play a major part. There are unsubstantiated 
reports in the study area that pregnant women generally do not take the iron and folate 
supplementations to avoid having big babies and hence caesarean sections. 
8.8.3 Birth weight 
Nulliparity and maternal anaemia were associated significantly with a low birth weight. The 
results agree with evidence from other studies that showed that maternal anaemia and low parity 
are risk factors for low birth weight (McGregor et al. 1983; Kramer 1987; Brabin et al 1990; 
Brabin and Piper 1997; Kasumba et al. 2000; Lone et al. 2004). Low parity and maternal anaemia 
are also known predictors of placenta parasitaemia and so it was expected that low birth weight 
would be associated with peripheral or placenta parasitaemia (Brabin et al. 1996; Brabin and Piper 
1997; Brabin et al. 1999; Shulman et al. 2001; Brabin et al 2003; Guyatt and Snow 2004) at 
delivery but in the present study neither peripheral nor placenta parasitaemia examined 
microscopically nor gestation at enrolment was associated with the incidence of low birth weight. 
It however, appears that the risk of low birth weight depends on how much malaria related 
damage has been caused in the placenta by previous infections (Kaushik et al. 1992; Menendez et 
al. 2000; Shulman et al. 2001). So an association between placenta parasitaemia and low birth 
weight in the study population is possible and might have been detected if placental biopsy had 
been done. 
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8.8.4 Adverse pregnancy outcomes 
The rates of abortions, preterm deliveries and still births among the study women were no more 
than the rates for non study women who delivered at St Theresa's hospital. Among the study 
women, the type of treatment did not have any association with the incidence of these events. 
There were no congenital defects judged to have been caused by the study drugs. This does not 
disprove the fact that the study drugs may have teratogenic effects. It only confirms the fact that 
these serious adverse effects known to be associated with these drugs are indeed rare and that a 
larger sample size than in the present study would be needed to detect them. Earlier studies 
involving standard therapeutic doses of the study drugs did not show excess risk of adverse 
foetal outcomes over local rates (\Vlolfe and Cordero 1985; Steketee et al. 1987). 
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8.9 Implications for research 
This study has shown that only 20 to 30% of pregnant women attending antenatal clinics had P. 
falciparum parasitaemia; screening and treatment improved haemoglobin concentrations in the 
women; AQ alone or its combination with SP was most efficacious and safe but least tolerable; 
SP was most tolerable. Although screening and treating mothers with slide positive malaria 
appears to be feasible and beneficial for the mother, the effect of this approach on placental 
malaria and birth weight compared to IPT is unknown. SP-IPT not only clears parasitaemia but 
also provides intermittent chemoprophylaxis. If treatment was offered only to women who were 
slide positive (up to 30%), the opportunity of providing intermittent chemoprophylaxis will be 
missed for the remaining 70% of women. On the other hand if AQ alone or its combination 
with SP was recommended for IPT, the minor adverse effects associated with it might reduce 
women's compliance to the regime. The current national policy of SP-IPT for pregnant women 
has been shown to be efficacious, easy to administer, safe and tolerable (Parise et al. 1998; 
Verhoeff et al. 1998; Shulman et al. 1999; Rogerson et a1.2000; Njagi et al. 2003; van Eijk et al. 
2004; Kayentao et a!. 2005). Currently, SP-IPT has been rated as having the most favourable 
effectiveness profile in terms of lower cost, compliance and reduced morbidity and mortality 
resulting from the prevention of maternal anaemia and low birth weight (Goodman et al. 2001; 
Newman et al 2003). However, as coverage of the programme increases to cover all pregnant 
women and resistance to SP increases or when the number of doses has to be increased due to 
increased HIV prevalence then this rating of SP may change; and SP-IPT may not be the long- 
term approach to decreasing the risks posed by antenatal malaria to the mother and her baby. 
If that happens, it is likely that SP would be replaced by AQ, AQ+SP or artesunate (AS) plus 
AQ combination (the current first line drug for uncomplicated malaria) for IPT. As the safety of 
AS+AQ combination for IPT in pregnant women is not proven it would be prudent to screen 
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women attending ANC using RDT and treat only those who are RDT positive. Even if AQ or 
AQ+SP are used for IPT the concern of tolerance and the low prevalence of parasitaemia (20- 
30%) warrant the need to consider the screening and treatment approach. However, there is no 
clear evidence to suggest that the screening and treatment approach is equally effective to reduce 
the adverse effects of malaria during pregnancy on mother and foetus. There is also some 
evidence that although ITNs and IPT are individually effective, the extra benefit of combining 
the two interventions is negligible (Njagi et al. 2003). The reduction in malaria related adverse 
pregnancy outcomes attributed to the large scale use of ITNs among Kenyan pregnant women 
are very encouraging (ter Kuile et al. 2003; ter Kuile et al. 2003). It has highlighted the need to 
address the issues of cost, retreatment and adequate and sustainable supply of bed nets to 
achieve the right impact from this intervention. 
These scenarios pose the following questions which need to be addressed scientifically: - 
i. What proportions of women who are RDT negative have placental malaria? 
ii. What are the consequences of restricting antimalarial treatment to pregnant women who 
are RDT positive to the health of the mother and her baby? 
iii. Is this "selective treatment" cost effective? 
iv. Would ITN plus RDT screening and treatment, provide better protection for the pregnant 
women and foetuses? 
These questions may be addressed by a three-arm study as follows: - 
i. OptiMAL® antigen screening plus treatment of dipstick positives with AQ+AS (the 
current Ghanaian national policy) plus ITN 
ii. SP-IPT for dipstick negatives plus ITN 
The objective would be to compare the efficacy, safety and cost effectiveness of RDT screening 
and treatment with SP-IPT. 
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The objective would be to compare the efficacy, safety and cost effectiveness of RDT screening 
and treatment with SP-IPT. 
Useful endpoints would be maternal Hb at 36 weeks of gestation; active or chronic placenta 
parasitaemia determined by histology, birth weight and the incidence of serious and non-serious 
adverse events. 
8.10 Implications for policy and practice 
Ghana's Ministry of Health currently recommends quinine as the first line drug of choice for 
treating malaria in pregnancy in the first trimester and, quinine or AS+AQ in the second and 
third trimesters. However, the seven-day regime of quinine and the adverse effects associated 
with it, might compromise adherence to the full course of quinine by both prescribers and 
pregnant women. Tinnitus and dizziness reported (McGready et al. 2001) to be frequently 
associated with quinine have the potential to make it intolerable (Fungladda et al. 1998). Quinine 
can also induce hyperinsulinaemia which potentially can aggravate hypoglycaemia (White et al. 
1983; Looareesuwan et al. 1985; Adam et al. 2005) associated with malaria in pregnancy. These 
potential adverse events related to quinine are likely to discourage the use of quinine during 
pregnancy and thus a regime of quinine may be difficult to implement. A regime of AQ+AS 
combination also remains untested as there was no local data to support its efficacy and safety 
for treating pregnant women with malaria. The present study has shown that AQ or AQ+SP 
combination is efficacious and reasonably safe for treating malaria in pregnancy. This means that 
for the time being, quinine or artemisinin based combination therapies are not necessary for 
treating malaria in pregnancy in Ghana. However, recommending the AQ+SP combination for 
treating malaria in pregnant women is limited because of the likelihood of rising SP resistant P. 
falcipanim as SP monotherapy is the current national policy for IPT during pregnancy. Thus the 
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AQ+SP combination may not provide a long term solution to the search of a safe and 
efficacious treatment of malaria in pregnancy (WHO 2003c). One option to prolong the use of 
the AQ+SP combination is to use the screening approach and offer AQ+SP combination 
therapy only to those women who have a positive dipstick test. However, this approach cannot 
be recommended until we know the answers to the questions mentioned in section 8.9. On the 
basis of the existing evidence, our recommendation would be to promote as much as possible 
the frill package of interventions recommended by the WI-10 namely; intermittent presumptive 
treatment, case management plus the prevention and treatment of maternal anaemia and 
insecticide treated nets (WHO 2004). To maximise the impact of these interventions pregnant 
women need to have full access to all three interventions or combinations of them that are 
feasible and sustainable. 
8.11 Conclusions 
The present study has shown that malaria in pregnancy is often symptomatic in the study 
population. A screening programme using OptiMAL® dipsticks could detect parasitaemia in the 
pregnant women with high sensitivity and specificity during routine antenatal clinic sessions. 
Although the screening needed extra staff, it did not cause any disruption at all to work at the 
antenatal throughout the study period. The AQ+SP combination was the most efficacious 
regime in the treatment of parasitaemic pregnant women. It was safe and reasonably tolerated 
and could be used for the treatment of malaria in pregnancy. However, given the current policy 
of using quinine or AS+AQ for the treatment of malaria in pregnancy in Ghana, the AQ+SP 
combination as first line drug needs to be considered by countries that are now contemplating 
changing their national antimalarial drug policies. 
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APPENDICES 
APPENDIX I INFORMATION SHEET AND CONSENT FORM 
Title: Safety and efficacy of Amodiaquine and SP versus chloroquine in the treatment of 
malaria in pregnancy. 
Investigators: Tagbor H, Chandramohan D, Browne E, Greenwood B. 
The following was repeated in the local Akan language for the understanding of eligible 
pregnant women. 
Malaria in pregnancy is life threatening to both the mother and the baby. In Ghana, 
chloroquine is the main drug we use for malaria treatment but it is no more effective for 
treating malaria, so more effective and safe drugs are needed urgently to treat malaria. 
Amodiaquine (camoquine) which is similar to chloroquine in its action against malaria parasites 
was removed from the essential drugs list because of its association with some rare but serious 
adverse effects when taken more frequently. Its use has been recommended again for the 
treatment of malaria in combination with fansidar or artesunate. Studies from Tanzania and 
Kenya suggest that it is efficacious and safe when used in children. We in Ghana are 
contemplating changing the amodiaquine and its combination of SP or artesunate and want to 
test amodiaquine and fansidar against chloroquine. So we would like you to help us do this by 
participating in the study. The findings will help the Ministry of Health to better control of 
malaria in pregnancy. 
If you agree to participate in this study, this is what it will involve. 
1. We will ask you some questions about yourself including your general health, your 
education level and living conditions. 
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2. We will take a little blood by a prick of your fingertip to test for malaria and thinning 
of blood. 
3. We will let you choose one of the 3 drugs by lottery. 
4. If we find malaria parasites in your blood we will give you the drug you chose. You 
take the first dose here and the rest at home. 
5. We will then visit you on the third and seventh day to find out how you are doing and 
take blood to test for malaria parasite and thinning of blood. 
Every information we have on you will not be disclosed to anyone by us. Participation in this 
study is voluntary. If you do not wish to participate in the study, it will not affect the regular 
care you have been receiving from this hospital now or in the future. 
Do you have any questions for us that will help you decide whether or not you want to take 
part in the study? 
Do you understand what taking part in this study will mean for? 
I certify that I have explained the above to that she 
understood what I said and she has agreed to freely join the study. 
Signature: Date: 
_/_/ 
Name: 
I have understood the explanation given to me by and I agree 
to join the study. 
Signature or Thumbprint: Date // 
Name: 
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APPENDIX 2 SCREENING FORM ONE 
NKORANZA ANTIMALARIAL DRUGS PROJECT 
SCREENING FORM ONE 
DATE: MIDWIFE'S NAME: 
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APPENDIX 3 SCREENING FORM TWO 
NKORANZA ANTIMALARIAL DRUGS PROJECT 
SCREENING FORM TWO 
Screening date: Screening number 
Name of eligible pregnant woman: 
Age: 
Date of birth: 
Village/Location : 
1. Her pregnancy is at least 16 weeks. 
2. She has P. falcparum parasitaemia of any density with or without symptoms. 
3. She is willing to participate and complete the test schedule, and has given informed consent. 
4. She is willing to be delivered by a midwife in a health centre or hospital. 
5. She lives within Nkoranza district. 
6. She has had repeated stillbirths, eclampsia or other past bad obstetric history. 
7. She has a history of severe adverse drug reactions to Septrin or Fansidar in the past 
8. She has a haemoglobin level below 5.0 g/dl. 
9. Has mixed infection 
10. She has multiple pregnancy 
11. She has malaria that is severe enough to require parenteral medication. 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
If responses to questions 1-5 are all YES, the PI/clinician or midwife should invite the pregnant woman to 
enter the study: If on the other hand a response to questions 6- 11 is YES, the woman should be given 
routine antenatal care as required by the national guidelines. 
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APPENDIX 4 RECRUITMENT FORM ONE 
NKORANZA ANTIMALARIAL DRUGS PROJECT 
RECRUITMENT FORM ONE 
IDENTIFICATION & BACKGROUND INFORMATION 
1 Date of recruitment 
3 Drug Code 
7 Contact Person 
10 House number 
13 Educational level reached 
1 None 
2 Primary 
3 JSS 
4 SSS 
5 Tertiary 
15 Religion 
1 Christianity 
2 Islam 
3 Traditional African Religion 
4 None 
5 Other (specify) 
17 Marital Status 
1 Married 
2 Single 
18 Socioeconomic Status 
1 Access to portable water 
2 Owns a farm 
3 Owns radio 
4 Owns TV 
5 Owns bicycle/motorbike 
6 Size of household 
7 Owns a house 
22 How many bed nets 
are there in your house? 
2 Study ID number 5 First name (as on card) 
4 ANC Card number 6 Last name (as on card) 
8 Location 
11 Date of birth 
i 
9 Landmarks 
12 Age (Years) 
14 Occupation 
1 Housewife 
2 Farmer 
3 Trader 
4 Salary worker 
5 Other (specify) 
I 
4 Dagomba/Frafra/Kokomba 
5 Ewe/Fante/Ga 
16 Ethnic Group 
1 Brong 
2 Akan 
3 Dagaba 
19 Type of building 
1. Block/Brick 
2. Mud 
3. Thatch 
Y/N- 
-YýN- 
-YýN- 
-Y/N- 
-Y/N- 
_Y/N_ 
I 
20 Type of roofing 
F-I 
71 
1. Corrugated Roofing Sheets 
2. Thatch 
21 Type of floor 
1. Cemented 
2. Uncemented 
I 
23 Do you use a bed net 
regularly? -Y/N- 
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APPENDIX 5 RECRUITMENT FORM TWO 
NKORANZA ANTIMALARIAL DRUGS PROJECT 
RECRUITMENT FORM TWO 
CLINICAL ASSESSMENT 
Study ID number 
1 PAST MEDICAL HISTORY 
Hypertension 
Diabetes 
Sickle cell disease 
Epilepsy 
Asthma 
Pallor 
Axillary Temperature 
Blood pressure 
Weight 
Height 
Fundal height 
Foetal presentation 
1. Cephalic 
2. Breech 
3. Transverse / oblique 
Foetal sound heard 
"" NS = Not sure 
Drug Code 
2 PRESENT MEDICAL HISTORY 
_Y/N_ 
Sick in last 5 days? 
Y/N_ I_Eyes OR no, phase circle 
_Y/N_ 
Fever & chills 
_Y/N_ 
Headache 
_Y/N_ 
Vomiting 
General malaise 
Cough 
Dizziness 
Painful micturition 
Tired easily 
General weakness 
Waist pain 
Lower abdominal pain 
3 PHYSICAL EXAMINATION 
_Y/N_ 
SPLEEN 
1 Enlarged 
2 Not enlarged 
LIVER 
1 Enlarged 
2 Not enlarged 
CVs 
1 Normal 
2 Abnormal 
Y/N_ 
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-Y/N- 
Y/N/NSv° 
Y/N/NS 
Y/N/NS 
Y/N/NS 
Y/N/NS 
Y/N/NS 
Y/N/NS 
Y/N/NS 
Y/N/NS 
Y/N/NS 
Y/N/NS 
i 
I 
I 
I 
I 
APPENDIX 6 RECRUITMENT FORM THREE 
NKORANZA ANTIMALARIAL DRUGS PROJECT 
RECRUITMENT FORM THREE 
OBSTETRIC ASSESSMENT 
Study Identification Number Drug Code 
1 Gravidity I 2 Parity I 
3 Last Menstrual Period 
5 Events in previous pregnancies 
Bled during pregnancy 
Sick& treated at hosp. 
Hospitalised 
Aborted pregnancy 
Y/N/NA 
Y/N/NA 
Y/N/Nr1 
Y/N/NA 
No of children alive 
No of children dead 
If yes, when 
1. Died before birth 
2. Pronounced dead 
after birth 
3. Died before one 
month old 
4. NA 
7 Events in current pregnancy 
Bled or bleeding Y/N_ 
Sick & treated at Hosp. --YIN- 
Hospitalised 
_Y/N_ 
4 Expected Delivery Date 
6 Previous Delivery 
1. Hospital Delivery 
2. Normal 
3. C/Section 
4. Vacuum Extraction 
5. Episiotomy 
6. NA 
I 
Home Delivery 
1. TBA 
2. Self/Relative 
3. NA 
Foetal Sound Heard 
_Y/N_ 
8 Gestation in weeks by: - 
Woman 
Fundal height 
Ultrasound scan 
Foetal Presentation 
1. Cephalic 
2. Breech 
3. Transverse / oblique 
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APPENDIX 7 RECRUITMENT FORM FOUR 
NKORANZA ANTIMALARIAL DRUGS PROJECT 
RECRUITMENT FORM FOUR 
DRUG HISTORY 
Study ID number 
Known drug reactions 
Dizziness 
Headache 
Sleeplessness 
Skin Rash 
Itchiness 
Palpitations 
Nausea 
Vomiting 
Jaundice 
Dark Urine 
Drug Code 
_Y/N_ 
Names of drugs allergic to (if known) 
_Y/N_ 
Septrin 
_Y/N_ 
Aspirin 
_Y/N_ 
Fansidar 
Chloroquine 
Other (Specify) 
_Y/N_ 
_Y/N_ 
Where did you get the drug 
_Y/N_ 
1. Health Facility 
2. Chemical Shop 
3 Herbalist 
4. Friend/Relative 
5. NA 
Have you taken chloroquine in last 2 months 
Y/N_ 
Have you taken fansidar in last 2 months 
-Y/N- 
253 
-Y/N- 
-Y/N- 
-Y/N- 
-Y/N- 
-Y/N- 
I 
APPENDIX 8 LABORATORY FORM ONE 
NKORANZA ANTIMALARIAL DRUGS PROJECT 
LABORATORY FORM ONE 
DAY 0 
Date 
MICROSCOPY 
PARASITE TYPE PARASITE COUNT 
P. F. TROPHOZOITES 
P. F. SCHIZONTS 
P. F. GAMETOCYTES 
P. M. TROPHOZOITES 
P. M. SCHIZONTS 
P. Ni. GAMETOCYTES 
P. O. TROPHOZOITS 
P. O. SCHIZONTS 
P. O. GAMETOCYTES 
TOTAL WBC 
NEUTROPHILS 
LYMPHOCYTES 
MONOCYTES 
EOSINOPHILS 
BASOPHILS 
HAEMOGLOBIN 
HAEMATOLOGY 
Laboratory Technician/Microscopist 
Screening Number 
BIOCHEMISTRY 
TEST 
AST 
ALT 
GGT 
TOTAL BILIRUBIN 
DIRECT BILIRUBIN 
INDIRECT BILIRUBIN 
RESULT 
ELISA urine dipstick positivity 
Chloroquine 
_Y/N_ 
SP 
-YIN- 
Both 
_Y/N_ 
Hookworm Infestation 
_Y/N_ 
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APPENDIX 9 LABORATORY FORM TWO 
NKORANZA ANTIMALARIAL DRUGS PROJECT 
LABORATORY FORM TWO 
DAY [31 [71 [141 [28] 
Date 
MICROSCOPY 
PARASITE TYPE 
P. F. TROPHOZOITES 
P. F. SCHIZONTS 
P. F. GAAIETOCYTES 
P. M. TROPHOZOITES 
P. M. SCHIZONTS 
P. M. GAMETOCYTES 
P. O. TROPHOZOITS 
P. O. SCHIZONTS 
P. O. GAAfETOCYTES 
TOTAL WBC 
NEUTROPHILS 
LYMPHOCYTES 
MONOCYTES 
EOSINOPHILS 
BASOPHILS 
HAEMOGLOBIN 
PARASITE COUNT 
Study ID number 
BIOCHEMISTRY 
TEST 
AST 
ALT 
GGT 
TOTAL BILIRUBIN 
DIRECT BILIRUBIN 
INDIRECT BILIRUBIN 
HAEMATOLOGY 
Laboratory Technician/Microscopist 
RESULT 
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APPENDIX 10 FOLLOW UP FORM ONE 
NKORANZA ANTIMALARIAL DRUGS PROJECT 
FOLLOW-UP FORM ONE 
DAY 3 FOLLOW - UP 
Date Study ID number Drug Code 
ASSESSMENT OF ADVERSE EVENTS 
Ask: Did you finish taking all the drugs? _Y/N_ 
If no, why. 
1. Adverse effects 
2. Forgot To Take 
3. N/A 
Ask: Did you experience any problems after taking the drugs? _Y/N_ 
Whether yes OR no, enquire about the following and tick "Yes" OR "No" 
against the mentioned experience 
REPORTED 
EVENTS 
Field Worker 
RESPONSE 
Dizziness 
--YIN- 
Headache 
_Y/N_ Sleeplessness 
_Y/N_ 
Skin Rash Y/N_ 
Itchiness 
_Y/N_ 
Palpitations 
_Y/N_ 
General Weakness 
_Y/N_ 
Nausea 
_Y/N_ 
Vomiting Y/N_ 
Sore Mouth 
_Y/N_ 
Painful Swallowing 
_Y/N_ 
Fever Y/N_ 
Dark Urine 
-YIN- 
Vaginal Bleeding 
_Y/N_ 
Other (specify) 
_Y/N_ 
Able to perform routine activities 
Yes 
No 
Field team's assessment 
Axillary Temperature 
Pallor 
jaundice 
OUTCOME 
1. Continue 
2. Need Escape Medication 
3. Delivered 
4. Travelled 
5. Missed her 
6. Consent Withdrawn 
Field Supervisor 
Verification by PI 
I 
-Y/N- 
-Y/N- 
I 
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APPENDIX 11 FOLLOW UP FORM TWO 
NKORANZA ANTIMALARIAL DRUGS PROJECT 
FOLLOW-UP FORM TWO 
DAY [7] [14] [28] 
Date Study ID number Drug Code 
ASSESSMENT OF ADVERSE EVENTS 
Ask: Did you experience any problems our last visit? _Y/N_ 
Whether yes OR no, enquire about the following and tick "Yes" OR "No" 
against the mentioned experience 
REPORTED 
EVENTS 
RESPONSE 
Dizziness 
_Y/N_ 
Headache 
_Y/N_ 
Sleeplessness 
_Y/N_ 
Skin Rash 
-YIN- 
Itchiness 
_Y/N_ 
Palpitations 
-YIN- 
General Weakness Y/N_ 
Nausea 
-YIN- 
Vomiting 
_Y/N_ 
Sore Mouth YIN- 
Painful Swallowing 
_Y/N_ 
Fever 
_Y/N_ 
Dark Urine 
_Y/N_ 
Vaginal Bleeding Y/N_ 
Other (specify) 
_Y/N_ 
Field Worker 
Able to perform routine activities 
Yes 
No 
Field team's assessment 
Axillary Temperature 
Pallor 
Jaundice 
OUTCOME 
1. Continue 
2. Need escape medication 
3. Delivered 
4. Travelled 
5. Missed her 
6. Consent withdrawn 
Field Supervisor 
Verification by PI 
I 
I 
-Y/N- 
-Y/N- 
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APPENDIX 12 DELIVERY FORM 
Date of delivery 
NKORANZA ANTINULARIAL DRUGS PROJECT 
DELIVERY FORM 
Study ID number 
Maturity 
1. Preterm Delivery (28-36 weeks) 
2. Term Delivery (37-42 weeks) 
3. Miscarriage (before 28 weeks) 
4. Stillbirth (after 28 weeks) 
Type of delivery 
1. Normal S VD 
2. Breech 
3. Vacuum Extraction 
4. C-Section 
Reasons for surgical intervention 
1. CPD 
2. Poor Maternal Effort 
3. Abnormal Presentation 
4. Foetal Distress 
5. APH 
6. OTHER (SPECIFY) 
7. Not Applicable 
Placental Weight 
Maternal Weight (before delivery) 
APGAR Score at birth 
Did baby need resuscitation? 
If Yes, what is the duration of resuscitation? 
Outcome of resuscitation 
1. Successful 
2. Floppy 
3. Dead 
PREGNANCY OUTCOME 
I 
I 
Mother's condition in labour 
Fever 
Pallor 
Jaundiced 
Bleeding 
Colour of liquor 
1. Whitish 
2. Yellowish 
3. Greenish 
-Y/N- 
-Y/N- 
-Y/N- 
Y/N- 
I 
Smell of liquor 
1. Normal 
2. Offensive 
Date & time of onset of labour 
Drug Code 
I 
I 
Date & time of end of 3rd stage labour 
Duration of labour 
hr. / mins. 
ASSESSMENT OF THE NEWBORN 
I Observed abnormalities 
1. Face 
1'/N_ 2. Fingers 
I 
Weight kg 
Length cm 
Head Circumference cm 
Arm Circumference cm 
Is baby jaundiced? 
-Y/N- 
Midwife Verification by PI / clinician 
3. Arms 
4. Legs 
5. Toes 
6. Body 
7. Other (specify) 
8. None 
1 
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APPENDIX 13 DELIVERY LABORATORY FORM 
NKORANZA ANTIMALARIAL DRUGS PROJECT 
DELIVERY LABORATORY FORM 
Delivery Date Study ID number Drug Code 
Mother's Hb Placental biopsy taken? 
YES/NO 
Mother's peripheral blood smear 
PARASITE TYPE PARASITE COUNT 
P. F. TROPHOZOITES 
P. F. SCHIZONTS 
P. F. GAMETOCYTES 
P. M. TROPHOZOITES 
P. M. SCHIZONTS 
P. M. GAMETOCYTES 
P. O. TROPHOZOITS 
P. O. SCHIZONTS 
P. O. GAMETOCYTES 
Cord blood smear 
PARASITE TYPE PARASITE COUNT 
P. F. TROPHOZOITES 
P. F. SCHIZONTS 
P. F. Gr1A1ETOCYTES 
P. M. TROPHOZOITES 
P. N1. SCHIZONTS 
P. M. GAMETOCYTES 
P. O. TROPHOZOITS 
P. O. SCHIZONTS 
P. O. GAMETOCYTES 
Laboratory Technician/Aficroscopist 
Placental blood smear 
PARASITE TYPE 
P. F. TROPHOZOITES 
P. F. SCHIZONTS 
P. F. GAMETOCYTES 
P. M. TROPHOZOITES 
P. M. SCHIZONTS 
P. M. GADIETOCYTES 
P. O. TROPHOZOITS 
P. O. SCHIZONTS 
P. O. GAMETOCYTES 
Placental impression smear 
PARASITE TYPE 
P. F. TROPHOZOITES 
P. F. SCHIZONTS 
P. F. GAMETOCYTES 
P. M. TROPHOZOITES 
P. M. SCHIZONTS 
P. M. GAMETOCYTES 
P. O. TROPHOZOITS 
P. O. SCHIZONTS 
1 P. O. GAMETOCYTES 
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PARASITE COUNT 
PARASITE COUNT 
APPENDIX 14 POSTPARTUM FORM 
NKORANZA ANTIMALARIAL DRUGS PROJECT 
POST PARTUM FOLLOW-UP FORM 
Follow-up Date 
Enquire about health of baby 
1. Alive 
2. Dead 
3. Sick 
Study ID number Drug Code 
r:::: 
If the baby is dead, 
Ask when OR how long ago he/she died? 
_/_/ / 
Ask what happened before he/she died? 
Field Worker 
Field Supervisor 
Verification by PI 
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Mother's Hb 
Peripheral Smear 
(P. falciparum count) 
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APPENDIX 16 Estimation of P. falciparum resistance to CQ and SP in children 
treated at St. Theresa's Hospital. 
The rationale for this sub study has been given in section 3.13.3 of this thesis. A flow diagram of 
the screening process that led to randomisation and enrolment of children into the study is 
shown in Figure 1. A total of 370 children who were brought to the OPD of the St. Theresa's 
Hospital, were screened with OptiMAL® tests. Two hundred and three (54.9%) who had positive 
antigen test with microscopic confirmation of parasitaemia, were randomised to receive either 
CQ or SP. One hundred and forty-three who were OptiMAL® dipstick negative and 24 who had 
positive dipstick tests but negative microscopy were excluded. 
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Figure 1: - Diagram showing the flow of children through a 28-day follow-up period after treatment. 
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The baseline characteristics of the children and factors associated with parasite density at 
enrolment are shown in Tables 1 and 2. More than 98% of the children had a history of fever 
while 78% had a high temperature (37.50 C or above) at enrolment as shown in Table 1. The 
mean age of the children was 2.2 years. There were no statistical differences between the groups 
with respect to baseline parasite density, age, history of fever or having a high temperature as 
shown in Table 2. Baseline parasite density was associated significantly with axillary temperature, 
history of fever and age. 
Table 1: - Baseline characteristics of children under 5 according to treatment arm. 
SP CQ Total 
n (%) n (%) n (%) 
Gender 
Female 50 (52.6) 53 (52.5) 103 (52.6) 
Male 45 (47.4) 48 (47.5) 93 (47.4) 
History of fever 
NO 2 (2) 2 (2) 4 (2) 
YES 100 (98) 99 (98) 199 (98) 
Temperature 
<37.5 27 (23.7) 23 (20.4) 50 (22) 
37.5 & above 87 (76.3) 90 (79.6) 177 (78) 
Mean (SD) 37.9 (0.9) 37.9 (0.9) 37.9 (0.9) 
Parasite density/µL 
32 - 999 13 (12.9) 7 (6.9) 20 (9.9) 
1000 & above 88 (87.1) 95 (93.1) 183 (90.1) 
Geometric mean (95% CI) 12909 (8843 - 18844) 14534 (10008 - 21107) 
Range (min to max) (32 - 520650) (128 - 352000) 
Age 
<3 years 49 (60.5) 53 (68) 102 (64.1) 
3 to 5 years 32 (39.5) 25 (32) 57 (35.9) 
Mean (SD) 2.3 (1.2) 2.1 (1.2) 2.2 (1.2) 
Median (IQR) 2 (2) 2 (2) 2 (2) 
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Table 2: - Factors associated with baseline parasite density 
Baseline parasite density/µL 
32 - 999 1000 & above Total p-value" 
Temperature/ 0C 
<37.5 8 (40) 33 (18) 41 (20.2) 
37.5 & above 12 (60) 150 (82) 162 (79.8) 
History of fever 
No 2 10 2 (1.1) 4 (2) 
Yes 18 90 181 (98.9) 199 (98) 
Age [years] 
<3 years 10 (66.7) 47 (32.6) 57 (35.8) 
3 to 5 years 5 (33.3) 97 (67.4) 102 (64.2) 
Gender 
Female 7 (36.8) 96 (54.2) 103 (52.6) 
Male 12 (63.2) 81 (45.8) 93 (47.4) 
0.04 
0.05 
0.01 
0.2 
Fisher's exact test 
As shown in Table 3 and Figure 2, the parasitological failure by day 14 was 11.8% and 24.2% 
respectively in the SP and CQ groups. The parasitological failures by day 28 were 24.2% and 
40.2% respectively for the SP and CQ groups. A comparison of the parasitological failure by day 
14 and at day 28 in pregnant women of the main study and the children is shown in Figure 3. In 
both pregnant women and children SP performed better than CQ at clearing parasitaemia by day 
14 and 28. However, the proportions of parasitological failure in pregnant women in both 
treatment arms were less than half the proportions in children at day 14 and about 75% of those 
in children by day 28. 
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Table 3: - Parasite prevalence at days 14 and 28 after the start of treatment in children under 5 years 
Parasite prevalence Unadjusted p-value Adjusted * p-value 
Nn (%) odds ratio (95% Cl) odds ratio (95% Cl) 
DAY 14 
SP 93 11 (11.8) 1.0 
CQ 91 22 (24.2) 2.4 (1.1-5.2) 0.03 1.4 (0.6 - 3.5) 0.5 
DAY 28 
SP 91 22 (24.2) 1.0 
CQ 92 37 (40.2) 2.1 (1.1 - 4.0) 0.02 1.3 (0.6-2-6) 0.6 
Odds ratios adjusted for gender, age and baseline parasite density 
Figure 2: - Parasitological outcomes in children under 5 years determined by microscopy 
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Figure 2: - Parasitological failure in pregnant women and children under 5 years determined by 
microscopy 
DAY 14 DAY 28 
CQ 
DAY 14 DAY 28 
SP 
The apparent differences would have been easier to explain if the parasitological failures in 
children were corrected for re-infections. The high parasitological failure in children compared to 
pregnant women may be due to the fact that 90.1% of the children compared to 
46.8% of 
pregnant women had parasite densities equal to 1000/µL or above at enrolment. The differences 
in parasite at enrolment may the result of low level of acquired immunity to P. fa/crparum infection 
in children compared to pregnant women. High parasite burden together with low level of 
acquired immunity have been shown to increase the likelihood of parasitological failures (Djimde 
et al. 2003; Ittarat et al. 2003; Mayxay et al. 2003). And so although the drugs may be ineffective in 
children, these differences (White 2002) may explain why they performed relatively better in the 
pregnant women. It appears that the parasitological failure rates observed in children in classical 
drug resistance studies may not be applicable to pregnant women. However, in both groups they 
are high enough to warrant a change in treatment policy for more efficacious antimalarial 
treatment regimes. 
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APPENDIX 17 Liver enzyme activities and bilirubin concentrations of non-parasitaemic and 
parasitaemic pregnant women at enrolment. 
Non-parasitaemic Parasitaemic 
n (%) n (%) 
AST (U/L) 
Up to 12 181 (90.5) 514 (59) 
12 to 24 19 (9.5) 262 (30.1) 
>= 25 NA' NA 95 (10.9) 
Mean (SD) 8.1 (2.3) 13.9 (10.8) 
Median (IQR) 7 (0) 10 (9) 
ALT (U/L) 
Up to 12 200 (100) 755 (86.8) 
12 to 24 NA NA 77 (8.8) 
>= 25 NA NA 38 (4.4) 
Mean (SD) 4.1 (0.7) 7.5 (7.8) 
Median (IQR) 4 (0) 4 (4) 
GGT (U/L) 
Up to 50 199 (99.5) 855 (99.5) 
51 to 100 1 (0.5) 3 (0.4) 
> 100 NA NA 1 (0.1) 
Mean (SD) 9.1 (9.5) 9.9 (9.3) 
Median (IQR) 5 (8) 8 (7) 
Total bilirubin (µmol/L) 
Up to 17.1 195 (97.5) 713 (81.9) 
17.2 to 34.4 5 (2.5) 117 (13.4) 
>= 34.5 NA NA 41 (4.7) 
Mean (SD) 6.3 (3.8) 12.1 (13.4) 
Median (IQR) 5 (3) 8 (9) 
Direct bilirubin (µmol/L) 
Up to 3.4 185 (92.5) 506 (58.1) 
3.5 to 6.8 12 (6) 205 (23.5) 
>= 6.9 3 (1.5) 160 (18.4) 
Mean (SD) 2.0 (1.3) 4.9 (5.9) 
Median (IQR) 2 (1) 3 (4) 
Indirect bilirubin (µmol/L) 
Up to 13.7 198 (99) 775 (89) 
13.8 to 27.4 2 (1) 77 (8.8) 
>= 27.5 NA NA 19 (2.2) 
Mean (SD) 4.3 (3.1) 7.2 (8.7) 
Median (IQR) 3 (3) 5 (6) 
*Nobody in these categories 
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